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ABSTRACT
UNCOVERING UNIQUE A/-LINKED GLYCAN STRUCTURAL ISOMERS IN 
CANCER VIA MSn DISASSEMBLY
by
Justin Michael Prien 
University of New Hampshire, September, 2007
Molecular glycosylation is involved in key developmental roles including 
control of cell differentiation, innate immunity and signal transduction. Equally as 
demonstrable are numerous aspects of tumor development, from cellular 
proliferation to angiogenesis and metastasis. This sensitivity to cellular 
pathological is reflected in the diversity of glycoforms presented on glycoproteins. 
In spite of the potential utility of using molecular glycosylation as potential 
diagnostic and therapeutic agents little has been accomplished in bringing these 
capabilities to the clinic. Reasoning for this omission must relate to the paucity of 
analytical protocols to understand the full details of glycan structure. Analytical 
advancement in ion trap sequential mass spectrometry (MSn) methodology 
provides an unprecedented approach for glycoanalytic investigation. With an 
MSn-based approach comprehensive structural detail of individual glycan 
epitopes and isomeric structures become evident and demonstrate that 
specificity when applied to metastatic tissue. Using VM mouse brain tumor cells 
as a model, this these systematically uncovers an anomalous set of A/-linked 
glycans distinct to malignant non-metastatic and metastatic tumors. By coupling
xi
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specific chemical workup and utilizing ion-trap MSn disassembly, this analytical 
approach introduces a concept that carbohydrate epitopes can serve as a 
sensitive measure of physiological function. Importantly, such understanding 
requires an indulgence in structural detail, details uniquely available to ion trap 
mass spectrometry. The application of this methodology toward early detection 
biomarker discovery and cancer biology could be far reaching.
xii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 1
CANCER GLYCOMICS
Alterations in A/-linked and Olinked glycoprotein structure have long been 
implicated in a myriad of pathological events associated with cancer (Dennis, 
J.W., Granovsky, M., et al. 1999). Glycans play paramount roles in all stages of 
tumor progression such as tumor growth and proliferation, angiogenesis, as well 
as tumor immunological defiance (Varki, A., Cummings, R., Esko, J., Freeze, H., 
Hart, G. and Marth, J. 1999) (Figure 1). This is unsurprising since proper 
glycoprotein glycosylation is cardinal to many basic cellular functions and 
biological recognition events during embryonic development such as protein 
folding, protein trafficking, quality control, cell signaling, cell-matrix interactions, 
and cell-cell interactions (Taylor, M.E., Drickamer, K. 2003). Glycans are not 
direct gene products, but synthesized by a step-wise process regulated by 
glycosyltransferases. Reduced or excessive expression of individual glycan 
structures, persistence of incomplete or truncated structures, and the emergence 
of novel glycan structures are often associated with alterations in 
glycosyltransferase activity in cancer (Varki, A., Cummings, R., Esko, J., Freeze,
H., Hart, G. and Marth, J. 1999). Common carbohydrate epitopes observed 
across many forms of cancer are increased (31,6 branching of A/-linked 
glycoproteins, over expression of sialyl-Lewis*^ antigens, and truncated T-, Tn,
1
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and sialyl-T/Tn antigens of O-linked glycoproteins (Brockhausen, I., Yang, J.M., 
Burchell, J., Whitehouse, C., Taylor-Papadimitriou, J. 1995, Campbell, B.J., 
Finnie, I.A., et al. 1995, Itzkowitz, S.H. 1992, Itzkowitz, S.H., Bloom, E.J., et al. 
1990, Korczak, B., Goss, P., et al. 1994, Rhodes, J.M. 1996, Roth, J. 2002). The 
glycodynamics within any cell is under tissue-specific control and a consequence 
of glycosyltransferase location, induction, amplification and suppression. Shifts 
in glycosyltransferase dynamics lead to disturbances in glycan structural 
patterning and subsequently lead to a constellation of deleterious events such as 
enhanced receptor activation, cellular adhesion, and motility capabilities, which 
imbue tumor cells with superior proliferative and dissemination capacities 
(Rivinoja, A., Kokkonen, N., et al. 2006).
Primary tumour
Transfom ted 





a Tumour ceii Fl'gure '• Glycans and tumor progression.
proliferation (a) Tumor growth and progression is 
potentiated by glycoproteins and 
glycosphingolipids through growth factor 
activation and apoptosis suppression, (b) 
Tumor cell invasion capabilities are 
enhanced by alterations in E-cadherin- 
dependent adhesion resulting from increased 
(31,6 branching and increased cell-cell 
repulsion by an elevated expression o f
  sialylated glycans. Additionally,
^glycosphingolipids, particularly the GM3 
structure, greatly enhances tumor repulsion, 
iiptvxyts (c) Carbohydrate epitope binding P-selectin,
L-selectin, and E-selectin adhesion receptors 
assist dissemination through their 
preferential binding o f sialyl-Lewis X /A  
structures on tumor cells. Additionally, 
ganglioside shedding induces an 
‘immunosilencing’ effect, (d) Tumor 
angiogenesis occurs in response to the N -  
^ e,'ular linked glycan promotion o f endothelial cell
migration. Modified from Fuster 2005.
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covalently linked to an asparagine
residue within a consensus peptide
A/-linked glycans are sugar chains ^  NeuAc 
•  Gal 
■  GlcNAc 
0  Man 
f \ /  Polypeptide
High-Mannose Hybrid-type Complex-type
sequence (Asn-X-Ser/Thr where X can
Figure 2. Common types of A/-linked 
be any amino acid other than proline) glycans.
of a polypeptide chain. In eukaryotes, A/-linked glycans share a common
pentasaccharide core with A/-acetylglucosamine (GlcNAc) inevitably linked to the
asparagine residue in a (3 conformation. A/-linked glycans are commonly divided
into three classes: high-mannose, hybrid, and complex (Figure 2). O-linked
glycans are sugar chains covalently linked to the side chain of serine or threonine
residues. To date, a consensus peptide sequence for O-glycan linkage has not
been uncovered. Mucins and proteoglycans are two common groups of
glycoproteins dominated by O-linked sugars. A series of simple core structures
with A/-acetylgalactosamine (GalNAc) linked to serine or threonine in an a
configuration is typical for the mucin family of glycoproteins. AMinked and O
linked glycans predominate on secreted and membrane bound glycoproteins.
This extracellular destination places glycans in a position to mediate intercellular
signaling, adhesion, and motility; processes drastically altered during malignant
transformation.
3
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1.1 M-linked Glvcan Biosynthesis
Enormous resources are allocated in the endoplasmic reticulum (ER) and 
Golgi apparatus to /V-glycosylate proteins. Estimates based on statistical 
analysis of databanks infer that greater than 50% of mammalian polypeptides 
may be N-glycosylated (Apweiler, R., Hermjakob, H., et al. 1999). This is 
concordant with the estimate that 0.5-1% of the translated genome represents 
glycosylation genes, a similar proportion levied to protein phosphorylation (Varki, 
A., Marth, J.D. 1995). Compositional and functional diversity of oligosaccharide 
moieties is a distinguishing characteristic of protein glycosylation (Kornfeld, R. 
and Kornfeld, S. 1976, Varki, A. 1993). Golgi glycosyltransferases are 
responsible for this breadth of structural diversity. Ironically, the structural 
elaborateness stems from conserved presynthesized dolichol-bound 
oligosaccharide core (Glc3Man9GlcNAc2) transferred en bloc to the polypeptide 
chain in the ER (Trombetta, E.S. 2003). Assembly of AZ-linked glycans occurs in 
four sequential phases, each comprised of several individual steps: (1) formation 
of a lipid-linked precursor oligosaccharide (LLO); (2) en bloc transfer of 
oligosaccharide to polypeptide; (3) trimming of the original sugar residues in the 
ER and c/s-golgi; and (4) maturation or addition of new sugars at the non­
reducing termini of the glycan in the medial and frans-Golgi. Eukaryotes have all 
conserved the first three phases of this process, but there is a loose phylogenetic 
relationship to the complexity and extent of trimming and maturation (Drickamer, 
K. and Taylor, M.E. 1998). These phases may reflect the evolution of the 
biosynthetic pathway, and increased biological pressure for N-glycan complexity.
4
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The formation of the lipid linked core oligosaccharide is a bi- 
compartmental event, occurring on both sides of the ER membrane (Figure 3). 
Synthesis begins in the cytosol, with the transfer of GlcNAc to the lipid dolichol 
via a UDP-GlcNAc nucleotide sugar donor, followed by the sequential addition of 
a second GlcNAc and five mannoses. The Man5GlcNAc2 moiety is then 
translocated across the membrane into the luminal compartment of the ER.
Once in the lumen, four additional mannose residues and three glucose residues 
are added by dolichol linked sugars producing the final lipid linked 
oligosaccharide core, Glc3Man9GlcNAc2, which is transferred en bloc to the 
asparagine residue within the glycosylation consensus sequences on the 
nascent polypeptide (Helenius, A. and Aebi, M. 2004).
Oligosaccharyltransferase (OST) catalyzes the transfer of Glc3Man9GlcNAc2 onto 
the nascent polypeptide as the polypeptide emerges in the lumen of the ER. En 
bloc LLO transfer is considered a co-translational event that facilitates proper 
folding as the polypeptide is translated (Hammond, C., Braakman, I., et al. 1994). 
Typically, the asparagine residue to which Glc3Man9GlcNAc2 attaches must meet 
three conditions: (1) a minimum consensus sequence surrounding the acceptor 
asparagine of Asn-X-Ser/Thr, where X can be any amino acid except proline; (2) 
sequence must be located in the proper three-dimensional structure of the 
protein; and (3) must be exposed in the correct intracellular compartment. The 
high specificity and compartmental localization of OST explains the consensus 
sequence and intracellular location requirements necessary for LLO transfer. 
Possibly, the incompatibility of the oligosaccharide hydrophilicity to the protein’s
5
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hydrophobic interior persuades LLO transfer to occur only onto future external 
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Figure 3. Biosynthesis of the conserved lipid-linked oligosaccharide precursor, Glc3 
Man9GlcNac2. Seven proximal sugar residues are added to dolichol on the cytosolic surface 
of the ER. The sugar moiety is then translocated or “flipped” into the ER lumen to complete 
glycan assembly. Translocation is catalyzed by an ATP-independent, bi-directional “flippase” 
(Hirschberg, C.B. and Snider, M.D. 1987). In yeast, FRT1, a 10 trans-membrane spanning 
polytopic membrane protein has been identified as the “flippase” (Helenius, J., Ng, D.T., et al. 
2002). Genes for homologous proteins have been reported in numerous eukaryotic genomes 
(Helenius, J., Ng, D.T., et al. 2002). Modified from Varki 1999.
Once bound to the polypeptide, trimming of distal sugars of the 
oligosaccharide precursor begins (Figure 4). Glucosidases I and II remove the 
terminal three glucoses. The removal of the final glucose signals that the 
glycoprotein is ready to move from the ER to cis-Golgi. However, if the 
glycoprotein is malfolded, it is reglycosylated, by a-glucosyltransferase and 
retained in the ER for further rearrangement. If proper configuration can not be 
achieved the protein is deglucosylated and degraded. This quality control step is 
invaluable to insure proper membrane-bound and secreted protein conformation. 
Studies using tunicamycin, an inhibitor of /V-glycosylation, exemplified the 
importance of A/-glycosylation for proper protein folding and secretion (Helenius,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
A. and Aebi, M. 2004). As the glycoprotein traverses the cis-Golgi, mannose 
residues are sequentially cleaved by a-mannosidases ultimately ending with a 
Man5GlcNAc2 structure. The trimmed Man5GlcNAc2 structure serves as 
scaffolding for the construction of more complex glycans in the medial and trans- 
Golgi (Figure 4). However, glycans on some proteins are only partially trimmed 
promoting the incidence of hybrid and high-mannose type structures. High- 
mannose structures, containing five to nine mannoses, are more abundant in 
rapidly dividing cells, such as embryonic, immunologic, and tumorigenic cells 
(Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999).
The formation of complex glycans is essential for the viability of 
multicellular organisms. A/-acetylglucosaminyltransferase I (GlcNAc-TI) is a 
medial Golgi enzyme transcribed by Mgatl gene, which catalyzes the initial 
branching step necessary for complex carbohydrate formation. The development 
of GlcNAc-TI and specialization of the medial Golgi, appear to be key 
evolutionary events fulfilling the need for an intercellular communication 
mechanism to promote compartmentalization and higher level multicellular 
organization. Mutant cell lines, but not homozygous viable mice can be 
generated harboring null mutations in Mgatl, the first step in complex glycan 
formation, exemplifying that the nexus of complex A/-linked glycoprotein function 
is the intercellular interactions within complex organisms (Ioffe, E. and Stanley,
P. 1994, Metzler, M., Gertz, A., et al. 1994). After the addition of a (31,2GlcNAc 
residue to the a1,3 arm of the core structure by GlcNAc-T1, Golgi mannosidases 
trim the a1,6 arm by removing the two remaining mannoses. At this point,
7
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distinct GlcNAc-transferases determine the branching patterns of the glycan, and 
ultimately these branching structures are extended by galactosyltransferases, 
sialyltransferases, and fucosyltransferases. Alterations in the glycodynamic 
equilibrium of these terminal elaborating enzymes have lead to increased 
GlcNAc-branched A/-glycans and Lewis antigen formation in many cancers 
(Dennis, J.W., Granovsky, M., et al. 1999).
A Glc ^  GlcNAc ^  NeuAc





02T  G lu co s id a se  ► ER mannosidase I
Glucosidase II
GlcNAc- T 0 4  Galactosyl- T P 4  Sialyl-




Mannosidase " T  Transferase Iv  ia, iB. ic r v  r \
Ohgosacharyl
transferase
Figure 4. en bloc transfer and processing of the precursor glycan. As the polypeptide 
translocates into the ER, Oligosaccharyltransferase (OST) scans the emerging polypeptide for 
Asn-X-Ser/Thr and begins adding the precursor glycan as early as the 12th to 14th residue. 
Once the glycan has been attached, the terminal glucose is removed co-translationally by 
glucosidase I. The penultimate glucose is then removed by glucosidase II. The remaining 
monoglucosylated glycan enters the calreticulin/calnexin cycle assisting in proper folding. If 
proteins are malfolded (i.e., exposed hydrophobic patches) a-glucosyltransferase 
reglucosylates the polypeptide forcing the peptide to re-enter the calreticulin/calnexin cycle 
until it is properly folded (Ellgaard, L., Molinari, M., et al. 1999). If improper folding continues 
the glycopeptide is bound by ER degradation-enhancing a-mannosidase-like protein (EDEM), 
translocated to the cytosol and degraded(Trombetta, E.S. 2003). Deglucosylation of the 
monoglucosylated glycoprotein signals that the protein is properly folded and may transit to 
the Golgi. a2-linked mannose residues are trimmed by a series of Golgi mannosidases. 
Hybrid-type glycans are formed when Golgi a mannosidases II do not cleave mannose 
residues after the attachment of a GlcNAc residue by GlcNAc-TI. Modified from Taylor 2003.
8
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1.2 O-linked Glvcan Biosynthesis
Contrary to A/-glycosylation, O-glycosylation does not require the 
synthesis and en bloc transfer of a lipid-linked oligosaccharide precursor. 
Subsequently, O-linked glycans do not have a common core but a series of 
common subtype core structures. The initiating step in O-linked assembly, which 
takes place in the Golgi opposed to the ER for A/-glycosylation, is the addition of 
a GalNAc sugar a-linked to a serine or threonine residue catalyzed by a family of 
-24 polypeptide A/-acetyl-a-galactosaminyltransferases (Hang, H.C. and 
Bertozzi, C.R. 2005). Through a step-wise glycosyltransferase process O- 
glycans can be extended into long elaborate chains; however, compared to their 
/V-glycan counterparts, O-glycans are less branched and commonly bi-antennary 
(Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999) 
(Figure 5). Core 1 (31,3 galactosyltransferase (Core 1 GalT) attaches a galactose 
in a (31,3 linkage to the peptide-proximal GalNAc, producing the most common 
O-glycan core. Utilizing the core 1 structure as a substrate Core 2 (31,6 N- 
acetylglucosaminyltransferase (C2GnT) attaches GlcNAc by a (31,6 linkage to the 
GalNAc, creating the Core 2 O-glycan subtype. Competing for the same 
hydroxyl substrate as Core 1 GalT, Core 3 (31,3 A/-acetylglucosaminyltransferase 
(C3GnT) attaches a GlcNAc in a |31,3 linkage. The action of C3GnT, produces a 
substrate incompatible to C2GnT, however Core 4 (31,6 N- 
acetylglucosaminyltransferase (C4GnT) acts upon the Core 3 substrate 
producing the scaffolding for bi-antennary elongation. Core 3 and Core 4
9
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structures are uncommon except in areas that produce copious quantities of 
mucins (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 
1999). Typically, core subtypes are elongated by the addition of polylactosamine 
units (Gal-GlcNAc repeats) and further elaborated with fucosyl- and sialyl- 
residues (Brockhausen, 1.1999). These elaborations play a key role in ligand- 
receptor binding and the extracellular duties of Olinked glycoproteins (Crocker, 
P.R. 2005). Cancer tissue Oglycan structural patterns differ from normal tissue 
exhibiting excessive sialylation, reduced sulphation, and increased truncation 
(Brockhausen, I. 2006). Colon and breast cancer tissue frequently express high 
levels of Lewis antigens as terminal elaborations. Truncated Oglycans, known 
as tumor-associated antigens or T antigens, are associated with advanced 
cancer, metastasis, and poor prognosis (Brockhausen, I., Yang, J.M., et al. 1995, 
Itzkowitz, S.H., Bloom, E.J., et al. 1990) (Figure 8).
• Gal o NeuAc
■ GalNAc A Fuc
■ GlcNAc
p p - i
/Ser/Thr
Core 1 A  Core 2 A  ■
’-GalNAo-T ■  Gal-T 33'igs GlcNAc-T IP3W36
Core 1 Core 2
Figure 5. O-Linked core biosynthesis. Core 1 and Core 2 O-glycan subtype formation is 
controlled by the activity of Core 1 GalT and Core 2 GlcNAc-T enzymes. Additional 
biosynthesis can yield O-glycans bearing fucosylated and sialylated lactosamines. Modified 
from Varki 1999.
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1.3 Glvcosvltransferases
Golgi glycosyltransferases dictate glycan structural elaborations. 
Glycosyltransferases act sequentially catalyzing the transfer of monosaccharides 
from specific sugar nucleotide donors onto a particular hydroxyl position of a 
specific precursor monosaccharide on a growing glycan chain (Schachter, H.
1986). That is, the product of one enzyme reaction becomes the preferred 
acceptor substrate for the subsequent action of another glycosyltransferase 
assembling the glycan structure stepwise. This sequential action is also a 
branched mechanism: the incipient step of assembly, or early branching point, 
irreversibly commits the newly formed substrate to a specific sub-group of 
elaborating glycosyltransferases which explicitly acts upon the unique structural 
scaffolding constructed by the previous step. This enzymatic glycan assembly is 
regulated through translational controls (Brockhausen, 1.1999, Buckhaults, P., 
Chen, L., et al. 1997, Chen, L., Zhang, W., et al. 1998, Miyoshi, E., Nishikawa,
A., et al. 1993, Yoshimura, M., Nishikawa, A., Ihara, Y., Taniguchi, S., Taniguchi, 
N. 1995), glycosyltransferase compartmentalization (Roth, J., Wang, Y., et al. 
1994, Rottger, S., White, J., et al. 1998), availability of sugar nucleotides and 
acceptor substrates, competition between enzymes for substrates, intraluminal 
concentration of the acceptors, and pH levels (Varki, A., Cummings, R., Esko, J., 
Freeze, H., Hart, G. and Marth, J. 1999). The protein microenvironment 
encompassing the glycosylation site also affects glycosyltransferase catalytic 
efficiency (Rademacher, T.W., Parekh, R.B, Dwek, R.A. 1988, Sheares, B.T. and 
Robbins, P.W. 1986).
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Glycan elaborations appear to reflect environmental modulations of the 
Golgi where ensuing pathways provide the requisite enzymes and substrates to 
assemble a fairly reproducible product. However, when temporal considerations 
are coupled with these multiple variables the ensuing structures exhibit 
variability. In the absence of any means for quality control, such variability 
becomes a direct expression of organelle-tissue physiology. As examples...
The regulation of glycosyltransferase gene expression contributes to the 
availability and quantity of glycosyltransferases in Golgi compartments 
(Buckhaults, P., Chen, L., et al. 1997, Chen, L., Zhang, W., et al. 1998, Miyoshi, 
E., Nishikawa, A., et al. 1993, Yoshimura, M., Nishikawa, A., et al. 1995). N- 
acetylglucosaminyltransferase V (GlcNAc-TV), the gene product of Mgat5, 
creates (31,6 branching of /V-linked glycans promoting tri- and tetra-antennary 
structures. During cancer transformation the RAS-RAF-MAPK signaling pathway 
is up-regulated stimulating increased expression of MgatS and subsequently 
increasing (31,6 branching. The (31,6 branch is the preferred site for 
poiylactosamine extensions and sialic acid capping, which increases the negative 
electrostatic potential of the glycoprotein as well as the tumor cell-surface, further 
enhancing cell detachment and motility (van den Eijnden, D.H., Koenderman, 
A.H., et al. 1988)(Figure 6). The cell-cell adhesion capabilities of tumor E- 
cadherin, a cell-surface aggregation molecule, is drastically diminished upon 
increased (31,6 branching (Yoshimura, M., Ihara, Y., et al. 1996). Additionally, 
increased (31,6 branching of the (3i subunit of tumor a5 [3i integrins disrupts 
tumor-cell focal adhesions increasing tumor cell motility (Guo, H.B., Lee, I., et al.
12
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2002). The presence of (31,6 branching correlates with increased tumor burden
and poor prognosis (Dennis, J.W., Laferte, S., et al. 1987, Fernandes, B., 
Sagman, U., et al. 1991).
Figure 6. Typical polylactosamine extension. A/-acetyllactosamine (Gal-GlcNAc) repeats are 
commonly added to the p1,6-branch of /V-linked glycans. The linkages within the repeats can 
vary. The most common repeat, termed type 2, consists of Gaipi ,4GlcNAc and GlcNAcpi ,3Gal 
linkages, while the less common type 1, consists of Galpl ,3GlcNAc and GlcNAcpi ,3Gal linkages. 
The length of the polylactosamine extension is determined by the dynamic balance of activity 
between the GlcNAc-transferase and the sialyltransferase.
During normal glycosylation (31,6 branching does not proceed unchecked. 
A/-acetylglucosaminyltransferase III (GlcNAc-TIII) competes with N- 
acetylglucosaminyltransferase V (GlcNAc-TV) for the substrate acceptor and 
nucleotide sugar donors. The activity of these competing enzymes determines 
the relative amount of enzyme products and the glycoprotein function (Figure 7). 
As mentioned above, GlcNAc-TV adds the (31,6 branch promoting tri- and tetra- 
antennary structures enhancing cell motility, while GlcNAc-TIII promotes a 
bisected structure enhancing cel! adhesion. An alteration in GlcNAc-TV or 
GlcNAc-TIII activity disrupts their delicate balance and in turn shifts the relative 
abundance of bisected and tri- and tetra-antennary /V-linked glycans. The over­
expression of GlcNAc-TIII suppresses lung metastasis of melanoma cells by 
inhibiting GlcNAc-TV activity (Yoshimura, M., Nishikawa, A., et al. 1995). The
Capping structure 






Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
repercussion of this structural decision may irreversibly commit the glycoprotein 
product either to specific pro-metastatic or anti-metastatic biological functions.
The spatial arrangement of glycosyltransferase enzymes along the Golgi 
biosynthetic conveyor belt is also an important factor controlling A/-linked and O- 
Iinked glycoprotein synthesis. Specific glycosyltransferases’ are partially 
segregated or compartmentalized in the c/'s-, medial, frans-Golgi cisternae and 
trans-Golgi network, while others appear to be ubiquitously situated throughout 
the Golgi apparatus (Colley, K.J. 1997, Roth, J., Wang, Y., et al. 1994, Rottger, 
S., White, J., et al. 1998). Spatial arrangements can buffer the competition 
between glycosyltransferases for the same substrate. As an example, core 1 
structures can be converted to a core 2, or alternatively, be sialylated (Figure 8). 
In breast cancer, these two enzymes colocalize and compete for the same 
substrate, while in normal tissue these enzymes are compartmentally segregated 
(Brockhausen, I. 2006). If core 1 becomes sialylated, it can no longer be 
converted to the core 2 subtype. The laxity in the regulation of
#  Gal 0  NeuAc
0  M an A Fuc
■  G lcN Ac
Figure 7. GlcNAc- 
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glycosyltransferase segregation during tumor transformation leads to increased 
substrate competition between biosynthetic enzymes upsetting the ratio between 
sialylated core 1 chains, sialyl-Tn chains, and the more complex core 2 chains 
(Burchell, J.M., Mungul, A., et al. 2001) (Figure 8). The enhanced expression of 
sialyl-Tn and Tn structures on the tumor cell surfaces potentiate tumor 
invasiveness (Julien, S., Krzewinski-Recchi, M.A., et al. 2001).
Terminal elaborations on glycan moieties appear more prevalent in 
metastatic cancers compared to primary tumors often showcasing increased 
amounts of sialyl-Lewis3 and sialyl-Lewisxconfigurations (Hanski, C.,
Klussmann, E., et al. 1996, Ito, H., Hiraiwa, N., et al. 1997) (Figure 9). In normal 
mucosa tissue both core 1 and core 2 type O-glycans are formed, but core 2 type 
are the preferential antennae for sialyl-Lewisx construction. In advanced 
colorectal cancers core 2 type O-glycan production is enhanced by up-regulation 
of (34-Gal-transferase. Over activation of a3-sialytransferases also contribute to 
the formation of sialyl-Lewisx elaborations (Brockhausen, I. 2006). Selectins are 
a family of adhesion molecules on activated platelets, leukocytes and 
erythrocytes that preferentially bind sialyl-Lewis structures (Varki, A., Cummings, 
R., Esko, J., Freeze, FI., Hart, G. and Marth, J. 1999). Tumor cell sialyl-Lewis 
ligands bind to the selectins allowing the tumor cell to disseminate through the 
blood stream without triggering an immune response. It is apparent cancer 
pathology is associated with the modification of many factors altering cell 
glycodynamics. As a consequence, an abnormal repertoire of glycan epitopes 
and structural patterns pertinent to every stage of tumor progression is produced.
15
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Figure 8. Formation of truncated O-linked structures.
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Figure 9. Formation of sialyl-Lewis antigens.
Modified for Brockhausen 2006
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1.4 M-linked Glvcans’ Role in Glycoprotein Function
Glycan structural heterogeneity modulates the function of the underlying 
polypeptide. Different copies of an individual glycoprotein may be modified with 
an assortment of biosynthetically related glycan structures at the same 
occupancy site. This heterogeneous glycosylation creates multiple variants of a 
glycoprotein, termed “glycoforms.” Individual glycoforms can have different 
molecular properties which may affect their degradation time or biological activity 
(Varki, A. 1993). The incidence of various glycoforms in a molecular population 
can affect overall potency, producing a gradient of biological activity. The serum 
half-lives and overall potency of the peptide hormone leutropin and erythropoietin 
are affected by the structural diversity of their glycan moieties. Leutropin 
glycoforms differing in /V-acetylgalactosamine-4 sulfate or sialic acid terminal 
elaborations drastically affects the hormones clearance rate by the liver and 
biological activity (Fiete, D., Srivastava, V., et al. 1991). In vivo studies have 
demonstrated changes in the relative levels of sialylated and branched /V-glycans 
affect the stability, half-life, and activity of erythropoietin (Takeuchi, M. and 
Kobata, A. 1991). Also, many cytokines and adhesion receptors, such as CD44, 
ICAM-1 and CD43 demonstrate extensive glycoform heterogeneity, which 
modifies the physical association between the receptor and its ligand by affecting 
receptor occupancy thresholds (Dennis, J.W., Granovsky, M., et al. 1999). CD44 
has been shown to play a role in tumor migration as well as ICAM-1 interaction 
with secreted mucins. During disease states, glycoform profiles are known to
17
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change creating a altered pattern. This distorted pattern may result in an 
alternative gradient of biological activity with potential adverse consequences.
1.5 /V-linked Glvcans’ Role in Glycoprotein Formation
The most discernable effects of glycosylation is at the cell surface and 
extracellular matrix where glycans exert their extrinsic functions, however the 
consequence of aberrant glycosylation on its intrinsic duties are no less 
detrimental. Cell-surface and secretory proteins must proceed through the ER 
and Golgi conveyor belt to reach their extracellular destination. Glycosylation 
has become an intricate quality control system that ensures secreted 
glycoproteins are correctly folded and prepared for subsequent multimer 
assembly, channeled, and localized properly (Dennis, J.W., Granovsky, M., et al. 
1999). By utilizing a common set of glycan structures as tags a multitude of 
glycoproteins can be sorted and directed to appropriate Golgi compartments for 
further elaboration and trafficked by appropriate vesicles for delivery to their final 
extracellular locale (Drickamer, K. and Taylor, M.E. 1998). In many cases, once 
the glycoprotein arrives at its destination the glycan no longer provides any 
essential function. The consequences of a malfunction in the glycosylation 
machinery can be devastating. Inappropriate levels of certain glycoproteins may 
be expressed on the cell surface or secreted, or misdirected to adverse cellular 
locations. MUC1 and MUC4 are well known glycoproteins found in the blood of 
breast, ovarian, and colorectal cancer patients (Fuster, M.M. and Esko, J.D. 
2005). Typically, these highly glycosylated negatively charged proteins are
18
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exclusively expressed on the apical domain of polarized epithelial cells protruding 
toward or secreted into the organ’s lumen. However, during malignancy mucins 
are expressed over the entire cell surface and secrete into the extracellular 
space, circulatory system, and lymph system. In a recent in vitro study, 
tunicamycin, an inhibitor of /V-glycosylation, greatly reduced the expression of 
MUC1 on the surface of human endometrial and breast cancer cell lines 
(Paszkiewicz-Gadek, A., Porowska, H., et al. 2006). Faulty A/-glycosylation 
processing may contribute to the ubiquitous distribution of mucins in cancer.
Within the tumor environment aberrancies in glycan processing lead to a 
unique array of terminal elaborations and structural patterns that are essential 
determinants in malignant function. Many structural differences have been 
reported, none the less the structure-function relationship regarding glycan 
structure and pathology is still quite nebulous. To elucidate the far-reaching 
biological consequences of glycosylation the full characterization of glycan 
structure, wherein detail sufficient to guide organic synthesis is obtained, is 
paramount. Contrasting biopolymers joined by identically positioned functional 
groups, oligosaccharide chains are resplendent with different linkage types 
(positional and anomeric), multiple linkages (branching topology) and multiple 
isobaric subunits (GlcNAc and GalNAc; Man, Glc, and Gal). As a result, a 
congruent sequencing strategy for dissecting all facets of glycan structure has 
been elusive. The absence of a fully comprehensive sequencing strategy has 
permitted the reporting of partial sequences, assumed structural motifs, and 
sequence arrays devoid of linkage and branching definition as acceptable
19
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conclusions by current literature standards. The omission of structural features is 
a potential missed opportunity to clarify mechanisms responsible for tumor 
progression, to uncover unique cancer biomarkers and to discover novel targets 
for cancer therapeutics. With new developments in analytical methodology and 
instrumentation fine structural changes resultant of cancer glycodynamics can 
now be comprehensively investigated providing greater insight into the molecular 
role glycosylation plays in cancer pathology.
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CHAPTER 2
GLYCOANALYTICS
The ultimate goal in glycomic investigation, with regard to structural 
analysis, has been to devise a general platform for complete comprehensive 
structural elucidation. Many classic analytical separation techniques such as 
chromatography, exo-and endoglycosidase enzymes, and nuclear magnetic 
resonance have been retrofitted for glycoanalysis with varied success (Dwek, 
R.A., Edge, C.J., etal. 1993, Rudd, P.M., Guile, G.R., etal. 1997). Though 
informative these divergent techniques require large sample sizes, secondary 
needs for product characterization, and fail to analyze one or many structural 
criteria individually. Since the introduction of electrospray ionization (ESI) and 
matrix assisted laser desorption ionization (MALDI) into biomolecular mass 
spectrometry (MS), MS-based analysis with superior sensitivity, low sample 
consumption, and aptitude for High-Throughput automation (HTP) is now the 
dominant method for glycan structural analysis (Reinhold, V.N., Reinhold, B.B., 
et al. 1996, Sutton, C.W., O'Neill, J.A., et al. 1994).
The primary focus in our laboratory has been the development of a 
straightforward platform for systematically defining all the structural facets within 
an oligosaccharide sequence (Ashline, D., Singh, S., et al. 2005, Reinhold, B.B., 
Hauer, C.R., et al. 1995, Reinhold, V.N., Reinhold, B.B., et al. 1996, Reinhold,
21
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V.N., Reinhold, B.B., et al. 1995, Sheeley, D.M. and Reinhold, V.N. 1998).
Glycan samples, when prepared as methyl derivatives and analyzed in an ion- 
trap mass spectrometer, appear to provide the best strategy for comprehensive 
structural understanding (Figure 10). As demonstrated by Hanneman (2006) and 
Ashline (2007) this method is an effective technique for uncovering unanticipated 
structural moieties and uncharacterized structural isomers in biological samples 
that have previously been overlooked by other methodologies.
Figure 10. Complete oligosaccharide characterization. Glycans establish unique interactions 
with individual lectins (carbohydrate binding proteins) modulating various biological processes. 
Lectins are highly specific to particular structural nuances and therefore complete structural detail 
including: (1) oligomer topology (e.g., linear, branching, and isobar); (2) inter-residue linkage; (3) 
anomericity; and (4) monomer identification is essential for understanding glycosylation’s role in 
cancer progression.
For MS-based glycomic analysis, a removal of glycans from their 
polypeptide backbones is necessary. Glycan synthesis is determined by an 
extensive enzymatic process that is very sensitive to malignant transformation. 
The lack of distinct rules governing which specific glycan moiety is covalently 
bound to a particular protein has confounding consequences; different copies of 
an individual protein can be modified with scores of distinct glycans and many 
different proteins may be modified by a common set of glycan structures.
G
Gal|31 -4GlcNAc|31 -2Mana 1^  ipi- cpi-2 1 -  . K
°  Manpi -4GlcNAcpi -4GlcNAcpi -Asn
NeuAca2-6Gaipi-4GlcNAcpi-2Mana1*^'^”^
2.1 Glvcan Release and Purification
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Consequently, an alteration in the glycan machinery affects all glycoproteins 
simultaneously resulting in a plethora of cell-surface and secreted proteins that 
will be aberrantly modified. From an analytical standpoint, a global glycoprotein 
glycan release should capture all A/-linked glycan structural changes that have 
occurred as a result of a cancer glycodynamics. Glycans within whole cell 
lysates are typically in very low abundance, however rich in physical and 
chemical diversity. Therefore, it is vital the release techniques employed do not 
loss quantitative information due to fractionation of the mixed glycan analyte. 
Equally important is judicious purification and contaminant removal after release. 
Residual salts, buffers, and biological contaminants have adverse effects on 
ionization processes reducing sensitivity and quality of mass spectral data. 
Through non-selective chemical and enzyme release methods heterogeneous 
glycans remain unfractionated and hence all important structural information is 
present and available for detection.
2.2 Chemical Release
Hydrazine hydrolysis is a non-selective chemical approach to release 
intact unreduced O- and A/-linked glycans (Patel, T., Bruce, J., et al. 1993).
High temperature A/-linked hydrazinolysis has proven advantageous, especially 
for the release of glycans with unique core elaborations (Hanneman, A.J., Rosa, 
J.C., et al. 2006). However, there are some drawbacks: (1) hydrazinolysis tends 
to generate high background levels which can overshadow low abundant glycans 
in mass spectra; (2) the re-A/-acetylation step, which accommodates for the
23
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partial loss of A/-acyl groups, may compromise the original composition of the 
glycan; and (3) with a small quantity of starting material any additional step 
increases the potential loss of valuable sample.
2.3 Enzymatic Release
The endoglycosidase enzyme, peptide- A/-(N-acetyl-(3-glucosylaminyl) 
asparagine amidase (PNGase F) is apt for global A/-glycan release from relatively 
small quantities of starting material. PNGase F specifically cleaves the amide 
bond between the innermost A/-acetylglucosamine residue of the glycan and the 
asparagine residue of the peptide yielding an intact unmodified glycan moiety 
and a slightly modified protein in which the asparagine residue is converted to an 
aspartate at the site of glycan attachment (Plummer, T.H., Jr. and Tarentino, A.L. 
1991). An analogous enzyme for Olinked release is not presently known. There 
are several advantages of this enzymatic approach: (1) PNGase F is specific 
only to A/-linked glycans cleaving nearly all except those carrying an a-1,3 fucose 
core, or positioned on C- or N-terminal asparagines (Maley, F., Trimble, R.B., et 
al. 1989, Tretter, V., Altmann, F., et al. 1991); (2) PNGase F release does not 
require a re-A/-acetylating step after release, thus maintaining original A/-acyl 
group moieties; and (3) PNGase F release shows little background noise upon 
mass spectral analysis. Enzymatic release, similar to hydrazine release, results 
in a glycan/peptide/buffer mixture requiring a series of separation techniques 
such as protein removal by C18 silica cartridges and salt and buffer removal by
24
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porous graphitized carbon (PGC) to ensure analyte purity prior to ESI and 
MALDI.
2.4 Permethvlation: A Basic Necessity
Chemical derivatization has been a fixture in the carbohydrate chemist’s 
repertoire for nearly a century. Originally utilized to improve glycan volatility, 
permethylation derivatization has serendipitously become an invaluable 
purification step for contemporary glycan analysis (Hakomori, S. 1964). The 
complete methylation of all labile hydroxyl groups converts hydrophilic glycans 
into lipophilic products allowing extraction by non-polar organic solvents and 
hence purifying the glycans from unwanted hydrophilic biological contaminants. 
Ciucanu and Kerek (1984) introduced a simple and efficient methodology for 
permethylation of oligosaccharides by adding a sodium hydroxide solution to a 
glycan sample dissolved in dimethyl sulfoxide (DMSO) followed by the addition of 
methyl iodide. This methodology has an extremely high product yield (> 98%), is 
specific with few chemical side products, enhances sensitivity up to an order of 
magnitude, offers predictable fragmentation patterning in tandem mass 
spectrometry (MS/MS) and sequential mass spectrometry (MSn) spectra, as well 
as facilitates simultaneous analysis of neutral and acidic sialylated glycan solutes 
(Ciucanu, I., Kerek, F. 1984, Ciucanu, I. and Costello, C.E. 2003, Hakomori, S. 
1964, Harvey, D.J. 1999, Reinhold, V.N., Reinhold, B.B., etal. 1996). The 
benefits of permethylation to MS analysis of glycan structures are immense and 
will be discussed further in the following sections.
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2.5 Analyte Ionization
Originally, mass spectrometry (MS) was limited to small molecules 
requiring thermal vaporization prior to ionization; however, with the advent of 
high-mass gas phase molecular ionization (i.e., electrospray ionization (ESI) and 
Matrix-Assisted Laser Desorption Ionization (MALDI)), the unparalleled 
selectivity, specificity, and efficiency of mass spectrometry (MS) could be applied 
to large biopolymer analysis (Fenn, J.B., Mann, M., et al. 1989, Karas, M. and 
Hillenkamp, F. 1988). For positive ion ESI, analyte and metal-salt solutions are 
forced through a capillary and aerosolized by a strong electric field as it expands 
into the warmed bath gas and high vacuum areas of the mass spectrometer. 
Water vaporization from the decreasing droplet surface induces instability as a 
consequence of the sodium charge density. Repulsive coulombic forces then 
shatters residual droplet structure with resultant metal-analyte adduction which 
are subsequently focused into the mass analyzer (de Hoffmann, E., Stroobant, V. 
2002). In MALDI, the analyte is mixed with matrix solution, spotted on the 
“target” and dried. Laser ablation of the target spot results into a plume. Here, 
for positive ion extraction, metal ion adduct to the analyte which are subsequently 
focused into the mass analyzer (de Hoffmann, E., Stroobant, V. 2002). Unlike 
ESI which produces both singly and multiply charged ions, MALDI only produces 
ions of a single charge. Both ESI and MALDI soft ionization processes result in 
large intact molecular ions that may subsequently be fragmented for structural 
determination.
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2.6 Tandem Mass Spectrometry (MS/MS)
In the field of proteomics, tandem mass spectrometry (MS/MS) is the 
dominant tool for protein structural elucidation. Tandem MS/MS is simply, two 
stages of mass analysis coupled by a dissociation event. This combination 
allows a selected molecular ion from the first analyzer to be ruptured by a 
collision event with an inert gas in a dissociation chamber and its product ions 
analyzed by a second mass analyzer. A process referred to as collision-induced 
dissociation (CID). In spatial MS/MS, such as the case with time-of-flight (TOF) 
instruments, two mass analyzers are physically separated by a dissociation 
chamber. A drawback to spatial MS/MS is the number of sequential rounds of 
dissociation is limited to the physical number of dissociation chambers. For 
linear polymers, like proteins and DNA, requiring only high mass accuracy and 
MS2 dissociation for sequencing, MS/MS supported by a spectral matching library 
is a very powerful method for analysis (Hunt, D.F., Yates, J.R., 3rd, et al. 1986, 
Walters, J.J., Fox, K.F., et al. 2002). Unfortunately, oligosaccharide structure 
replete with different linkage types (positional and anomeric), multiple linkages 
(branching topology) and multiple isomeric subunits (GlcNAc and GalNAc; Man, 
Glc, and Gal) are beyond the CID capabilities and hence the structural 
elucidating power of tandem MS/MS. To compensate improved sample 
preparation methods have been adopted (Mechref, Y. and Novotny, M.V. 2006, 
Novotny, M.V. and Mechref, Y. 2005). Chromatography partially resolves and 
dilutes glycan mixtures providing an easier interpretation of MS/MS data.
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(Mechref, Y. and Novotny, M.V. 2006, Novotny, M.V. and Mechref, Y. 2005). 
A/ano-LC-MALDI/TOF/TOF experiments have been successful at partially 
resolving branching, linkage, and isomeric detail from relatively simple complex 
glycan mixtures; however, characterization of unknown structures and complex 
biological mixtures remains to be demonstrated.
2.7 Sequential Mass Spectrometry (MSn)
A more elegant approach toward glycoanalytic investigation is sequential 
mass spectrometry (MSn) using ion trap analyzers. This gas-phase method 
provides extensive structural detail appearing to bring a complete structural 
understanding with the introduction of adjunct separation techniques. For this 
application, no analyzer surpasses the operational features of the ion trap. The 
fundamental operating characteristics of the ion trap would appear to be 
designed fro structural elucidation of complex oligosaccharides (Ashline, D., 
Singh, S., et al. 2005, Flanneman, A.J., Rosa, J.C., et al. 2006, Reinhold, V.N., 
Reinhold, B.B., et al. 1996, Reinhold, V.N., Reinhold, B.B., et al. 1995, Sheeley, 
D.M. and Reinhold, V.N. 1998). The strength of MSn methodology is its ability to 
track precursor-product masses through sequential CID explicitly linking 
individual CID spectra. That is, the product ion of the previous dissociation 
becomes the precursor ion for the subsequent dissociation until a structure is 
completely understood or ion current is exhausted. Individual CID spectra are
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rich in substructural detail (i.e., linkage, branching, and monomer identity) based 
on unique mass fingerprints while the product-precursor spectral relationship 
correlates the substructural data to its proper location within the structural 
topology of the glycan. Two bioinformatics tools, FragLib (a fragment library 
matching tool for substructural analysis) and OSCAR (an automated algorithm for 
assimilating multiple disassembly pathways into an oligosaccharide topology), 
manage the extensive data that is needed to support MSnfor oligosaccharide 
structural analysis (Lapadula, A.J., Hatcher, P.J., et al. 2005, Zhang, H., Singh,
S., et al. 2005). An MSn approach is the most suitable analytical method for 
discovering unanticipated structural motifs and minor structural isobars.
2.8 Structural elucidation via MS"
Permethylation is a technique necessary for understanding fragments of 
complex glycan structures. This replaces Methylation converts all protons and 
the products are methyl esters and ethers (Ciucanu, I., Kerek, F. 1984, Ciucanu,
I. and Costello, C.E. 2003). Upon disassembly, the methylated product ions 
exhibit compositions that suggest the point of fracture. For example, 
compositions that include a hydroxyl group (Y- ion) or a double bond (B- ion) 
indicates a glycosidic bond cleavage (Domon, B. and Costello, C.E. 1988)(Figure 
11). With a double bond in the B-ion a point of lability is introduced for further 
rupture via a classical retro-Diels-Alder (RDA) mechanism (Ashline, D., Singh, S., 
et al. 2005, Reinhold, V.N., Reinhold, B.B., et al. 1996, Velardo, M.A., Bretthauer, 
R.K., et al. 1993) (Figure 12). A-type ions are the product of RDA decomposition
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and a component of linkage assignment, anomeric configuration, and monomer 
identification via MSn (Ashline, D., Singh, S., et al. 2005) (Figure 12-14, 
respectively). Both native and methylated oligosaccharides produce B-type and 
Y-type ions upon glycosidic bond rupture, however only the methylated analogue 
show abundant cross-ring cleavages. Methylation contributes to RDA 
decomposition by enhancing tt electron instability and consequently provoking 
ring rupture, tt electron migration prior to CID RDA initiation may account for 
multiple cleavage events and hence multiple A-ion products. The specific bonds 
cleaved via the RDA mechanism assign a unique mass fingerprint to A-type ions 
(Ashline, D., Singh, S., et al. 2005). The presence, absence, and combination of 
A-type ions within a spectrum can aid in the identification of different linkages 
and hence assign position (Ashline, D., Singh, S., et al. 2005)(Figure 12). The 
advantages of permethylation are invaluable for unraveling oligosaccharide 
structure.
Metal ion adduction is another invaluable component for MSn 
oligosaccharide sequencing. Studies have shown the number of diagnostic 
fragments generated by CID is greatly improved with metal ion chelation over 
protonation (Cerny, R.L., Tomer, K.B., et al. 1987). Metal ion binding influences 
RDA decomposition by lowering the activation energy necessary for ring rupture 
through electron delocalization patterning (Botek, E., Debrun, J.L., et al. 2001). 
Metal ion adduction also influences ion intensity. However, the detailed 
mechanism of this phenomenon is poorly understood. It has been postulated 
that a metal ion becomes preferentially situated according to the specific axial/
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equatorial methoxy group configuration within an unsaturated pyranose ring 
influencing ring electron delocalization and consequently biasing one cross-ring 
cleavage over another. Regardless of mechanistic detail ion intensity patterns 
are reproducible and can be empirically used for determination of 
oligosaccharide anomericity and monomer identification (Ashline, D., Singh, S., 
et al. 2005) (Figures 13 and 14, respectively). The combination of metal ion 
adduction and permethylation are indispensable components for the analysis of 
linkage position, anomeric configuration and monomer identification.
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(A) Fragmentation Nomenclature





































Figure 11. Fragmentation nomenclature, retro-Diels-Alder reaction, and A-ion 
fragmentation. (A) A (cross-ring), B and C (glycosidic) are ions retaining charge on the 
non-reducing terminus. X (not shown) Y and Z (glycosidic) are ions retaining charge on the 
reducing terminus. Subscript numeric progression begins at the non-reducing end for A, B, 
and C ions whereas numeric progression begins at the reducing end for X,Y, and Z ions. A- 
ion superscript numeration depicts pyranose ring bonds that are broken. Modified from 
Domon and Costello 1988. (B) Retro-Diels-Alder (RDA) reaction in a 1,4 linked B2-type 
disaccharide. B-type ion precursors are very informative for linkage analysis resulting from 
their specific cross ring cleavage induced by CID. Linkage position can be assigned based 
on cross ring cleavage product ion mass (A-type ions). (C) Generic B-type ion cross-ring 
cleavages of various linkages. A-type ions must be present in the spectrum for definitive 
linkage assignment. Modified from Ashline 2005.
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Figure 12. Characterization of linkage. (A) MS spectra of terminal disaccharides from 
known milk tetrasaccharides. B-type ion fragments possess both the same anomeric 
configuration and monomer composition, differing only in linkage. Both Glc-P(1-3)-GlcNAc 
and Gal-p(1-4)-GlcNAc show a cross-ring cleavage at m/z 412 ( 0,4 A ion). However, Gal- 
P(1-4)-GlcNAc shows a cross ring cleavage at m/z 329 (3,5A ion), while Gal-p(1-3)-GlcNAc 
shows a cross ring cleavage at m/z 384 (3,SA ion). (B) MS3 spectrum of terminal 
disaccharide from known trisaccharides. B-type ion fragments possess both the same 
anomeric configuration and monomer composition, differing only in linkage. Glc-a(1-4)-Glc 
shows a cross-ring cleavage fragment at both m/z 315 ( 4 A ion) and m/z 329 ( ,SA ion), 
while Glc-a(1-6)-Glc shows only a cross-ring cleavage at m/z 329 (3,5A ion). The absence 
of a 2,4A ion is typical of a 1,6 linkage. As illustrated, the unique mass fingerprint of A-type 
ions can discriminate amongst different linkages. Modified from Ashline 2005.
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Figure 13. Anomeric configuration. MSn spectra of terminal disaccharides from known 
trisaccharide. B-type ion fragments possess both the same linkage and monomer 
composition, differing only in anomericity. Spectra of both Glc-a(1-4)-Glc and Glc-P(1-4)-Glc 
have a similar A-type ion fragmentation pattern, however pattern intensity differences in the 
ions m/z 413, m/z 415, and m/z 227 are distinct and reproducible. Preferential metal-ion 
localization is a possible explanation for disparities in A-type ion intensity and creates a 
reproducible pattern that is specific to a given anomeric configuration. Modified from Ashline 
2005.
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Figure 14. Monomer identification within disaccharide B-type fragments. The
trisaccharides Gal-a(1-4)-Gal-p(1-4)-Glc (m/z 681) and Glc-a(1-4)-Glc-a(1-4)-Glc generated 
B-type isobars at m/z 445 in MS2. Shown are the MS3 spectrum of the B-type isobars, Gal- 
a(1-4)-Gal and Glc-a(1-4)-Glc. A-ion fragments masses are the same in each spectrum, 
however ion intensities differ among the galactosylene and glucosylene spectrum. The major 
cross-ring ion in the galactosylene spectra was at m/z 329, with a minor peak at m/z 315. 
Additionally, glycosidic bond cleavages at m/z227 (Y-ion), m/z241(B-ion) and m/z259 (C-ion) 
have intensities one-fourth the most intense. The intensity pattern within glucosylene 
spectrum is significantly different, m/z 329 is still the major A-ion fragment in the spectrum, 
however it is only half the intensity of most intense ion, m/z 259. The remaining fragments all 
were less than 10% of the major ion. Although fragment masses are identical in both 
spectrum 3,5A fragment intensity at m/z 329 suggests galactosylene might be more susceptible 
to RDA decomposition than its glucosylene analogue. The comparison of these spectra 
exemplifies how monomer stereochemistry influences ion pattern intensity. Preferential metal 
ion localization to specific equatorial/axial positions and its influence on electron delocalization 
is a possible explanation for disparities in A-type ion intensity. Modified from Ashline 2005.
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2.9 Spectral Matching
A number of libraries exist to support the interpretation of mass spectra of 
carbohydrates; the fail however to support sequential MSn analysis of 
permethylated complex glycans. For this reason, a suite of bioinformatics tools 
has been devised in-house to handle permethylated carbohydrate MSn data.
One component is a spectral matching library called FragLib (Zhang, H., Singh,
S., et al. 2005). FragLib consists of MSn disassembled permethylated synthetic 
standards and spectra from well characterized biological samples. Inter-residue 
linkage, anomeric configuration, and monomer identification information 
embedded as A-ion distinct fragment patterns in a CID spectrum is matched 
against the library-stored empirical spectra to assess structural similarity. A 
spectral similarity score is computed determining the probability of a match 
(Figure 15). FragLib is a unique effort for numerous reasons: (1) FragLib spectra 
are permethylated metal ion adducts, rather than native structural fragments; (2) 
FragLib utilizes empirical spectra as a matching reference opposed to the 
respective theoretically generated spectral libraries used in GlycosidlQ (Cooper, 
C.A., Joshi, H.J., et al. 2003, Joshi, H.J., Harrison, M.J., et al. 2004) and 
GlycoFragment/GlycoSearchMS (Lohmann, K.K. and von der Lieth, C.W. 2003, 
Lohmann, K.K. and von der Lieth, C.W. 2004); (3) FragLib library is composed of 
only MSn spectra, while GlycosidlQ and GlycoFragment/GlycoSearchMS library 
spectra are based on MS/MS spectra. FragLib’s objective evaluation of 
structural detail dramatically enhances the efficiency and confidence to which 
oligosaccharide structure is accurately characterized (Zhang, H., Singh, S., et al.
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2005). Spectral matching confirmation by FragLib provides validation for novel 
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Figure 15. Screen capture of NIST MS tool for FragLib spectral library searching. MS6
spectrum of a human milk glycan (isolated as m/z 1274—>834—>760->433) was searched 
against the FragLib’s spectral library and with a 95.4% confidence matched the spectral 
pattern of Fuc-a-(1,3)-Gal-(1-OH). The spectral matching and confidence scoring of FragLib 
creates an objective method to evaluate glycan structural detail. Modified from Zhang 2005.
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2.10 Glvcan Topology
Oligosaccharide topology is considered to represent the linear and 
branching makeup of different monomers. A fragment pathway provides an 
opportunity to position and decipher glycan topology. This extracts structural 
information embedded in CID spectra to be placed within the original 
oligosaccharide topology and contributing to the overall structure (Figure 16). To 
assist in this precursor-product understanding a de novo sequencing algorithm 
named OSCAR, Oligosaccharide Subtree Constraint Algorithm, has been 
developed (Lapadula, A.J., Hatcher, P.J., et al. 2005). OSCAR utilizes the 
composition masses of precursor-product component losses to understand the 
precursor ions were are reassembled into the original glycan topology. A 
possible set of structures are initially calculated based on the glycan composition 
and OSCAR eliminates candidates structures based on known constraints 
established by fragment pathways. Only candidate structures that meet the 
constraints remain as possible structures. Given multiple fragmentation 
pathways a single topology meeting the constraints of all the pathways will be 
selected as the overall glycan topology. The algorithm does not assume 
biosynthetic dogma or make attempts to match an unknown against a database. 
Without the bias of presumed biosynthetic pathways and previously reported 
structures OSCAR is free to propose novel topologies. This is particularly 
advantageous for the discovery of unique structures related to disease.
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Figure 16. OSCAR. MSn disassembly of an A/-linked glycan following the fragmentation 
pathway: m/z 1187-*894.4~->649.2—>431.1-^259.0. The tracking of the product-precursor
masses through successive rounds of CID threads structural information embedded in each CID 
spectra into the topology of the glycan. More complex glycans are typically characterized through 
multiple fragmentation pathways. OSCAR (middle column) begins with a candidate set of isobaric 
structures. At each fragmentation step new constraints are added removing candidate structures 
that fail to meet the impinging inference rules. Eventually only a single topology will meet all the 
constraints and remains as the correct glycan topology. Modified from Lapadula 2005.
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2.11 Structural Isomer Analysis
The discovery and characterization of structural isomers within 
carbohydrate samples has been a longstanding and difficult problem. 
Constitutional and stereoisomers are frequently grouped under the heading of 
structural isomers having the same mass or m/z value in a mass spectral profile. 
For this reason, assigning a single detailed structure from a composition is 
inaccurate. As previously described, disassembly of a larger oligosaccharide into 
smaller pieces and the related change in composition provides information 
related to topology and linkage. These details expose an opportunity to resolve 
structural isomers a prospect usually considered outside the domain of mass 
measurement (Ashline, D.J., Lapadula, A.J., et al. 2007)(Figure17).
Glycosylation in cancerous cells is abnormal; as a result structural isomers 
are highly likely, may be synthesized. Glycan structures can only be reported if 
they are detected; a factor dependent on the CID capabilities of the 
instrumentation. If MS2 is the CID limit, then only the structures differentiable 
with certainty at MS2 can be reported. That is, other structures maybe present 
just undetectable by the chosen instrumentation and analytical method. MS 
structural characterization of cancerous samples has only been investigated by 
MS/MS analytical methods. MSn methodology can expose structural isomers 
unique to cancer that have previously gone undetected by other methodologies.
40


























/  866.51333.61125.6 1537.81797.11129.61797.0
1000 m/z 1500 2000
MS5 m/z 1040.0
1500 2000











loss of fucose-subs 
reducing-end GlcNAc
678.4 /
/  770.9 1070.6
490.4 852.5
843.5





\  1028.5458.3 449.3 / 621.31111.6 1537.8
/  1277.6 491.3 
431.217 /
500 1000m/z 1500 2000 500 m/z 1000
Structures consistent with MS" fragmentation of m/z 1040 glycan
Expected structure(s) Additional isobaric structure
Figure 17. MSn disassembly of a purified IgG G1 structure from normal human plasma.
The fragmentation pathway: m/z 1040—>910-»780^-1070 indicates the presence of a minor
isobaric structure previously undetectable by less intrusive MS/MS methodologies. All expected 
structures are detectable. An additional isobaric structure having two terminal HexNAcs as 
opposed to the expected single terminal HexNAc and single terminal Hexose has also been 
detected. The MS2 spectra m/z 910.0 peak represents a neutral loss of HexNAc. Disassembly of 
m/z 910 in MS3 demonstrates the neutral loss of a second terminal HexNAc at m/z 780.5. M/z 
1070.6 of the MS4 spectrum represents the neutral loss of the anticipated fucose-substituted 
reducing-end GlcNAc. MS5 spectrum is consistent with a biantennary glycan opposed to a 
bisecting glycan. Modified from Ashline 2007.
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CHAPTER 3
VM MOUSE BRAIN TUMOR CELLS
The primary cause of death from cancer is tumor metastasis (Chambers, 
A.F., Groom, A.C., et al. 2002, Steeg, P.S. 2006). While conventional therapies 
can be very successful combating primary tumors, few treatments have shown 
success against metastatic disease (Chambers, A.F., Groom, A.C., et al. 2002, 
Steeg, P.S. 2006). Metastasis is the step-wise process by which tumors 
dissociate from the primary neoplasm, infiltrate surrounding tissue, enter the 
circulatory system, invade distant organs, and proliferate into a secondary tumor 
mass. The dearth of in vivo metastatic models representing the complete 
metastatic cascade drastically hinders the development of novel therapies 
against metastatic cancers. In vivo metastatic models requiring tumor cell 
injection fail to represent the initial steps of primary neoplasm formation and 
progression as well as intravasation (Khanna, C. and Hunter, K. 2005, Steeg, 
P.S. 2006). Spontaneous models exhibit most of the metastatic cascade; 
nevertheless, these models originate from tumor cell xenographs into an 
immuno-compromised animal model. The immune system plays a major role 
during the metastatic process (Steeg, P.S. 2006). Therefore, an immuno­
compromised organism may inappropriately represent tumor cell evasion of the 
host’s immune system as well as invasion of distant organs (Khanna, C. and
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Hunter, K. 2005). Although these models are beneficial, there is still a great 
need for a more fitting in vivo metastatic model.
Recently, two highly metastatic autochthonously arising brain tumors in 
the VM mouse strain were reported (El-Abbadi, M., Seyfried, T.N., et al. 2001, 
Huysentruty, L.C., Banerjee, D., Seyfried, TN. Submitted). Malignant 
transformation of brain tissue is rare in both mice and man; however, the inbred 
VM strain exhibits a higher incidence of spontaneous tumors compared to other 
mouse strains, approximately 1.5% opposed to 0.01% (Fraser, H. 1971, Morgan, 
K.T., Frith, C.H., et al. 1984). These tumors, therefore, arise without chemical 
carcinogen tumor induction, tumor cell injection, or tumor cell transplantation. In 
contrast to most malignant tumors that invade distant organs, brain tumors 
remain within the central nervous system (CNS) and aggressively infiltrate only 
the surrounding neuronal tissue (Chamberlain, M.C. 2006, Vural, G., Hagmar, B., 
et al. 1996). Most VM mouse brain tumors are consistent with these brain 
malignancy characteristics even when injected subcutaneously (Fraser, H. 1971, 
Morgan, K.T., Frith, C.H., et al. 1984). Interestingly, the VM mouse tumors, 
identified as VM-M2 and VM-M3, aggressively metastasize to distant organs 
including the brain, spinal cord, lung, spleen, kidney, and liver after 
subcutaneous implantation into the flank (El-Abbadi, M., Seyfried, T.N., et al. 
2001, Fidler, I.J. 2003, Huysentruty, L.C., Banerjee, D., Seyfried, TN. Submitted). 
Tumor cell lines were subsequently established from the subcutaneously grown 
highly invasive VM-M2 and VM-M3 tumors as well as another malignant, but 
noninvasive tumor identified as VM-NM1. Currently, the content and distribution
43
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of ganglioside glycoconjugates of the VM-M2, VM-M3, and VM-NM1 cell lines are 
undergoing investigation. Studies showed an elevation in sphingomyelin and 
phosphatidic acid content and Gm2 , Gmi, and GDiagangliosides in the VM-M2 and 
VM-M3 cell lines, but not in the VM-NM1 tumor cell line (Huysentruty, L.C., 
Banerjee, D., Seyfried, TN. Submitted). GM3 and Gd3 gangliosides were present 
in the VM-NM1 cell line, while undetectable in the VM-M2 and VM-M3 samples. 
Gangliosides, such GM3 and GD3 , regulate growth signaling cascades through 
interactions with tyrosine kinase receptors (Varki, A., Cummings, R., Esko, J., 
Freeze, H., Hart, G. and Marth, J. 1999). GM3 and Go3 are over-expressed in 
lung cancers, melanomas and neurogenic tumors and promote tumor growth and 
proliferation (Hakomori, S. 1990, Hakomori, S. 1996), while inhibit tumor 
progression through reduced angiogenesis and increased cell-cell adhesion 
(Abate, L.E., Mukherjee, P., et al. 2006, Bai, H. and Seyfried, T.N. 1997). The 
behavioral characteristics of VM-NM1 are consistent with Gm3 and Gd3 
expression exhibiting an accelerated growth rate and invasive, but non­
metastatic behavior. The converse manner of VM-M2 and VM-M3, slow growth 
rate and aggressive metastatic behavior, is also consistent with Gm3 and Gd3 role 
in tumor growth and progression (Huysentruty, L.C., Banerjee, D., Seyfried, TN. 
Submitted). GM3 is the precursor for the synthesis of complex gangliosides, such 
as Gm2 , Gm-i, and GDia. (31,4-A/-acetylgalactosyltransferase ((31,4GalNAc-T) 
transfers a GalNAc residue to a galactose residue of GM3 to from GM2- 
Galactosyltransferase II (Gal-TII) then adds a galactose residue to GM2 forming 
the Gmi glycoconjugate. GMi is then converted to Goia by the addition of sialic
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acid residue. Gm2 ,Gmi, and Gpiagangliosides promote angiogenesis and cell 
proliferation (Lang, Z., Guerrera, M., et al. 2001, Liu, Y., Li, FL, et al. 2004, 
Manfredi, M.G., Lim, S., et al. 1999, Ziche, M., Morbidelli, L., et al. 1992). 
Gangliosides, such as Gp-ia, also promote tumor repulsion and invasion because 
of their highly anionic nature (Bestagno, M., Occhino, M., et al. 2003, Carr, A., 
Rodriguez, E., et al. 2003). Additionally, shedding of gangliosides into the 
circulatory system confers an immunosilencing response protecting the tumor 
(Bestagno, M., Occhino, M., et al. 2003, Carr, A., Rodriguez, E., et al. 2003).
The slow growth rate and aggressive metastatic behavior of VM-M2 and VM-M3 
is consistent with a gangliosidic profile exhibiting reduced precursor gangliosides, 
Gm3 and Gd3 > and elevated complex gangliosides, Gm2, Gmi, and Goia- The 
behavioral converse of VM-NM1, accelerated growth rate and residence, is also 
consistent with Gm2, Gmi, and Gdi3 role in tumor progression. The reduced levels 
of the Gm3 precursor and elevated levels Gm2,Gmi, and Gdi3 products may result 
from the over-expression or activity of glycosyltransferases responsible for the 
synthesis of these complex gangliosides. VM-M2 and VM-M3’s characteristic 
metastatic ganglioside profile, spontaneous manifestation and aggressive 
metastatic nature make them suitable models for investigating tumor metastasis.
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CHAPTER 4
PROJECT AIM
Aberrancies in glycan processing lead to a unique array of terminal 
elaborations and structural patterns that are essential determinants in malignant 
function (Fuster, M.M. and Esko, J.D. 2005). Many structural differences have 
been reported, none-the-less the structure-function relationship regarding glycan 
structure and pathology is still quite nebulous. Ion trap MSn methodology 
provides an unprecedented opportunity for glycoanalytic understanding (Ashline, 
D., Singh, S., et al. 2005, Hanneman, A.J., Rosa, J.C., et al. 2006, Reinhold, 
V.N., Reinhold, B.B., et al. 1996, Reinhold, V.N., Reinhold, B.B., et al. 1995, 
Sheeley, D.M. and Reinhold, V.N. 1998). Utilizing this technique the details of 
individual glycan epitopes and isomeric structures can be resolved. Cancerous 
tissues need to be analyzed with greater scrutiny to unearth anomalies not 
available to previous investigators. This study extends ion trap applications to 
the modulation of carbohydrates in cancer. To approach this problem two goals 
should be considered: (1) systematically uncover and characterize anomalous N- 
linked glycan structures distinct to cancers; and (2), distinguish differences in 
structural isomer expression between non-metastatic and metastatic cancers.
To attain these goals VM-M2 and VM-M3 cell lines will be used as a metastatic 
model and the VM-NM1 cell line as a non-metastatic model.
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CHAPTER 5
EXPERIMENTAL METHODS
5.1 Propagation of VM Mouse Tumor Cells
VM mouse tumor cell lines were established from spontaneous brain 
tumors in the cerebrum of three adult mice, 2 males and a female. Tumors were 
identified as poorly defined masses (about 3 x 1 x 1  mm) with yellowish soft 
regions. To preserve in vivo viability, each tumor was resected and implanted 
intracranially into host VM mice as previously described (El-Abbadi, M., Seyfried, 
T.N., et al. 2001). As cranial domes appeared in host mice, tumors were 
resected and implanted intracranially to another set of host VM mice. After a 
total of three intracranial passages, the tumors were grown subcutaneously and 
cell lines were prepared from each tumor.
Cell lines were grown in Dulbecco’s Modified Eagle medium (DMEM, 
Sigma, St. Louis, MO) with high glucose (25 mM) supplemented with 10% fetal 
bovine serum (Sigma) and 50 mg/mL penicillin-streptomycin (Sigma). The cells 
were cultured in a C02 incubator with a humidified atmosphere containing 95% 
air and 5% C02 at 37°C. The cells were grown in 150 x 10 mm culture dishes 
until confluent and cells were then removed by a cell scraper. Cells were 
pelleted, rinsed with phosphate-buffered saline (PBS) and frozen at -80°C.
47
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5.2 Isolation and Purification of Proteins
Cells were lysed from frozen pellets with 1 mL of CHAPS membrane 
disruption buffer containing 4 % CHAPS, 8 M urea, 40 mM Tris-HCL pH = 8, 65 
mM dithiothreitol (DTT) and mammalian protease inhibitor cocktail (Sigma, St. 
Louis, MO). After 5 cycles of sonication of 6 minutes at 8°C, samples were 
centrifuged at 12,000 rpm for 20 minutes in an Eppendorf® mini-spin. A Bradford 
Assay (Pierce, Rockford, IL) was performed on 50 pL of supernatant to quantify 
protein amount using the photometer mode of a UV-Viz Spectrophotometer 
(Shimadzu Corporation, Kyoto, Japan).
Total cell lysate protein purification was accomplished by dialysis using .5- 
3.0 mL 7000 MWCO dialysis cassettes (Pierce, Rockford, IL). Dialysis consisted 
of 3 hours in 20 mM ammonium bicarbonate (NH4HCO3), 0.05% sodium dodecyl 
sulfate (SDS) at 4°C; followed by overnight dialysis in 10 mM NH4HCO3, 0.02% 
SDS at 4°C; then for 3 hours in 5 mM NH4HCO3 at 4°C. Cassette membrane 
was hydrated prior to use. Equal quantities of protein (0.5 mg) were prepared for 
each cell type.
5.3 /V-linked Glvcans Release
Purified proteins were dissolved in 100 pL of 1X denaturing buffer (5% 
SDS and 10% (3-mercaptoethanol) and denatured by heating at 100° C for 20 
minutes. Samples were cooled to room temperature at which time 10 pL of 10X 
G7 buffer (0.5 M sodium phosphate, pH= 7.5), 10 pL of NP-40, and 4 pL of
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glycerol-free Peptide: N-glycosidase F (PNGase F) (New England Biolabs, 
Beverly, MA) were added. Samples were vortexed (10 seconds), centrifuged (45 
seconds) and then placed at 37° C for 48 hours.
5.4 /V-linked Glycan Separation
Following release samples were brought up to 1 mL of volume with a 
solvent consisting of 95% (v/v) HPLC grade water, 5 % (v/v) HPLC grade 
acetonitrile, 0.1 %(v/v) trifluoracetic acid. Proteins were removed through non 
retentive solid phase extraction by passing the sample through a 4 mL C18 solid 
phase extraction column (SPE) (Alltech Associates, Deerfield, IL). The columns 
were conditioned in advance with five washing of 2 mL each of the following 
solutions: (1) 100% HPLC grade methanol; and (2) 95% (v/v) HPLC grade 
water, 5 % (v/v) HPLC grade acetonitrile, 0.1 %(v/v) trifluoracetic acid. The 
sample was loaded and column was washed with 5 mL of 95% (v/v) HPLC grade 
water, 5 % (v/v) HPLC grade acetonitrile, 0.1 %(v/v) trifluoracetic acid. The flow­
through was immediately collected and eluant dried in a SpeedVac® 
Concentrator (Savant Instruments, Holbrook, NY).
5.5 A/-linked Glvcan Purification
Additional purification and desalting of the A/-linked glycan samples were 
performed by retentive solid phase extraction using porous graphitized carbon 
(PGC) columns as described previously with minor adaptations (Packer et al.
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1998). Dry PGC (Carbograph 120/400, Alltech Associates, Deerfield, IL) was 
sequentially rinsed with three washes of 5 ml of each of the following solutions: 
(1) 1 M sodium hydroxide; (2) HPLC grade water; (3) 80% (v/v) HPLC grade 
acetonitrile, 20% (v/v) HPLC grade water, and 0.1 %(v/v) trifluoroacetic acid; (4) 
25% (v/v) HPLC grade acetonitrile, 75% (v/v) HPLC grade water, and 0.1 %(v/v) 
trifluoroacetic acid; (5) 25% (v/v) HPLC grade acetonitrile, 75% (v/v) HPLC grade 
water; (6) HPLC grade water. After each washing the tube was vortex and 
centrifuged and supernatant removed. Pre-conditioned PGC was load into a 1.5 
mL reservoir column (Alltech Associates, Deerfield, IL) and conditioned with an 
additional 3 mL of HPLC grade water. Dried glycan sample was reconstituted in 
1 mL of HPLC grade water and loaded into cartridge. Salts were removed by 5 
washing of 1 mL of HPLC grade water and flow-through discarded. Neutral 
glycans were collected by elution with 5 washings of 1 mL of 25% (v/v) aqueous 
acetonitrile. Acid glycans were collected by elution with 5 washing of 1 mL of 
25% (v/v) aqueous acetonitrile, 0.05% trifluoracetic acid. Immediately following 
collection neutral and acidic glycan eluants were dried in a SpeedVac® 
Concentrator (Savant Instruments, Holbrook, NY).
5.6 A/-linked Glycan Reduction
A/-linked glycans were reduced with a solution of sodium borohydride 
(NaBH4) (200 pL of 10 mg/mL NaBH4 in 0.01 M NaOH) for 1 hour on ice followed 
by room temperature overnight. The reduction reaction was terminated by drop- 
wise addition of acetic acid until sample pH = 5. Borate esters were removed by
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successive evaporations under nitrogen gas with the following solutions: (1) 3 mL 
HPLC grade ethanol; (2) three times with 2 mL of 1% (v/v) acetic acid in 
methanol; (3) three times with 2 mL of HPLC grade toluene. The reduced 
glycans were reconstituted in 1 mL of HPLC grade water and desalted on a 
DOWEX AG 50 W X8-400 cation exchange resin (Sigma-Aldrich, St. Louis, MO). 
Cation exchange resin was pre-conditioned by washings 10 times with 5 ml of 
HPLC grade water. Pre-conditioned resin was loaded into a 1.5 mL reservoir 
column (Alltech Associates, Deerfield, IL). Glycan sample was loaded and eluant 
was immediately collected and dried in a SpeedVac® Concentrator (Savant 
Instruments, Holbrook, NY)
5.7 Permethvlation
Reduced glycan permethylation was carried out as described by Ciucanu 
and Kerek (1984). Briefly, dried glycans were further dehydrated by desiccation 
with P20 5 under a vacuum atmosphere overnight. Dried glycans were dissolved 
in 0.5 mL of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis MO). Pre­
dried 99.9% sodium hydroxide powder was added to glycan solution, then 
flushed with argon gas, capped, wrapped in parafilm and vortexed for 30 
minutes. While keeping the sample cool 100 pL of methyl iodide was added to 
the sample, and then flushed with argon, wrapped in parafilm and aluminum foil 
and vortexed for 1 hour. On ice the reaction mixture was diluted with 2 mL 10% 
(v/v) acetic acid aqueous solution and 2 mL HPLC grade dichloromethane. 
Sample mixture was shaken vigorously and pressure released. Methylated
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glycans were removed in the organic phase and placed in a clean test tube. 1 
mL HPLC grade dichloromethane was added to original test tube, shaken, and 
organic layer removed and pooled in the clean test tube with the previous organic 
phase. Organic phase test tube was washed five times with 1.5 mL of HPLC 
grade water removing the water layer after each washing. Methylated glycans 
were then dried under nitrogen gas and stored at -20° C. Methylated glycans 
were resuspended in 100 uL 75% (v/v) HPLC grade methanol aqueous solution 
for mass spectrometry analysis.
5.8 MALDI-TOF Mass Spectrometry
Reduced glycan spectra were generated using a MALDI-CFR (Kratos- 
Shimadzu Analytical, Manchester, UK) equipped with an ultraviolet 337 nm 
wavelength nitrogen laser. Before each use the instrument was calibrated 
externally for positive reflectron mode using a mixture of three peptide standards 
(Angiotension II, P14R, and ACTH). For each analysis the glycan sample was 
reconstituted in 100 pi of HPLC grade water. 1 pL of reconstituted sample was 
mixed with 1 pL of 2,5-dihydroxy benzoic acid matrix (DHB) (12 mg/mL in 50% 
(v/v) acetonitrile aqueous solution) and spotted onto a stainless steel MALDI 
target plate. Samples were ablated with 40-60% of the maximum power while 
the laser rastered over the target surface accumulating 1000 profiles generated 
by 5 laser shots per profile with the post extraction parameter optimized at m/z 
2500. Processing of spectra profiles was performed with Kratos Launchpad 
software.
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5.9 MALDI-IT-TOF Mass Spectrometry
MALDI-IT-TOF sequential mass spectrometry (MSn) spectra of reduced 
permethylated glycans were generated using an Axima QIT instrument (Kratos- 
Shimadzu Analytical, Manchester, UK). Before each use the instrument was 
calibrated externally with fullerite in “Mid Mass” mode and with insulin B in the 
“High Mass” mode. For each analysis the permethylated glycan sample was 
reconstituted in 100 uL 75% (v/v) HPLC grade methanol aqueous solution. 1 pL 
of reconstituted sample was mixed with 1 pL of 2,5-dihydroxy benzoic acid matrix 
(DHB) (12 mg/mL in 50% (v/v) acetonitrile aqueous solution) and spotted onto a 
stainless steel MALDI target plate followed by 0.4 pL HPLC grade ethanol. 
Ethanol recrystallization was found to improve signal to noise ratio. Samples 
were ablated with 40% of maximum power while the laser rastered over the 
target spot accumulating between 400-3000 profiles, depending on signal 
intensity, with 2 laser shots per profile. Ion fragmentation was generated by low 
energy collision induced dissociation (CID) with argon gas. The collision energy 
in the ion trap was dependent on the precursor ion intensity and number of 
rounds of sequential mass spectrometry. Processing of MSn spectra was 
performed by Kratos Launchpad software.
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5.10 ESI-IT Mass Spectrometry
MSn glycan mass spectra were obtained with an LTQ (ThermoFinnigan, 
San Jose, CA) instrument equipped with TriVersa Nanomate® automated 
nanoelectrospray ion source supported with automation and related 
computational tools. Samples were infused at a flow rate of 0.30 |il_/min and 
spectra were collected using Xcalibur 2.0 software (ThermoFinnigan, San Jose, 
CA). Signal averaging was accomplished by adjusting the number microscans 
within each scan, generally ranging between 3-20. Collision parameters were left 
at default values with normalized collision energy set to 35% or to a value leaving 
a minimal precursor ion peak. Activation Q was set at 0.25, and activation time 
for 30 ms.
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CHAPTER 6 
THE CANCER GLYCOME
For decades aberrant glycosylation has been associated with cancer. 
While the associations are extensive little information exists on the actual 
carbohydrate structures themselves. For example, MgatS expression enhances 
tumor metastasis (Dennis, J.W., Granovsky, M., et al. 1999); however, the actual 
glycan structures affected by this glycosyltransferase are not known. Complete 
characterization of glycan structures associated with cancer progression requires 
a two pronged investigative approach equally comprehensive in breadth and 
depth. Four major criteria each having multiple components must be met to 
achieve this aspiration: (1) identification of all molecular ions consistent with 
known glycans in each sample; (2) determine their relative abundance; (3) 
discern cancer specific glycosylation patterns; and (4) structural characterization 
of all structures. Once characterized aberrant glycosyltransferase activities may 
be correlated to better understand cancer progression. Herein, a murine brain 
tumor is utilized to evaluate this MSn-based glycoanalytic approach.
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6.1 Glvcome Mapping
The initial step toward investigating alterations in glycosylation is 
identifying the total glycan content, or glycan breadth, in each sample. This task 
can be performed by molecular composition analysis. Sample permethylation 
coupled with MALDI/TOF-MS profiling is a useful tool for molecular composition 
analysis that is highly sensitive, accurate, reproducible, and consistent with 
orthogonal methods such as chromatographic analysis with reducing-end labels 
(Wada, Y., Azadi, P., et al. 2007). As discussed previously, sample 
permethylation enhances ionization efficiencies, increases ion intensity, and 
stabilized labile neuraminic acid residues allowing for analysis of neutral and 
acidic glycans in the same spectra. Within a MS profile a molecular ion peak, 
m/z value, represents an individual glycan composition, while the collection of 
molecular ions in the spectra encapsulates all the glycan compositions present in 
the sample. Hence, MS profiling of permethylated glycans creates a glycome 
map depicting all the glycans present in the sample. It must be emphasized that 
molecular composition analysis simply determines the presence of potential 
glycans composed of specific monosaccharide building blocks; it does not 
elucidate how the monosaccharide building blocks are positioned relative to 
another (i.e., actual glycan structure). Under the umbrella of a single molecular 
ion peak, a collection of structures with the same atomic composition arranged in 
different configurations, termed structural isomers, exist. The identification and 
prevalence of structural isomers can not be discerned by MALDI MS profiling.
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Characterization of structural isomers requires further analysis and will be 
discussed in greater detail in the following chapters.
MALDI-TOF/MS glycomic profiling identified 173 individual molecular ions 
present in the astrocyte control (C8-D30), malignant highly invasive astrocytoma 
(VM-NM1), as well as the two unique metastatic brain tumors (VM-M2 and VM- 
M3) consistent with neutral and sialylated glycans within a mass tolerance 
window of one Dalton according to GlycoMod
(http://www.expasy.org/tools/glycomod/)(Figure 18). Search tools like GlycoMod, 
which match experimental molecular ion masses to known oligosaccharide 
compositions, have greatly reduced the time required for identification of 
molecular ions consistent with known glycans. Experimental values of all glycan 
compositions that underwent subsequent characterization analysis were within ± 
0.2 Daltons of the hypothetical mass proposed by the database. Determining the 
prevalence of the identified glycan compositions is, however, a little more 
challenging.
6.2 Molecular Composition Prevalence: Relative Quantitation
Molecular composition abundance can be delineated from MALDI- 
TOF/MS profiles by evaluating the relative ion intensity of each relevant peak 
with regard to another in a sample. Small fluctuations in ion intensity are intrinsic 
to the MALDI desorption-ionization process. This methodological inconsistency 
can potentially create ion intensity discrepancies on a run-to-run or spot-to-spot 
basis. To ensure the validity of the glycomic profile ion intensity values run-to-
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run, ion intensity values from three individual cell culture work-ups of each cell- 
type spaced out over time were analyzed. To ensure validity of relative ion 
intensities glycomic profiles spot-to-spot, multiple MALDI target spots for each 
sample were analyzed.
The relative abundance of all 173 individual glycan molecular composition 
from the MS profiles of the astrocyte control (C8-D30), malignant highly invasive 
astrocytoma (VM-NM1), as well as the two unique metastatic brain tumors (VM- 
M2 and VM-M3) were determined in three ways: (1) %of Total Glycan Pool 
(%TGP) defined as the intensity of each individual molecular composition 
mass/charge value (m/z) normalized to the intensity sum of all the glycans within 
the m/z range [1100-3500] in the sample; (2) % of Neutral Glycan Pool (%NGP) 
defined as the intensity of each individual molecular composition mass/charge 
value (m/z) normalized to the intensity sum of all the neutral glycans within the 
m/z range [1100-3500] in the sample; and (3) % relative to M5N2 defined as the 
intensity of each individual molecular composition m/z value normalized to the 
intensity of M5N2, the major ion peak in the Astrocyte control.
Most relative glycan quantification has consisted of determining relative 
amounts of oligosaccharides in a sample by examining relative ion abundances 
in a single spectrum. However, this collative method is not ideal for measuring 
true relative amounts of particular glycans between samples due to the ion 
intensity discrepancies mentioned. In the field of proteomics isotopic labeling 
techniques are commonly used for relative quantitative investigation (Gygi, S.P. 
and Aebersold, R. 1999). By labeling pair-wise samples with tags of different
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mass and then pooling, quantitative differences between samples may be 
assessed through comparison of the relative peak intensities of relevant peaks 
within the same MS spectrum. Several groups, including ours, are working 
toward developing a labeling technique to compare quantitative global glycan 
expression between biological samples in a single run (Hitchcock, A.M., Costello, 
C.E., et al. 2006, Hsu, J., Chang, S.J., et al. 2006, Kaji, H., Saito, H., et al. 2003, 
Uematsu, R., Furukawa, J., et al. 2005, Xiong, L., Andrews, D., et al. 2003), Until 
an established method for true glycan relative quantitation surfaces interpretative 
comparisons of glycan composition prevalence between samples as described in 
the previous paragraph must suffice.
6.3 Cancer-Specific Glycomic Patterns
Comparative analysis of glycome maps from normal and cancer samples 
provide insight into cancer-induced glycomic patterns. A glycomic pattern may 
be defined as a differential expression in the prevalence of a multitude of 
molecular compositions that all possess a common denominator, such as 
multiple fucose monomers or neuraminic acid residues. In a few recent studies, 
a causal relationship between changes in glycomic patterns and cancer cell 
growth and metastasis has recently been demonstrated (An, H.J., Miyamoto, S., 
et al. 2006, Dube, D.H. and Bertozzi, C.R. 2005, Kobata, A. and Amano, J. 2005, 
Kyselova, Z., Mechref, Y., Al Bataineh, M. M., Dobrolecki, L.E., Hickey, R.J.,
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Vinson, J., Sweeney, C.J., and Novotny, M.V. 2007, Zhao, J., Qiu, W., et al. 
2007). A comparative analysis of MALDI-MS permethylated N-linked glycome 
profiles of the Astrocyte control (C8-D30), malignant highly invasive Astrocytoma 
(VM-NM1), and two unique metastatic brain tumors (VM-M2 and VM-M3) was 
used to establish glycosylation patterns unique to malignant non-metastatic 
astrocytoma and malignant metastatic brain cancer cell lines (Figure 18). Once 
cancer specific trends have been established structural characterization of 
isomers present within relevant molecular compositions associated with the 
glycosylation pattern can be undertaken.
To better distinguish glycosylation patterns distinct to cancer all identified 
glycan compositions were sub-categorized into different factions according to 
glycan type (i.e., high mannose, hybrid, complex bi- and tri- antennary type (with 
or without fucosylation), etc). The prevalence of the different glycan types were 
then compared between samples establishing differences in glycosylation 
patterns associated with cancer.
Four distinct patterns unique to cancer are immediately discernable upon 
this type of analysis (Table 1 and Table 2): (1) decreased relative abundance of 
high mannose glycans prevalence; (2) increased prevalence of neutral di- 
fucosylated glycans with a concomitant suppression of neutral mono-fucosylated 
glycans; (3) increased relative amount of neutral bi-antennary, tri-antennary, and 
tetra-antennary glycans; and (4) increased sialylation, particularly truncated 
glycans. These four patterns are consistent with previous studies indicating a
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shift in glycosylation patterning toward more complex glycan compositions 
cancer.
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Figure 18. Positive ion MALDI-MS profiles of permethylated reduced A/-linked glycans.
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Prevalence of A/- 























Neutral Hybrid 12.91 1.42 12.29 5.42 8.59 16.04 9.86 4.18
Sialylated Hybrid 4.22 2.65 5.69 3.84 5.05 Mil 5.23 48.57
Neutral Bi-Antennary 5.86 1.20 8.75 6.45 5.70 8.67 4.85 38.27
Sialylated Bi-Antennary 3.56 24.21 6.63 3.16 4.64 24.24 4.75 34.71
Neutral Tri-Antennary 5.37 12.58 7.82 11.52 5.56 7.38 5.18 14.94
Sialylated Tri-Antennary 3.56 11.76 6.63 5.60 4.64 13.54 4.75 13.02
Neutral Tetra-Antennary 1.80 12.58 2.22 11.52 1.69 7.38 1.79 54.94
Sialylated Tetra-Antennary 1.18 34.83 1.97 6.98 1.57 11.21 1.71 66.45
Neutral > 5 GlcNAc 
residues 1.07 31.10 1.70 10.34 1.29 8.90 1.36 62.30
Sialylated >5 GlcNAc 
residues 0.74 36.60 1.22 3.87 0.98 5.82 1.06 70.41
Fucosylated 40.96 9.31 41.79 2.27 39.14 2.98 27.22 19.97
Neutral Mono-Fucosylated 29.14 5.42 24.36 6.68 26.26 6.57 15.35 6.62
Neutral Di-Fucosylated 4.85 2.99 5.91 0.58 4.12 4.12 3.67 47.83
Sialylated Mono- 
Fucosylated All 29.06 7.51 8.13 6.08 20.05 5.37 50.97
Sialylated Di-Fucosylated 1.11 33.49 2.13 5.27 1.26 8.37 1.30 68.88
Sialylated Tri-Fucosylated 0.66 32.43 1.06 8.09 0.82 12.02 0.92 72.35
Neutral Truncated 10.86 2.08 10.08 4.81 6.49 11.58 5.43 8.28
Sialylated Truncated 2.58 11.91 3.14 6.14 7.19 32.25 5.02 7.49
Table 1. Prevalence of A/-linked glycans in total glycan pool. The first value represents mean 
relative intensity normalized to entire glycan pool. The second value represents the coefficient of 
variation, defined as the standard deviation divided by the mean value multiplied by 100.
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Categories Astrocyte Astrocytoma VM-M2 VM-M3
High Mannose 46.27 9.37 40.51 0.33 43.55 5.93 57.81 18.54
Neutral Hybrid 15.64 5.59 16.81 6.196 11.94 11.11 12.96 22.66
Neutral Bi-Antennary 7.13 2.96 12.28 1.72 8.21 17.03 6.88 53.54
Neutral Tri-Antennary 6.48 18.49 10.75 10.70 7.76 11.87 7.37 70.88
Neutral Tetra- 
Antennary 2.63 8.37 3.73 9.35 3.60 38.26 3.22 64.05
Neutral > 5 GlcNAc 
residues 1.31 35.03 2.39 8.38 1.85 17.26 1.97 75.32
Neutral Mono- 
Fucosylated 35.75 9.97 34.51 5.52 37.90 1.22 21.71 12.56
Neutral Di- 
Fucosylated 6.15 8.59 8.80 0.00 6.30 11.52 5.74 63.28
Neutral Truncated 9.32 4.79 10.80 1.06 6.65 9.89 5.61 21.98
Table 2. Prevalence of A/-linked glycans in neutral glycan pool. The first value represents mean 
relative intensity normalized to the neutral glycan pool. The second value represents the 
coefficient of variation, defined as the standard deviation divided by the mean value multiplied by 
100.
6.3.1 High Mannose Glycans
Typical of ‘brain-type’ glycosylation high mannose glycans predominate 
the spectra of the astrocyte control (C8-D30), non-metastatic malignant 
astrocytoma (VM-NM1), as well as the two metastatic malignant tumor cell lines 
(VM-M2 and VM-M3) (Figure 19). As illustrated in Table 1, high mannose 
glycans represent 38.11% of the total glycan pool in the astrocyte control, while 
depreciate to 28.88 % in the non-metastatic astrocytoma (VM-NM1) and 30.55% 
in metastatic cell line VM-M2. Interestingly, high mannose glycans represent
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43.41% of the total glycan pool for the VM-M3. The observed abundance of high 
mannose glycans for all the samples appear elevated compared to previous N- 
glycan studies on whole mouse brain tissue (Chen, Y.J., Wing, D.R., et al. 1998, 
Zamze, S., Harvey, D.J., et al. 1998). It is well documented glycosylation of 
glycoproteins expressed in tissue and glycosylation of non-tissue glycoproteins 
grown in cell culture may differ in glycan expressivity (Norgard-Sumnicht, K.E., 
Roux, L., et al. 1995). The high expressivity is likely the result of growth in 
culture. More importantly, the relative abundance of high mannose glycans were 
consistent across all three sample sets run-to-run as well as spot-to-spot 
evidenced by a percentage error of less than 15% for all samples. Percentage 
error is an indicator of how well the mean represents the ion intensity values from 
which it came. Therefore, the relative high expression of oligomannosidic 
glycans is representative of the biology, not an artifact of the sample work-up.
The relative abundance of individual oligomannose compositions is also 
different between samples as Table 3 depicts. The M5N2 structure is the major 
oligomannosidic glycan in C8-D30, VM-NM1, and VM-M3 representing 39.23%, 
29.22%, and 29.28% of the oligomannosidic pool respectively, while M6N2 is the 
major oligomannosidic glycan in VM-M2 representing one-quarter of the 
oligomannosidic pool. The M5N2 structure is the substrate of GnT-l and complex 
glycan formation (Ioffe, E. and Stanley, P. 1994). M6N2 requires the action of an 
a2-mannosidase to cleave a final mannose before complex glycan may be 
formed (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J.
1999). The elevation in M6N2 could be a potential indicator of distorted glycan
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processing by ER a2-mannosidase during cancer metastasis or irregularity in the 
dolichol-linked precursor oligosaccharide.
The expression of M7N2 is roughly identical in all the samples; however 
M8N2 and M9N2 are elevated in the VM-NM1 and VM-M2 cell lines. Opposed to 
the astrocyte in which M8N2 and M9N2 represents 2.59% and 1.51% of the total 
glycan pool and 6.79% and 3.86% of the oligomannosidic pool respectively,
M8N2 and M9N2 represent 3.15% and 1.94% of the total glycan pool and balloon 
to 10.90% and 6.74% of the oligomannosidic pool in VM-NM1. M8N2 and M9N2 
represent 8.37% and 6.14% of the oligomannosidic pool in VM-M2. M8N2 does 
not appear to be elevated in VM-M3. High levels of Man(7-9) glycans are 
hallmarks of brain glycosylation (Krusius, T. and Finne, J. 1977). The high 
abundance and easy accessibility to oligomannosidic glycans on neural cell 
surfaces have led many to postulate a functional role for high mannose glycans 
in neural development (Schmitz, B., Peter-Katalinic, J., et al. 1993). It has been 
demonstrated that interactions between neuronal cell surface glycoproteins L1 
and NCAM involves oligomannosidic glycan recognition and consequently 
modulates the underlying proteins’ functional properties during neural 
development (Chandrasekaran, S., Dean, J.W., 3rd, et al. 1991, Fahrig, T., 
Schmitz, B., et al. 1990, Horstkorte, R., Schachner, M., et al. 1993). The 
increased relative abundance of high mannose glycans may impart protein- 
protein interactions normally reserved for neuronal development.
A molecular ion consistent with the molecular composition, H10N2, is also 
present in all the samples. Albeit in low abundance, H10N2 expression is
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elevated in the astrocytoma (VM-NM1) and metastatic cancer (VM-M2), 
compared to the astrocyte control, 1.20%, 1.14%, and 0.70% of the 
oligomannosidic pool, respectively. During protein folding the 
calreticulin/calnexin cycle binds GICiMan9GlcNAc2 moieties on nascent proteins 
to assist in proper protein folding (Trombetta, E.S. 2003). Once the protein is 
properly folded the glucose monomer is removed by glucosidase II and the 
protein may transit to the Golgi. If malfolding continues monoglucosylated 
glycoproteins are degraded by various degradation processes in the ER and 
cytosol. The differential expression of H10N2 in VM-NM1 and VM-M2 implies 
increased levels of malfolded proteins maybe present in non-metastatic 
astrocytoma, VM-NM1, and metastatic cancer, VM-M2. A low abundant Golgi 
endo-a-mannosidase can act on monoglucosylated glycoproteins that have 
escaped the calreticulin/calnexin cycle and entered the Golgi (Spiro, M.J., 
Bhoyroo, V.D., et al. 1997, Tulsiani, D.R., Hubbard, S.C., et al. 1982). The 
product of endo-a-mannosidase is a M8N2 structure. The relative abundance of 
M8N2 is elevated in both VM-NM1 and VM-M2.
The expression of paucimannose glycans, Man(2-4)GlcNAc2 is also quite 
distinguishable between the astrocyte control, non-metastatic astrocytoma, and 
metastatic cancer cell lines. The metastatic VM-M2 and VM-M3 cell lines exhibit 
elevated levels of paucimannose compositions M3N2 and M4N2 compared to the 
astrocyte control, while VM-NM1 demonstrates a relative decrease in M3N2 
compared to the control. Paucimannose glycans have been reported in the brain 
(Chen, Y.J., Wing, D.R., et al. 1998). These reported paucimannose structures
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all possess a fucose-substituted reducing end GlcNAc. Core a1,6- 
fucosyltransferase requires a substrate with a (31,2GlcNAc residue on the a1,3 
arm of the tri-mannosyl core for fucose attachment to occur. This insinuates a 13- 
hexosaminidase, which cleaves the (31,2GlcNAc, is involved in the formation of 
these paucimannose core fucosylated glycans (Chen, Y.J., Wing, D.R., et al. 
1998). Here, all cell lines, particularly VM-M2 and VM-M3, express 
paucimannose glycans lacking core fucosylation. Additionally, M2N2 is also 
present in control (C8-D30), astrocytoma (VM-NM1), as well as (VM-M2 and VM- 
M3) samples. The formation of M3N2 and M2N2 requires trimming of a3-linked 
and a6-linked mannose residues on the a1,6 arm of the chitobiose core.
Typically, the addition of a (31,2-linked GlcNAc residue by GnT-1 is obligatory for 
removal of both mannose residues by a-Mannosidase II (Taylor, M.E.,
Drickamer, K. 2003). An alternative pathway does exist. The Golgi enzyme a- 
mannosidase III does not require a (31,2 GlcNAc substrate, but acts directly on 
M5N2 to generate M3N2. The production of M4N2, M3N2, and M2N2 may result 
from over-activity of either the a-mannosidase enzymes (Harpaz, N. and 
Schachter, H. 1980).
The prevalence of M5N3, the product of GnT-1 and substrate for a- 
mannosidase II, is roughly the same in the astrocyte and VM-NM1 when 
percentage errors are considered (Table 4). The products of a-mannosidase II 
activity, M4N3 and M3N3, are elevated in VM-NM1, 1.55% and 1.85% 
respectively, compared to the astrocyte control, 1.24% and 1.35% respectively. 
VM-M2 demonstrates an elevation in M4N3, 1.36%, with a concomitant
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suppression of M3N3, 0.93%, compared to the astrocyte control. Based on 
relative abundances of M5N3, M4N3, and M3N3 it appears that GnT-1 and a- 
mannosidase II activity appear normal in VM-NM1, while 3-hexosaminidase 
activity is suppressed leading to the subsequent build-up of 3-hexosaminidase 
precursors, M4N3 and M3N3. Conversely, low levels of M3N3 and high levels of 
3-hexosaminidase product, M3N2 and M2N2, suggests over activity of 3- 
hexosaminidase in the metastatic cell line, VM-M2. Therefore, over-activation of 
the conventional pathway GnT-1, a-mannosidase II, and 3-hexosaminidase is 
responsible for the formation of M4N2, M3N2, and M2N2 paucimannose glycans 
in the metastatic cell line VM-M2. This result does not exclude possible 
contributions by a-mannosidase III. Alternatively, the high relative expression of 
M4N3, M3N3 and low abundance of M3N2 and M2N2 in VM-NM1 suggests a 
bottleneck in the conventional paucimannose pathway. This result does not 
exclude a-mannosidase III activity contributing to the reduced paucimannose 
glycan formation. Further analysis will help discern the involvement of both 
pathways in non-metastatic and metastatic cancers.
The differential expression of high mannose glycans between the normal, 
astrocytoma, and metastatic cell lines indicates aberrancies in glycosylation 
processing in the ER, c/'s- and medial-Golgi with regards to cancer progression. 
The biological relevance of these aberrantly expressed oligomannosidic glycan 
products in the various stages of cancer progression is not known.
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%  of 
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TGP
%  of 
HMP
H3N2 ;v T 4 .4 T ' 12.7 11.6 2.7 s l lv i f t S T '.: 20.6 :;T67f/ 11.0 34.3 25 5
H4N2 1391.8 707.4 4.1 18.7 10.7 2.6 15.0 9.1 3.0 16.2 9.7 5.1 23.3 11.9
H5N2 1595.8 T !0 9 ;4 ; :t ■ 29 7 ; 8.4 20 6 T fe a s T ;i6 7 ; 7 0 :6 7 ::|f.67. 7T3-PT 31.6 ;:3 0 .£
H6N2 1799.9 't o . 4 7 7 0 -7 7 ■;?37-37 6.2 16.6 .77.6:7;; 20.8 ;;i§;27 .76 .67 40.6 /: 15.47
H7N2 2004.1 1013.6 3.5 20.4 9.2 3.5 14.1 12.3 3.5 12.8 11.3 3.1 26.3 7.1
H8N2 2208.1 1115.6 2.6 15.7 6.8 3.2 15.5 10.9 2.6 9.6 8.4 2.5 26.5 5.7
H9N2 2412.2 1217.6 1.5 19.6 3.9 1.9 12.1 6.7 1.9 0.4 6.1 1.8 12.5 4.2
H10N2 2616.3 1319.7 0.3 6.5 0.7 0.3 19.1 1.2 0.4 19.3 1.1 0.3 37.1 0.8
% Total 
Glycan Pool 38.1 13.5 n/a 28.8 1.6 n/a 30.7 14.3 n/a 43.4 15.2 n/a
Table 3. Prevalence of high mannose glycans. The first value represents mean relative intensity 
normalized to the total glycan pool. The second value represents the coefficient of variation, 
defined as the standard deviation divided by the mean value multiplied by 100. %HMP is the 
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H3N3 1432.8 727.9 1.35 9 5 10.67 5 9 7B6K 1.9 16 3b 30.5 0.93 8 3 9.86 9.4 1.29 0 6 •i/5® 1.45
H3N3F1 1606.8 814.9 2.29 1.2 18.09 2.3 2.31 19.3 19.85 9.6 1.33 0.0 14.26 1.2 0.91 13.2 5.23 1.8
H4N3 1636.7 829.9 1.24 14 1 9.81 17 5 1.55 4.2 13.61 24 6 1.36 M I 16.39 16 / 2 38 10.9 13 81 4 1
H3N3F2 1783.8 903.4 3.91 9.7 30.89 6.2 3.32 15.5 28.70 13.5 2.61 36.4 20.75 27.1 1.90 34.4 5.43 18.1
H4N3F1 1811.1 917.1 2.15 15.9 16.95 12.4 1.98 7.8 17.32 21.2 1.75 6.5 17.90 5.5 1.03 31.8 6.15 15.7
H5N3 1840.9 932.0 1.34 22 4 M is 18.9 1.17 0.5 10.33 28 j 1.00 2 / 2 8.67 )2 1 1.27 14.3 7 33 0 7
H5N3F1 2015.1 1019.1 0.85 10.3 6.72 6.8 1.24 6.7 10.82 12.3 0.81 36.8 6.38 47.9 0.89 66.0 5.43 77.2
H6N3 2045.0 1034.0 0.83 9.9 6.59 13.4 0.84 8.9 7.49 37.2 0.75 22.2 9.28 20.0 1.16 2.8 6.77 17.7
H5N3F2 2189.1 1106.1 0.38 34.5 3.04 37.7 0.70 31.2 6.50 17.4 0.34 4.0 3.75 5.1 0.56 60.6 3.42 22.3
H6N3F1 2219.1 1121.1 0.47 21.9 3.76 25.3 0.82 19.9 7.43 17.3 0.33 10.4 3.75 10.7 0.47 61.2 2.90 72.8
H7N3 2249.1 1136.1 0.44 21.9 2.42 15.6 0.55 19.2 3.32 6.7 0.31 15.2 2.88 3.4 0.73 51.9 6.46 23.2
H7N3F1 2423.2 1223.1 0.26 14.8 2.08 18.2 0.48 18.1 4.39 15.6 0.30 17.3 3.16 16.1 0.42 9.2 2.8 10.6
H7N3F2 2597.3 1310.2 0.40 51.9 1.49 52.4 0.48 12.4 3.85 20.8 0.43 13.0 4.14 15.1 0.38 84.0 3.05 10.4
% Neutral 
Glycan Pool 15.91 0.7 n/a 17.29 6.2 n/a 12.24 11.1 n/a 13.41 22.6 n/a
Table 4. Prevalence of neutral hybrid (N3) glycans. The first value represents mean relative 
intensity normalized to the total glycan pool. The second value represents the coefficient of 
variation, defined as the standard deviation divided by the mean value multiplied by 100.
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6.3.2 Bi-. Tri-. and Tetra-Antennary Glycans
In contrast to high mannose glycan content, complex type glycans are 
elevated in the astrocytoma (VM-NM1) compared to the astrocyte control (C8- 
D30). Neutral bi-, tri-, and tetra-antennary type glycans represent 8.75%, 7.82%, 
and 2.22% of the total glycan pool in VM-NM1, while only 5.86%, 5.37%, and 
1.80% of the total glycan pool in the astrocyte control as shown in Table 1. VM- 
M2 and VM-M3 do not exhibit an appreciable difference from the astrocyte with 
regard to the relative abundance of the neutral bi-, tri-, and tetra-antennary type 
glycans. Curiously, specific individual glycan compositions within each complex 
glycan class are expressed differentially between the astrocyte, astrocytoma and 
two metastatic cancer lines (Table 5 and 6). Two glycomic patterns distinct to 
the tumor cell lines were observed: (1) elevations in neutral non-fucosylated 
complex oligosaccharides bearing galactose extensions; and (2), elevations in 
neutral mono-fucosylated and di-fucosylated complex oligosaccharides bearing 
galactose extensions, particularly in VM-NM1.
Complex glycans are fabricated on the ‘conserved’ tri-mannose core 
scaffolding remaining after precursor A/-linked glycan trimming is completed in 
the ER and c/s-Golgi (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and 
Marth, J. 1999). After the addition of a [31,2 linked GlcNAc by GnT-1, and a- 
mannosidase trimming, distinct A/-acetylglucosaminyl transferases attach 
additional GlcNAc residues, which varying in linkage position, onto the underlying 
tri-mannose core. The activities of these A/-acetylglucosaminyl transferases 
determine the branching patterns of complex glycans (Dennis, J.W., Granovsky,
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M., et al. 1999). Neutral truncated glycans H3N4, H3N5, and H3N6 compositions 
are the products of various A/-acetylglucosaminyl transferases. In the astrocyte 
control H3N4, H3N5, and H3N6 represent 12.11%, 10.54%, and 20.71% of the 
neutral bi-antennary, tri-antennary, and tetra-antennary glycan pools, while dip to 
8.67%, 8.36%, and 15.18% in VM-NM1 and 8.69%, 6.94%, and 13.21% in VM- 
M2 (Tables 5 and Table 6). H3N4, H3N5, and H3N6 are substrates for the 
sequential addition of monosaccharide residues by galactosyltransferases, 
sialyltransferases, and fucosyltransferases in the frans-Golgi (Varki, A., 
Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999). Interesting, 
the relative abundance of molecular compositions corresponding to glycans with 
subsequent galactose additions, H6N4, H7N4, H6N5, H7N5, H8N5, H9N5 are 
elevated in VM-NM1, VM-M2, and VM-M3 compared to the astrocyte control 
(Figure 19 and rows shadowed gray in Tables 4 and 5). Oligosaccharides that 
lack a capping structure and bear terminal galactose residues are atypical low 
abundant species in normal ‘brain-type’ glycosylation (Chen, Y.J., Wing, D.R., et 
al. 1998). Such is the case for the astrocyte control. Although still in low 
abundance (i.e. less than 1% of total glycan pool) complex oligosaccharides 
bearing exposed galactose terminal residues are more prevalent in VM-NM1, 
VM-M2, and VM-M3 than in the astrocyte control.
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Comparative Analysis of Neutral Non- 
Fucosylated Complex Oligosaccharides
□  Astiocyte  
■  V M -NM 1
I IV M -M 2
□  V M -M 3
■
H6N4 H7N4 H6N5 H7N5 H8N5 H9N5
Figure 19. Comparative analysis of neutral non-fucosylated complex molecular composition 
prevalence. The vertical axis represents the % of neutral glycan pool. The horizontal axis 
represents the molecular composition. Evaluations are based on the mean of a population of 3 
for each cell line type. Error bars represent the coefficient of variation, standard deviation/mean x 
100, which indicates the percent variance of molecular composition peak intensities between the 
individual samples of a population.
(3-galactosyltransferases (GalT) transfer uridine-5-phosphate-galactose 
(UDP-Gal) to terminal GlcNAc residues of complex glycans forming an N- 
acetyllactosamine motif (Taylor, M.E., Drickamer, K. 2003). The formation of N- 
acetyllactosamine is the catalyst for terminal elaboration formation, such as sialyl 
Lewis epitopes, blood antigens, polylactosamine repeats, and neuraminylated 
capping structures. An over-expression of (3-1,4-galactosyltransferases has been 
associated with lung, colorectal, as well as human astrocytomas (Chen, W.S., 
Chang, H.Y., et al. 2005, Jiang, J., Chen, X., et al. 2006, Xu, S., Zhang, S., et al. 
2002, Xu, S., Zhu, X., et al. 2001, Zhu, X., Jiang, J., et al. 2005). At least three
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galactosyltransferases, (3-1,4-GalT-l, (3-1,4-GalT-ll, and (3-1,4-GalT-V are 
uncharacteristically expressed in astrocytomas compared to normal brain tissue 
(Xu, S., Zhu, X., et al. 2001). (3-1,4-GalT-l expression is completely absent in 
normal adult brain astrocytes, while |3-1,4-GalT-l expression is present and 
constant in grade II, III, and IV astrocytomas. (3-1,4-GalT-ll expression is up- 
regulated and constant in grade II, III, and IV astrocytomas, while only trace 
levels are detectable in the normal adult brain. A basal level of (3-1,4-GalT-V 
expression is constitutive in the normal brain, meanwhile (3-1,4-GalT-V 
transcription levels escalate corresponding to astrocytoma progression, the 
highest levels in grade IV astrocytoma.
(3-1,4-GalT-l expression occurs normally in the fetal mouse brain, however 
3-1,4-GalT-l expression decreases precipitously immediately following 
birth(Zhou, D., Chen, C., et al. 1998). The resurgence of 3-1,4-GalT-l expression 
in grade II, III, and IV astrocytomas may usurp glycoprotein glycosylation 
patterns normally restricted to fetal development and hence promote tumor 
growth and proliferation. Increased branching is a common feature of tumor 
progression, particularly 31, 6  branching initiated by 31,6 -/V-acetylglucosaminyl 
transferase V (GnT-V) (Dennis, J.W., Laferte, S., Waghorne, C., Breitman, M.L., 
Kerbel, R.S. 1997). Interestingly, 3-1,4-GalT-V preferentially galactosylates 31,6 
branched GlcNAc residues (Shirane, K., Sato, T., et al. 1999). The coordinated 
over-expression of GnT-V and 3-1,4-GalT-V further supports the involvement of 
31, 6  branching in tumor biology. The change in galactosyltransferase expression 
may lead to the uncharacteristic galactosylation of specific adhesion molecules
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dramatically affecting the protein’s biological function and in turn promoting tumor 
growth and progression.
In humans, (3-lactosamine sequences are substrates for 
fucosyltransferases and sialyltransferases activity. However, in murine animals, 
(3-lactosamine is also the substrate for a1,3-galactosyltransferase (Varki, A., 
Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999). Similar to 
terminal sialic acid addition, a1,3-galactose is an alternative terminal cap that 
prohibits further glycan elongation. Interestingly, the gene for a1,3- 
galactosyltransferase is present in humans and New World Monkeys, however it 
is not expressed. When exposed to this antigenic epitope, humans immediately 
produce antibodies coating the foreign substance containing the a1,3-galactose. 
Hyperacute rejection of xenotransplanted organs is a classic example of the 
immune response to a1,3-galactose (Galili, U. 2001). In the murine cancer 
samples, VM-NM1, VM-M2, and VM-M3, molecular compositions comprised of 
excessive hexose residues, such as H6N4, H7N4, H8N4, and H9N4 are elevated 
relative to the astrocyte control. Aberrant a1,3-galactosyltransferase activity may 
lead to excessive a1,3-galactosyl capping of (3-lactosamine sequences 
accounting for the increase in relative abundance of H6N4, H7N4, H8N4, and 
H9N4 in VM-NM1, VM-M2, and VM-M3.
Galectins are a family of 14 carbohydrate binding lectins that preferentially 
bind glycoconjugates with A/-acetyllactosamine disaccharide units. Galectins are 
involved in a myriad of developmentally regulated functions such as cell-cell 
adhesion, cell-matrix adhesion, and receptor activation. In the brain, Galectin-1
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induces astrocyte differentiation and the production of neurotrophic factors, which 
promote neuronal survival, axonal growth, and activity-dependent synaptic 
plasticity during development (Endo, T. 2005, Sasaki, T., Hirabayashi, J., et al. 
2004). Aberrant galectin expression, particularly galectin-3, transpires in various 
forms of breast, colon, prostate, and brain cancers (Danguy, A., Camby, I., et al. 
2002, Shekhar, M.P., Nangia-Makker, P., et al. 2004). In brain cancer, galectins 
participate in key biological events including proliferation, apoptosis, 
transcriptional regulation, intracellular signaling, cell-cell adhesion, cell-matrix 
adhesion, and cell migration promoting tumor growth and proliferation (Stillman, 
B.N., Mischel, P.S., et al. 2005). Interestingly, galectin-3 binding is enhanced 
when (3-lactosamine is substituted with a1,3-galactose, a1,3-GalNAc, or a1,2- 
fucose residues, meanwhile galectin-1 binding is dramatically suppressed by 
these substitutions (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and 
Marth, J. 1999).
The glycomic profiles of VM-NM1, VM-M2, and VM-M3 clearly indicate 
elevation in molecular compositions consistent with increased neutral galactose 
extended glycans, compared to the astrocyte control. Structural characterization 
of the glycans composed of the differentially expressed molecular compositions 
will help elucidate the particular glycosyltransferases aberrantly expressed in 
VM-NM1, VM-M2, and VM-M3.
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%  of 
NGP
%  of 
N4 
Pool
H3N4 1677.9 850.5 0.86 23.6 12.11 1.06 8.7 8.67 0.71 16.0 8.69 0.64 14.5 9.23
H3N4F1 1852.0 937.5 1.84 7.9 25.86 1.80 0.6 14.7 1.25 27.6 15.28 0.58 19.6 8.43
H4N4F1 2056.1 1039.6 0.68 1.2 9.54 1.05 2.3 8.53 0.61 29.8 7.41 0.46 60.0 6.74
H5N4 2086.0 1054.5 0.61 1.7 8.57 0.94 13.1 7.64 0.6 24.9 7.47 0.71 31.1 10.25
H5N4F1 2259.3 1141.2 0.67 12.5 9.36 1.26 3.7 10.28 0.67 10.4 8.11 0.55 72.8 8.06
H6N4 2290.2 1156.6 0.40 5.3 5.59 0.83 10.5 6.76 0.55 15.5 6.71 0.58 39.1 8.43
H5N4F2 2434.2 1228.6 0.32 14.1 4.51 0.92 5.4 7.49 0.80 20.9 9.77 0.47 14.4 6.80
H6N4F1 2464.3 1243.7 0.37 0.4 5.21 0.82 4.4 6.69 0.66 53.2 8.05 0.55 64.2 8.00
H7N4 2494.3 1258.7 0.28 0.6 3.92 0.48 16.9 4.47 0.58 10.0 7.09 0.55 22.8 8.04
H5N4F3 2608.3 1315.7 0.30 20.3 4.21 0.69 9.1 5.59 0.41 14.5 4.97 0.39 82.0 5.71
H6N4F2 2638.4 1330.7 0.31 13.0 4.41 0.90 20.2 7.35 0.50 29.3 6.12 0.45 61.5 6.49
H7N4F1 2668.4 1330.7 0.26 11.7 3.71 0.73 24.1 5.98 0.56 20.5 6.78 0.42 69.6 6.04
H7N4F2 2842.4 1432.7 0.22 4.1 3.02 0.72 33.5 5.86 0.29 22.9 3.56 0.54 10.6 7.79
H8N4F1 2872.5 1447.8 0.25 8.0 3.51 0.44 6.8 3.58 0.34 2.9 4.14 0.79 5.1 11.48
% Neutral 
Glycan Pool 7.13 1.4 n/a 12.28
8.4 n/a 8.21 17.0 n/a 6.88 53.3 n/a
Table 5. Prevalence of neutral bi-antennary (N4) glycans. The first value represents mean 
relative intensity normalized to the neutral glycan pool. The second value represents the 
coefficient of variation, defined as the standard deviation divided by the mean value multiplied by 
100.
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%  of 
N5 Pool
H3N5 1923.1 973.1 0.68 4.6 10.54 0.90 17.0 8.36 0.54 4.2 6.94 0.67 56.6 9.11
H3N5F1 2097.1 1060.1 1.22 20.3 18.84 1.54 8.9 14.36 0.93 10.1 11.94 0.60 27.6 8.18
H4N5 2127.1 1075.1 0.64 8.8 9.93 0.88 26.1 8.14 0.48 10.0 6.16 0.43 54.4 5.88
H4N5F1 2301.2 1162.1 0.54 21.5 8.39 0.69 9.1 6.38 0.63 9.0 8.17 0.40 71.0 5.42
H5N5 2331.2 1177.1 0.41 2.9 6.29 0.62 8.6 5.76 0.43 7.5 5.56 0.47 80.4 6.41
H5N5F1 250*3.3 1279.2 0.43 30.6 6.65 0.63 1.4 5.83 0.53 9.4 6.78 0.42 90.2 5.64
H6N5 2535.3 1279.2 0.31 11.9 4.81 0.59 5.2 5.51 0.44 10.5 5.64 0.49 67.5 6.62
H5N5F2 2679.4 1351.2 0.29 18.1 4.54 0.67 6.7 6.22 0.56 17.3 7.20 0.50 80.7 6.74
H6N5F1 2709.4 1366.2 0.35 26.8 5.43 0.65 9.8 6.03 0.41 20.4 5.30 0.36 76.7 4.94
H7N5 2737.4 1380.2 0.28 20.0 4.27 0.52 0.7 4.88 0.40 21.7 5.14 0.52 22.5 7.03
H6N5F2 2883.5 1453.3 0.29 41.2 4.45 0.62 2.6 5.76 0.40 9.1 5.19 0.34 22.59 4.67
H7N5F1 2913.5 1468.3 0.21 14.1 3.26 0.58 10.7 5.36 0.44 16.1 5.68 0.40 16.63 5.46
H8N5 2943.5 1483.3 0.19 13.6 3.00 0.53 14.9 4.91 0.38 23.7 4.84 0.45 16.56 6.09
H8N5F1 3117.6 1570.3 0.21 12.5 3.22 0.49 20.5 4.54 0.42 19.8 5.38 0.45 24.40 6.12
H9N5 3147.6 1585.3 0.20 29.2 3.15 0.42 16.7 3.88 0.37 14.8 4.76 0.41 18.2 5.60
H9N5F1 3321.6 1672.3 0.21 28.0 3.20 0.44 17.1 4.13 0.41 27.7 5.30 0.45 10.5 6.13
% Neutral 
Glycan Pool 6.48 18.5 n/a 10.75 10.7 n/a 7.76 11.8 n/a 7.37 20.6 n/a
Table 6. Prevalence of neutral tri-antennary (N5) glycans. The first value represents mean 
relative intensity normalized to the neutral glycan pool. The second value represents the 
coefficient of variation, defined as the standard deviation divided by the mean value multiplied by 
100.
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Fucosylated structures are the predominant class of glycans in the 
astrocyte, VM-NM1, and VM-M2 cell lines accounting for 40.96%, 41.79%, and 
39.14% of the total glycan pool, respectively. Fucosylated structures comprise 
only 27.22% of the total glycan pool in VM-M3. Although the prevalence of 
fucosylation is similar in the astrocyte, VM-NM1, and VM-M2 cell lines, a 
differential expression of individual neutral mono-fucosylated and di-fucosylated 
molecular compositions exist between the samples. An inverse relationship 
between increasing fucosylation and decreasing relative abundance is a loose 
‘rule of thumb’ for many neutral galactose extended glycans in the astrocyte 
control. Conversely, a direct relationship between increased fucosylation and 
elevated relative abundance holds true for many neutral galactose extended 
glycans in VM-NM1 as outlined in Figure 20. The relative abundance of H6N4, 
H6N4F1, and H6N4F2 depreciates from 0.4% to 0.37% to 0.31% respectively in 
the astrocyte, while relative abundance escalates from 0.63% to 0.82% to 0.90% 
in VM-NM1. In the astrocyte, the prevalence of H7N4, H7N4F1, and H7N4F2 
descends from 0.28% to 0.26% to 0.22% as fucose residues increases, while 
ascends from 0.48% to 0.73% and 0.72% in VM-NM1. H5N5, H5N5F1, and 
FI5N5F2 are a third sequential fucosylated series exemplifying the reciprocal 
trend associated with relative abundance and fucosylation between the astrocyte 
and astrocytoma (Figure 20).
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Comparative Analysis of H6N4, Comparative Analysis of H7N4,
N6N4F1, H6N4F2 H7N4F1, H7N4F2
i □  Astrocyte
H6N4 H6N4F1 H6N4F2 H7N4 H7N4F1 H7N4F2
Comparative Analysis of H5N5,
H5N5F1, H5N5F2
1 .0 -
0.9 “j □  Astrocyte 
0  8 - .  HVM-NM1
H5N5 H5N5F1 H5N5F2
Figure 20. Comparative analysis of sequential fucosylation. The vertical axis represents the % 
of neutral glycan pool. The horizontal axis represents the molecular composition. The 
evaluations are based on the sample mean of 3 astrocyte samples and 3 VM-NM1 samples. 
Error bars represent the coefficient of variation, standard deviation/mean x 100, which indicates 
the percent variance of molecular composition peak intensities between the individual samples of 
a population.
A cohort of eleven low abundant molecular compositions consistent with 
neutral mono-fucosylated oligosaccharides laden with hexose residues are 
strikingly more prevalent in VM-NM1 compared to the astrocyte control (Figure 
21 and shadowed rows of Table 7). This assemblage is also elevated in VM-M2 
and VM-M3, albeit suppressed relative to VM-NM1. Three hybrid type 
compositions, H5N3F1, H6N3F1, and H7N3F1, four bi-antennary or bisecting 
type compositions, H5N4F1, H6N4F1, H7N4F1, and H8N4F1, three tri-antennary 
type compositions, H7N5F1, H8N5F1, and H9N5F1, and one tetra-antennary 
type composition, H6N6F1 are the constituents of this up-regulated cohort. The
80
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
prevalence of seven di-fucosylated compositions H5N3F2, H5N4F2, H7N3F2, 
H6N4F2, H5N5F2, H7N4F2, H6N5F2 are also elevated in VM-NM1, VM-M2, and 
VM-M3 relative to the astrocyte control (Figure 21 and shadow rows of Table 8).
Comparative Analysis of Neutral Hybrid Mono- 
Fucosylated Molecular Compositions
Comparative Analysis of Neutral Mono- 
Fucosylated with Four GlcNAc residues
O Astrocyte 1.4 ~
■  VM-NM1
1.2 - BBS
0  Astrocyte J 
■  VM-NM1 
□  VM-M2
H5N3F1 H6N3F1 H7N3F1 H5N4F1 H6N4F1 H7N4F1 H8N4F1
Comparative Analysis of Neutral Mono-
Fucosylated Glycans with Five GlcNAc Comparative Analysis of
Neutral Di-Fucosylated Complex Glycans
0 Astrocyte
H7N5F1 H8N5F1 H9N5F1 to n. m co r-- m <o
X  X  x  I  x  I  x
Figure 21. Comparative analysis of neutral mono-fucosylated and di-fucosylated molecular 
composition relative abundance. The vertical axis represents the % of neutral glycan pool. The 
horizontal axis represents the molecular composition. The evaluations are based on the 
population mean of 3 astrocyte samples, 3 VM-NM1 samples, and 3 VM-M2 samples. Error bars 
represent the percentage error, standard deviation/mean x 100, which indicates the percent 
variance of molecular composition peak intensities between the individual samples of a 
population.
Antennal fucosylation is the most likely explanation for the rise in 
prevalence of large neutral mono-fucosylated and di-fucosylated molecular 
compositions. Three key determinant lead to this postulation: (1) an increase in 
(3-1,4-A/-acetyllactosamine motifs; (2) elevations in di-fucosylated molecular
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compositions; and (3) the absence of a differential expression between neutral 
truncated non-fucosylated compositions and neutral truncated fucosylated 
compositions in the cancer samples compared to the astrocyte control.
A common feature of ‘brain-type’ glycosylation are complex and hybrid 
glycans adorned with sialyl Lewis x, sLex, and Lewis x, Lex, epitopes (Chen, Y.J., 
Wing, D.R., et al. 1998, Zamze, S., Harvey, D.J., et al. 1998). Intriguingly, rare 
tissue-specific non-core substituted glycans with one or more terminal sLexor Lex 
motifs are also present in the brain (Chen 1998). (3-1,4-A/-acetyllactosamine is 
the substrate for outer-arm fucose additions to either the GlcNAc or galactose 
residues, forming Lewis X, Lex , or H type blood antigens, respectively. Sialyl 
Lex, epitopes are formed by the subsequent addition of sialic acid to a 
fucosylated (3-1,4-A/-acetyllactosamine trisaccharide motif (Varki, A., Cummings, 
R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999). It is no surprise that an 
increase in substrate availability, i.e., (3-lactosamine, will lead to increased levels 
of specific outer-arm fucosylated glycan structures.
A single a1,6-linked fucose is the constitutive core substitution of 
mammalian glycoproteins. In non-mammalian systems, C. elegans and D. 
melanogaster, di-fucose substituted reducing-end core GlcNAc motifs, as well as, 
single fucose residues a1,3-linked to the reducing end GlcNAc are common 
(Aoki, K., Perlman, M., et al. 2007, Stillman, B.N., Mischel, P.S., et al. 2005). To 
date, di-fucose-substituted reducing-end cores have not been reported in 
mammalian tissues glycans. Additionally, all AHinked glycans analyzed during 
this study were enzymatically released by PNGase F. As mentioned previously,
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PNGase F specifically cleaves non-core substituted and a1,6-linked core 
substituted glycans from glycopeptide backbones (Tretter, V., Altmann, F., et al.
1991). Therefore, the second fucose residue is most likely positioned on the 
outer arm.
If core fucosyltransferase activity is responsible for the higher abundance 
of large neutral mono-fucosylated structures in the cancer samples, one would 
expect an alteration in the ratio of relative abundance between small neutral non- 
fucosylated glycans and small neutral fucosylated glycans in the cancer samples. 
The ratios of H3N3 to H3N3F1 for the astrocyte, VM-NM1, VM-M2 and VM-M3 
are 2:3, 9:11, 2:3, and 3:2, respectively. The relative proportion of H4N3 to 
H4N3F1 in the astrocyte, VM-NM1, VM-M2 and VM-M3 are 2:3, 9:11, 9:11, and 
7:3, accordingly. The ratios of H3N4: H3N4F1 are 3:7, 4:6, 2:3, and 1:1 in the 
astrocyte, VM-NM1, VM-M2, and VM-M3 samples. Additionally, the proportion of 
H3N5 to H3N5F1 in the astrocyte, VM-NM1, VM-M2, and VM-M3 are 7:13, 2:3, 
2:3, and 1:1. The proportion of neutral truncated mono-fucosylated glycans is 
greater relative to the neutral truncated non-fucosylated glycans in the astrocyte 
control. In VM-NM1 and VM-M2, the relative proportion of neutral truncated 
mono-fucosylated glycans is still greater than the neutral truncated non- 
fucosylated proportion; however, their relative proportions are closer to 1:1. For 
VM-M3, the proportion of neutral truncated mono-fucosylated glycans is less than 
the neutral truncated non-fucosylated glycan proportion. This insinuates that 
core a1,6-fucosyltransferase is not elevated in the astrocytoma, and two 
metastatic cell lines. Although the evidence compiled suggests an up-regulation
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of outer-arm fucosyltransferase activity is responsible for the increased 
prevalence of large neutral mono-fucosylated and di-fucosylated complex 
oligosaccharides, only through more extensive analysis can fucose residue 
positioning be determined.
Through comparative analysis of neutral complex molecular compositions 
two glycomic patterns distinct to the tumor cell lines were observed: (1) 
elevations in neutral non-fucosylated complex oligosaccharides bearing 
galactose extensions; and (2), elevations in neutral mono-fucosylated and di- 
fucosylated complex oligosaccharides bearing terminal galactose extensions, 
particularly in VM-NM1. These two distinct glycomic patterns are far from 
mutually exclusive. Both patterns appear to be the product of multiple aberrantly 
expressed glycosyltransferases acting synergistically to create these cancer- 
specific patterns. Complete structural characterization of all the structures 
present within each molecular composition associated with these two cancer 
specific patterns will elucidate the actual glycan structures and sub-structural 
motifs aberrantly expressed and hence uncover the glycosyltransferases 
responsible for these cancer specific structures.
84
































H2N2F1 1157.7 590.4 9.96 19.3 78.53 19.8 3.67 17.5 31.1 1.3 15.33 8.8 162.6 7.7 4.06 73.2 22.2 16.3
H3N2F1 1361.8 692.4 8.1 11.3 64.3 14.7 6.81 8.6 59.4 19.3 6.24 12.2 66.2 13.3 3.39 10.7 18.8 53.0
H4N2F1 1565.8 794.4 1.61 7.9 12.74 4.5 1.63 12.7 14.1 16.3 1.0 2.3 10.65 1.1 0.78 10.2 4.55 11.2
H3N3F1 1606.8 814.9 2.29 1.2 18.1 2.3 2.31 19.4 19.85 9.6 1.33 0.0 14.14 1.2 0.91 39.4 5.23 1.79
H4N3F1 1811.1 917.1 2.15 15.8 12.25 21.4 1.98 0.8 10.81 51.2 1.75 6.5 10.82 11.0 1.03 86.6 4.07 34.1
H3N4F1 1852.0 937.5 1.84 7.9 14.57 4.5 2.01 0.6 17.74 18.1 1.25 17.7 13.34 28.7 0.62 37.4 3.44 34.1
H6N2F1 1974.1 998.6 0.7 16.8 5.53 20.3 0.78 26.7 7.2 53.4 0.44 5.3 4.70 6.5 0.62 95.6 3.77 76.4
H5N3F1 2015.1 1019.1 0.85 10.3 6 72 6 8 1.24 6 6 10.82 12.3 0.81 36.9 8.54 35.8 0.89 93.1 6.43 77 2
H4N4F1 2056.1 1039.6 0.68 1.2 5.45 2.3 1.1 2.3 9.2 26.6 0.6 29.9 6.5 31.0 0.5 11.7 2.8 7.18
H3N5F1 2097.1 1060.1 1.22 20.3 9.63 16.9 1.54 8.9 13.79 37.2 0.93 10.2 9.84 11.3 0.60 27.6 3.59 41.7
H6N3F1 2219 I 1121.1 0.47 19.9 3 ./f i 25 3 0 82 19.9 /.43 47 3 0.33 10.4 3.46 11.6 0.47 10.9 2.90 72.9
H5N4F1 2259.3 1141.2 0 67 12.5 6 27 9.1 1.26 3 7 11.21 32.3 0.67 10 4 /.06 9 1 9 0.55 71.9 3 42 83.3
H4N5F1 2301.2 1162.1 0.54 21.5 4.29 18.1 0.69 9.1 6.14 37.3 0.63 9.0 6.73 10.2 0.40 77.4 2.46 81.7
H3N6F1 2342.2 1182.6 0.53 3.6 4.17 0.1 0.56 9.3 5.05 37.6 0.48 3.8 5.08 5.0 0.42 104.3 2.55 73.9
H7N3F1 2423.2 1223.1 0.26 14.8 2.61 14.2 0.48 18.1 5.70 9.6 0.30 17.2 3.57 30.5 0.45 10.2 2 .9 / 107 8
H6N4F1 2464.3 1243.7 0 .3 / 0.4 3.63 20.b 0.82 4.4 6.68 49.1 0.60 53 2 m 34.5 0.55 98.8 9.98 66.9
H5N5F1 2505.3 1264.2 0.43 20.6 2.73 0.1 0.63 1.4 5.27 38.8 0.53 9.4 4.24 34.1 0.42 17.7 2.14 89.5
H4N6F1 2546.3 1284.7 0.31 19.3 2.17 2.9 0.52 5.4 4.82 15.6 0.35 16.6 4.57 13.5 0.34 45.2 2.38 96.3
H7N4F1 2668.4 1345./ 0 26 11.76 2.60 34.4 o 73 14.1 6.69 41.6 0 56 20.5 m 41 9 0 49 81 8 2.36 75.4
H6N6F1 2709.4 1366.2 0.35 16.83 2.48 9 6 0.65 9 8 5.58 45 5 0.41 20.3 4.14 30.4 0.36 60 8 2.63 94.5
H5N6F1 2750.4 1386./ 0.29 18 4 2.55 28 8 0.49 13.8 4.34 11.7 0.34 13.8 4.28 8.2 0.41 4.9 1.9/ 90 5
H8N4F1 28/2.!) 1447.8 0.25 8.00 1.80 0 ./ 0.44 0 8 3.77 1.0 0.34 2.9 4.12 0.1 0 ./9 5.1 4.05 1.5
H7N5F1 2913.5 1468.3 0.21 14.13 2.27 45.5 0.98 10.8 4.96 46.0 0.44 6.1 4.24 24 1 0.40 30.0 2.68 45.6
H6N6F1 2954.5 1488 8 0.30 14.0 1.70 3.9 0.47 1.7 3.91 25.3 0.34 13.7 3 8 / 3.6 0.41 7.1 2.69 103.4
H8N5F1 311 /  0 1570.3 0.21 12.4b 1.81 21.2 0.49 10.5 4.63 39.9 0.32 19.8 4.00 38 4 0 45 25.9 2.28 41.6
H6N7F1 3199.6 1611.3 0.20 50.33 2.01 68.2 0.48 1.9 5.09 1.8 0.34 26.9 3.86 18.2 0.35 35.1 2.76 103.8
H5N8F1 3240.6 1631.8 0.26 70.9 1.48 41.9 0.53 50.6 3.17 18.9 0.34 7.5 3.64 6.3 0.45 14.9 2.89 99.3
H9N5F1 3321.6 1672.3 0 21 0.06 1.90 18.0 0.44 13.° 4.21 17.2 0.41 16 2 4.12 27.7 0.45 188 9.04 42 6




35.75 9.9 n/a 34.51 5.5 n/a 37.90 1.2 n/a 21.71 12.5 n/a
Table 7. Prevalence of neutral mono-fucosylated glycans. The first value represents mean 
relative intensity normalized to the neutral glycan pool. The second value represents the 
coefficient of variation, defined as the standard deviation divided by the mean value multiplied by 
100.
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%  of 
Di-Fuc 
Pool
%  of 
NGP
%  of 
Di-Fuc 
Pool
H3N3F2 1783.8 903.4 3.91 9.7 75.31 3.32 15.5 40.09 2.61 36.4 44.56 1.90 34.3 36.26
H5N3F2 2189.1 1106.1 0.38 34.5 7.36 0.70 31 2 8.49 0.34 4  1 5.81 0.56 60.6 10.69
H5N4F2 2434.2 1228.6 0.32 14.1 6.20 0.92 5 5 11.09 0 80 40.9 13.69 0.47 64.4 8.92
H7N3F2 2597.3 1310.2 0.19 49.4 3.60 0.44 2.3 5.25 0.35 1 5 8 5.94 0.49 97.1 9 29
H6N4F2 2638.4 1330.7 0.31 1 3 0 6.05 0.90 20.2 10.89 0.50 29.3 8.57 0 45 61.5 8.52
H5N5F2 2679.4 1351.2 0.29 18.2 5.67 0.67 6.7 8.06 0.56 17.3 9.54 0.50 80.7 9.48
H7N4F2 2842 4 1432.7 0.22 4.1 4.15 0.72 33.5 8.68 0.29 22.9 4.99 0.54 106.9 10.22
H6N5F2 2883.5 1453.3 0.29 41.1 5.56 0.62 2.7 7.47 0.40 9.1 6.87 0.34 72.6 6.56
% Neutral 
Glycan Pool 5.19 8.6 n/a 8.29 2.1 n/a 5.86 11.5 n/a 5.24 63.3 n/a
Table 8. Prevalence of neutral di-Fucosylated Glycans. The first value represents mean relative 
intensity normalized to the neutral glycan pool. The second value represents the coefficient of 
variation, defined as the standard deviation divided by the mean value multiplied by 100.
6.3.3 Sialylated Glycans
Sialyltransferases located in the frans-Golgi and trans-Go\g\ network add 
sialic acids residues to either (3-lactosamine or its fucosylated Lewis structure 
equivalent (Dennis, J.W., Granovsky, M., et al. 1999). The resulting products of 
sialyltransferase activity are terminal capping sequences that prohibit further 
monomer elaboration. Multiple analogs of sialic acid exist. Although absent in 
humans, murine systems possess an analog of A/-acetyl neuraminic acid that has 
an additional oxygen atom (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart,
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G. and Marth, J. 1999). This alternative sialic acid moiety, termed A/-glycolyl 
neuraminic acid, gains an additional methyl group upon permethylation and 
therefore, easily distinguishable from its analog. Reports demonstrate the 
presence of the A/-glycolyl neuraminic acid residues in GM2 gangliosides in 
human cancers (Hirabayashi, Y., Kasakura, H., et al. 1987, Marquina, G., Waki,
H., et al. 1996). A/-Glycolyl neuraminic acid expression, denoted gA, is present in 
the astrocyte, astrocytoma and two metastatic cancer cell lines. Sialyl Lewisx 
and NeuAca2,3Gal|31,4GlcNAc terminal motifs are common in brain-type 
glycosylation (Zamze, S., Harvey, D.J., et al. 1998). Although sialic acid may be 
a2, 6-linked to a penultimate galactose, a2,6-linked sialic acids are in very low 
abundance in comparison to a2,3 linked sialic acids in normal brain (Krusius, T. 
and Finne, J. 1977, Liedtke, S., Geyer, H., et al. 2001, Zamze, S., Harvey, D.J., 
et al. 1998). An odd di-sialylated NeuAca2,3Galf31,3(a2,6NeuAc) GlcNAc 
terminal motif is also present in ‘brain-type’ glycosylation (Zamze, S., Harvey, 
D.J., et al. 1998).
The interconnectedness of abnormal sialylation and cancer progression 
and metastasis is well-documented (Hoff, S.D., Matsushita, Y., et al. 1989, 
Itzkowitz, S.H., Yuan, M., et al. 1986, Le Marer, N. and Stehelin, D. 1995, 
Mannori, G., Crottet, P., et al. 1995). Over-expression of Sialyl-Lex, Sialyl-Ley, 
and Sialyl-Lea terminal sequences as well as sialylated polylactosamine motifs on 
/V-and O-linked glycans are commonly observed in carcinomas. Uncharacteristic 
sialylation of truncated O-linked glycans, such as sialyl-Tn, and gangliosides, 
such as GMi, GM3,GD2, and GD3also correlate with tumor growth (Hakomori, S.
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1996, Hakomori, S. and Kannagi, R. 1983, Hakomori, S., Nudeiman, E., et al. 
1983, Itzkowitz, S.H. 1992, Itzkowitz, S.H., Bloom, E.J., et al. 1990, Lang, Z., 
Guerrera, M., et al. 2001, Manfredi, M.G., Lim, S., et al. 1999, Zamze, S.,
Harvey, D.J., et al. 1998). Very little is known about changes in terminal 
sialylation associated with brain cancers.
A drastic elevation in the relative abundance of sialylated structures is 
associated with the VM-NM1, VM-M2, and VM-M3 compared to the astrocyte 
control. Molecular compositions consistent with sialylated oligosaccharides 
comprise 19.72% of the total glycan pool in the astrocyte, while these 
compositions inflate to 30.90%, 36.47%, and 30.15% in the astrocytoma, VM-M2, 
and VM-M3 cell lines, respectively (Table 1). Concealed in this global elevation 
of sialylation are two distinct cohorts of molecular compositions uniquely 
expressed in the cancer cell lines. The first cohort consists of two sets of 
sialylated oligosaccharides. All the constituents of each individual set have an 
identical neutral monosaccharide composition of either H5N4 or H6N4. The 
second cohort consists of 7 sialylated truncated compositions all of which bear 4 
GlcNAc residues. Interestingly, the second cohort is specific to the metastatic 
cancer cells.
Ten low abundant molecular compositions consistent with sialylated 
oligosaccharides with a common H5N4 backbone are dramatically elevated in 
VM-NM1 compared to the astrocyte control as shown in Figure 22. H5N4gA1, 
H5N4A2, H5N4A1gA1, H5N4gA2, H5N4A3, H5N4F1A1, H5N4F1A2, 
H5N4F1gA2, H5N4F2A1 and H5N4F2A2 represent 0.51%, 0.74%, 0.38%,
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0.40%, 0.29%, 0.72%, 0.51%, 0.36%, 0.59%, 0.32% of the total glycan pool, 
respectively, in the astrocytoma, while only comprise 0.30%, 0.32%, 0.23%, 
0.26%, 0.17%, 0.42%, 0.35%, 0.19%, 0.27%, and 0.22% of the total glycan pool 
in the astrocyte. A second set of seven low abundant molecular compositions 
consistent with sialylated oligosaccharides with a common H6N4 backbone are 
dramatically elevated in VM-NM1 compared to the astrocyte control as shown in 
Figure 24. H6N4A1, H6N4A2, H6N4A1gA1, H6N4A3, H6N4F1A1, H6N4F1A2, 
and H6N4F2A1 comprise 0.56%, 0.33%, 0.36%, 0.32%, 0.81%, 0.33%, and 
0.68% of the total glycan pool in VM-NM1, while only represent 0.31%, 0.22%,
0.19%, 0.06%, 0.34%, 0.19%, and 0.26% of the total glycan pool in the astrocyte. 
The relative abundance of these molecular compositions is also elevated in VM- 
M2 and VM-M3, although mildly compared to VM-NM1. See Appendix A for a 
table representation of sialylated molecular composition relative abundance 
between the astrocyte control, astrocytoma, and two metastatic cancers.
Three molecular compositions from each cohort, H5N4A2, H5N4F1A1, 
and FI5N4F2A1 of the first set and H6N4A1, H6N4F1A1, and H6N4F2A1 of the 
second set, are appreciably more abundant in VM-NM1 than in the astrocyte 
control. As demonstrated in section 6.3.2, the corresponding neutral molecular 
compositions, FI5N4, FI5N4F1, and H5N4F2 as well as FI6N4, H6N4F1, and 
H6N4F2 are also dramatically elevated in VM-NM1 compared to the astrocyte 
control (Figure 20 and Figure 21).
Glycan assembly is a step-wise enzymatic process dictated by Golgi 
glycosyltransferases. Glycosyltransferases act sequentially catalyzing the
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transfer of monosaccharides from specific sugar nucleotide donors onto a 
particular hydroxyl position of a specific precursor monosaccharide on a growing 
glycan (Schachter, H. 1986). That is, the product of one enzyme reaction 
becomes the preferred acceptor substrate for the subsequent action of another 
glycosyltransferase assembly the glycan structure stepwise. It is likely that a 
specific glycosylation pathway consisting of multiple glycosyltransferases is 
aberrantly expressed consequently producing a multitude of aberrant cancer 
specific neutral and sialylated glycan products.
Sialyltransferases require specific substrates in order to add sialic acids. 
Intriguingly, the relative abundance of molecular composition likely possessing 
these substrates, (3-lactosamine and its fucosylated equivalent, Lex, are greatly 
elevated in VM-NM1, VM-M2, and VM-M3 compared to the astrocyte control. 
Aberrant galactosyltransferase activity may be the initial enzymatic step 
responsible for instigating the up-regulation of all constituents in the H5N4 and 
H6N4 cohorts. A/-acetyllactosamine formation becomes the substrate for 
subsequent action of fucosyltransferases and sialyltransferases, culminating in 
the assembly and over-expression of Le, sialyl-Le and NeuAc-Gal terminal 
elaborations creating a multitude of up-regulated neutral and acid glycan 
products all with a common molecular backbone. Figure 24 is a general 
schematic illustrating two potential glycosylation pathways that when up- 
regulated could sequentially add galactose, fucose, and sialic acid 
monosaccharides to a common neutral oligosaccharide backbone.
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Comparative Analysis of Sialylated H5N4 Molecular 
Compositions
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Figure 22. Comparative analysis of sialylated H5N4 molecular composition prevalence. The 
vertical axis represents the % of neutral glycan pool. The horizontal axis represents the molecular 
composition. The evaluations are based on the population mean of 3 astrocyte samples and 3 
VM-NM1 samples. Error bars represent the coefficient of variation, standard deviation/mean x 
100, which indicates the percent variance of molecular composition peak intensities between the 
individual samples of a population.
Comparative Analysis of Sialylated H6N4 Molecular 
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Figure 23. Comparative analysis of sialylated H6N4 molecular composition prevalence. The 
vertical axis represents the % of neutral glycan pool. The horizontal axis represents the molecular 
composition. The evaluations are based on the population mean of 3 astrocyte and 3 VM-NM1 
samples. Error bars represent the coefficient of variation, standard deviation/mean x 100, which 
indicates the percent variance of molecular composition peak intensities between the individual 
samples of a population.
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Figure 24. Schematic of two proposed glycosylation pathways potentially up-regulated in VM- 
NM1, VM-M2, and VM-M3 fabricating H5N4 products.
A second collection of sialic acid containing molecular compositions is 
uniquely elevated in the metastatic cancer cell lines, VM-M2 and VM-M3 as 
depicted in Figure 25. In VM-M2, the molecular composition H3N4A1, H3N4gA1, 
H3N4A1gA1, H3N4gA2, H4N4A1, H4N4gA1, and H5N4gA1 represent 3.05%, 
0.96%, 0.88%, 0.58%, 2.94%, 1.09%, and 1.11 % of the total glycan pool, 
respectively. In VM-M3, these compositions represent 1.62%, 0.52%, 0.53%, 
0.42%, 1.59%, 0.54%, and 0.60% in VM-M3, while comprise only 0.51%, 0.385,
0.25%, 0.27%, 0.49%, 0.37%, and 0.30% of the total glycan pool in the astrocyte
control and 0.49%, 0.41%, 0.33%, 0.33%, 0.68%, 0.52%, and 0.51% in VM-NM1. 
All elevated molecular compositions are sialylated truncated glycans contain four 
GlcNAc residues. Glycoproteins containing truncated Olinked glycans bearing 
terminal sialic acids are commonly associated with metastatic progression 
(Brockhausen, 1.1999). To my knowledge, this is the first report of sialylated 
truncated A/-linked glycans associated with metastatic cancers. H3N4A1 is 
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H3N4A1, is most likely a truncated bi-antennary or bisecting glycan lacking 
galactose extension. As mentioned, the preferred substrate for sialyltransferases 
activity is (3-lactosamine (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. 
and Marth, J. 1999). If H3N4A1 lacks (3-lactosamine, then where is the sialic acid 
attached? Aberrant sialyltransferase activity adding a sialic acid directly to a 
GlcNAc, over activity of ct-mannosidases in the ER and cis-Golgi trimming one of 
the three core mannose residues of a bisecting glycan, or abnormal dolichol- 
linked precursor formation are all plausible explanations for the presence of 
H3N4A1. As described in section 6.3.1, non-substituted reducing-end 
paucimannose glycans are elevated in VM-M2 and VM-M3. Paucimannose 
structures may be potential substrates for abnormal sialylated structures, such as 
H3N4A1.
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Figure 23. Comparative analysis of sialylated truncated molecular composition prevalence. The 
vertical axis represents the % of neutral glycan pool. The horizontal axis represents the molecular 
composition. The evaluations are based on the population mean of 3 astrocyte samples, 3 VM- 
NM1 samples, 3 VM-M2 samples, and 3 VM-M3 samples. Error bars represent the coefficient of 
variation, standard deviation/mean x 100, which indicates the percent variance of molecular 
composition peak intensities between the individual samples of a population.
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6.4 Cancer-Specific Glvcomic Pattern Discovery through Glvcomic Profiling
Comparative analysis of glycome maps is a necessary step for 
distinguishing glycosylation patterns unique to cancer. Unlike protein synthesis, 
which is linear and template driven, A/-linked glycan assembly occurs through a 
multiple step process controlled by a repertoire of individual glycosyltransferases. 
Changes in glycosyltransferase expression and activity have a direct influence 
over the A/-linked glycans formed and can lead to a differential expression of a 
myriad of glycans. By observing the differential expression of multiple molecular 
compositions all of which possess a universal feature glycomic patterns specific 
to cancer glycosyltransferase dynamics may be determined. Four distinct 
glycomic patterns were discovered: (1) decreased relative abundance of high 
mannose glycans prevalence; (2) increased prevalence of neutral di-fucosylated 
glycans with a concomitant suppression of neutral mono-fucosylated glycans; (3) 
increased relative amount of neutral bi-antennary, tri-antennary, and tetra- 
antennary glycans; and (4), increased sialylation. These four distinct patterns 
are not mutually exclusive. Aberrant a1,3-galactosyltransferase, (3- 
galactosyltransferase, fucosyltransferase, and sialyltransferase activities are 
likely responsible for the differential expression of the specific molecular 
composition constituents embodying the four glycosylation patterns unique to 
VM-NM1, VM-M2, and VM-M3. Out of the complete glycome, consisting of 173 
known oligosaccharide molecular compositions, 37 differently expressed 
molecular compositions common in hexose and fucose content embody the four
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glycomic patterns distinct to cancer. These 37 pertinent compositions were 
selected for structural characterization via MSn disassembly.
95
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 7
STRUCTURAL CHARACTERIZATION OF NEUTRAL MONO- 
FUCOSYLATED GLYCANS
Although comparative analysis of glycomic maps uncovered 37 relevant 
molecular compositions effected by cancer glycodynamics, molecular 
composition cannot be directly interpreted into the actual structure. Under the 
umbrella of a single molecular ion peak, a collection of structures with the same 
atomic composition arranged in different configurations, termed structural 
isomers, exist. For example, two isomers of H5N4F1, the first isomer adorned 
with a Lex epitope, and the second isomer bearing a fucose-substituted reducing- 
end GlcNAc may both be present under the umbrella of the FI5N4F1 molecular 
ion peak. These two isomers are the products of two different glycosylation 
pathways and each performs a unique biological functions specific to the 
orientation of the fucose residue. MALDI-MS profiling alone can not discern 
these isomeric structures. Although inferences about glycosyltransferase activity 
and structural motifs based on the relative expression of multiple molecular 
compositions having a universal denominator are made, the actual structures 
present may not be deduced from an MS1 profile. To uncover actual structures, 
presumed and unanticipated, each of the 37 differentially expressed MS1
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molecular ion peaks underwent detailed structural characterization via ion trap 
MSn disassembly.
Fucosylated oligosaccharides rich with hexose content are dramatically 
elevated in VM-NM1, VM-M2, and VM-M3 compared to astrocyte control (section 
6.3.2). It is unknown whether elevations in a putative structure or unanticipated 
cancer specific isomers are responsible for the changes in expression. 
Comparative MSn analysis was performed on H5N3F1, FI6N3F1, FI5N4F1, 
H7N3F1, H6N4F1, H7N4F1, H6N6F1, H8N4F1, H7N5F1, H8N5F1, and H9N5F1 
to investigate the whether the presence and potential differential expression of 
isomeric structures is responsible for changes in relative expression shown by 
glycomic mapping. Unsurprisingly, all 11 mono-fucosylated molecular ion MS2 
spectra in all the samples revealed multiple structural isomers, which vary in 
relative abundance according to cell-type. Intriguingly, the non-metastatic 
astrocytoma (VM-NM1) and metastatic cancers (VM-M2 and VM-M3) divulged 
multiple unique isomers that are completely absent from the astrocyte control.
MS2 analysis involves the recognition of facile glycosidic cleavage ions 
and oligomer termini, which may be subsequently selected for further 
fragmentation by MSn to utilize diagnostic cross-ring fragmentations for 
assessment of linkage (Ashline, D., Singh, S., et al. 2005, Hanneman, A.J.,
Rosa, J.C., et al. 2006, Reinhold, V.N., Reinhold, B.B., et al. 1996, Reinhold, 
V.N., Reinhold, B.B., et al. 1995, Sheeley, D.M. and Reinhold, V.N. 1998) 
(Ashline, D., Singh, S., et al. 2005, Flanneman, A.J., Rosa, J.C., et al. 2006, 
Reinhold, V.N., Reinhold, B.B., et al. 1996, Reinhold, V.N., Reinhold, B.B., et al.
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1995, Sheeley, D.M. and Reinhold, V.N. 1998). Structures may be isomeric with 
regards to both topology and linkage. Some topological isomers are 
distinguishable by the presence of distinctive primary fragment ions (B- and Y- 
ions) resulting from labile glycosidic bond cleavages in a MS2 profile. Isomers 
differing in linkage position, however, are only distinguishable by diagnostic cross 
ring cleavage fragmentation ions (A-ions) generated in subsequent rounds of 
fragmentation (MSn>2).
Three topological isomers are immediately apparent in the electrospray 
MS2 spectra of the permethylated-reduced H6N3F1 ion, m/z2219.1 (m ^ 1121.1 
doubly-charged), in all the samples (Figure 26). Based on biosynthetic rule and 
glycomic patterns acquired during glycomic profiling three putative structures; (1) 
a core fucose-substituted hybrid glycan possessing a single terminal (3- 
lactosamine; (2) a non-core fucosylated hybrid glycan with a Lex epitope; and (3) 
a core fucose-substituted hybrid glycan possessing Galal ,3Gal(31,4GlcNAc- 
extension should be present. The MS2 fragmentation ions are consistent with 
this speculation. Collision induced glycosidic rupture yielded a B-type ion, m/z 
486.3, and its complement Y-ion fragment, m/z 1755.8 consistent with a structure 
possessing a terminal disaccharide Hex-HexNAc and its fucose bearing Y-ion 
complement. Fragment ions m/z 660.5 and m/z 1581.7 are B- and Y-ion 
complements. The ion at m/z 660 is consistent with a B3-ion composed of 
hexose, fucose, and /V-acetylglucosamine monomers. The ion at m/z 1581.7 is 
its non-fucosylated reducing-end complement. Fragment ion m/z 690 is typical of 
a B3-ion, which includes two hexoses and a single A/-acetylglucosamine. The
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fragment ion at m/z 1557.7 is consistent with its Y-type complement. VM-NM1 
exhibits a unique ion at m/z 864.5 and its complement at m/z 1377.6.
Anomalous ion fragments, at any MSn level, are prognostic of unanticipated 
structural isomers. Although the presence of diagnostic B- and Y-ions confirm 
the existence of at least three topological isomers at the MS2 level, the topology 
and linkage of the B- and Y-ion fragment ions cannot be characterized correctly 
and confidently. For example, the m/z 690 ion could have a number of 
topologies (Hex-Hex-HexNAc-; Hex-HexNAc-Hex; or HexNAc-Hex-Hex-, etc). 
Further MSn disassembly is necessary to adequately determine the identity and 
potential structural isomers within these B-ion fragments.
The ion intensity pattern of these diagnostic fragments differs 
tremendously between the samples. In the astrocyte control, the B3-ion at m/z 
660 is in very low abundance, 2% of the base ion, the B2 ion, m/z486, is 16% of 
the base ion, and m/z 690 is moderately abundant at 24% of the base ion (Figure 
26). Interestingly, the ion at m/z 690 is the base ion for VM-M2, while m/z 486 
and m/z 660 represent 4% and 19%, respectively. VM-M3 exhibits an ion 
intensity pattern similar to VM-M2, with m/z 690 being the predominant B-ion 
fragment. The pattern of B-ion intensities for VM-NM1 is distinct from both the 
astrocyte control and two metastatic cancers. The ion at m/z 660 is the 
predominant B-ion, 68% of the base ion, while m/z 690 and m/z486 only 
represent 18% and 8%, respectively. An anomalous fragment ion at m/z 864.5 is 
also present and abundant, 27% of the base ion, in VM-NM1.
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Although further MSn disassembly is necessary to confirm B-ion topology 
and assign linkage, the fragmentation ions at m/z 486, m/z 660, and m/z 690 are 
consistent with an exposed lactosamine disaccharide, a Lewis terminal epitope, 
and a Gal-Gal-GlcNAc termini, respectively. Each of these terminal epitopes are 
products of different glycosylation pathways and fulfill different biological roles. 
The differential expression of fragment ions m/z 486, m/z 660, and m/z 690 
between the astrocyte, astrocytoma, and metastatic cancers suggest cancer- 
specific changes in glycosyltransferase activity lead to the production of specific 
biologically relevant carbohydrate terminal epitopes. Interestingly, Lewis X 
epitopes are up-regulated in the non-metastatic malignant astrocytoma (VM- 
NM1), while the relative abundance of the terminal Gal-Gal-GlcNAc is greater in 
the metastatic cancers (VM-M2 and VM-M3). Lewis epitopes have been 
correlated with increase adhesive properties (Varki 1999). The increase in Lewis 
epitopes is consistent with the aggressive burrowing non-metastatic behavior 
typical of astrocytomas. Meanwhile the Galal ,3Gal(31,4GalNAc epitope 
promotes galectin-3 binding which correlates with tumor progression and 
metastasis. Galal ,3Gal(31,4GalNAc epitopes also diminish binding capacity to 
galectin-1, which is involved in astrocyte differentiation and neuronal survival 
(Endo, T. 2005, Sasaki, T., Hirabayashi, J., et al. 2004).
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Figure 26. Comparative analysis of ESI-MS2 spectra, m/z2219.1 (*1121.1 doubly-charged).
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To determine the identity of structural isomers represented by fragment 
ions m/z 486, m/z 660, m/z 690, and m/z 864 subsequent rounds of product 
isolation and fragmentation were performed on each fragment ion. Comparative 
analysis of fragment ion from the collision induced dissociation (CID) of m/z486 
show nearly identical spectra for the astrocyte control, VM-NM1, and VM-M2 
cells (Figure 27). The MS3 spectra provide fragment ions at m/z241 (B-ion), m/z 
268 (internal B/Y-ion), and m/z 259 (C-ion) consistent with a glycosidic cleavage 
between a terminal hexose residue and an internal A/-acetylhexosamine. The 
ions at m/z 329, m/z 315, and m/z 412 correspond to cross-ring cleavage 3,5A-, 
2,4A-, and 0,5A-ions, respectively. This A-ion fragment pattern is consistent with 
the terminal Gaipi ,4GlcNAc B2-type disaccharide moiety of the tetrasaccharide 
milk standard, lacto-/V-neotetraose (Ashline, D., Singh, S., et al. 2005). These 
fragmentation assignments are in agreement with previous reports demonstrating 
terminal (3-lactosamine disaccharide sequences are almost exclusively |31,4- 
linked in normal murine brain tissue (Chen, Y.J., Wing, D.R., et al. 1998). These 
findings strongly suggest a core fucose-substituted hybrid glycan possessing a 
single terminal (3-lactosamine is a putative structural isomer with the molecular 
ion composition, m/z 2219.1 in all the samples (Figure 33, structural isomer 1). 
The abundance of (3-lactosamine drops from 18% of the base ion in the astrocyte 
control, to 8% and 4%, in VM-NM1 and VM-M2 respectively. Interestingly, the |3- 
lactosamine ion, m/z486, is suppressed in VM-NM1 and VM-M2, while ions 
consistent with galactose-extended and fucosylated 3-lactosamine epitopes are 
elevated insinuating an elevations in galactosyl- and fucosyltransferases.
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Figure 27. ESI-MS3 spectral comparison of permethylated B2-ion fragment, m/z486, from the 
astrocyte control (C80-D30), astrocytoma (VM-NM1) and metastatic cancer (VM-M2) cell lines.
Although largely absent in humans, terminal Galal ,3Gaipi ,4GlcNAc 
sequences are common in the many mammalian organisms, including the mouse 
(Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999). The 
MS2 product ion m/z 690, which is consistent with a molecular composition 
composed of two hexose monomers and a HexNAc, underwent CID analysis 
(Figure 29). MS3 spectra from both the astrocyte and astrocytoma sample 
provide B-ion (/7Vz241, m/z445), Y-ion (m/z268, m/z472), C-ion (m/z259, m/z
103
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
463) and B/Y-ion (m/z 227) fragments consistent with a Hex-Hex-HexNAc 
topology. VM-M2 and VM-M3 demonstrate a fragmentation pattern identical to 
VM-NM1 (data not shown). Fragment ion m/z 472 is indicative of an internal B/Y- 
ion and was selected for MS4 analysis (Figure 28 and Figure 29). The MS4 
spectra of m/z472 from both samples present B/Y-ion (m/z227, m/z 268), and 
C/Y-ion (m/z 245) fragments confirming an internal Flex-FlexNAc topology. 
Fragment ions, m/z 301, m/z 315, and m/z 398 represent 2,4A, 3,5A, and 0,4A-ions, 
respectively. This A-ion fragmentation pattern is consistent with a 4-linked Hex- 
FlexNAc internal B/Y-ion (Figure 28). Fragment ion m/z445 from the MS3 m/z 
690 spectra is consistent with a Hex-Flex B2-ion. MS4 spectra of m/z 445 were 
obtained from the astrocyte and astrocytoma samples. Both samples present B- 
ion (m/z 241), C-ion (m/z 259) and B/Y-ion (m/z 221) fragments consistent with a 
Flex-Hex topology as well as fragment ion m/z 329 (3,5A-ion), which is consistent 
with the B2 ion from the trisaccharide standard globotriositol,
Galal ,4Gal(31,4GlcNAco/(Ashline, D., Singh, S., et al. 2005). The astrocytoma 
also has relatively intense fragments at m/z 315 (2’4A-ion), m/z 343 (3,5A-ion), and 
m/z371 (0,4A-ion). This A-ion fragmentation pattern parallels the fragmentation 
pattern of the standard linear B2 trisaccharide Galal ,3Gal(31,4GlcNAc (Ashline, 
D., Singh, S., et al. 2005). These fragmentation patterns suggest that two 
structural isomers differing in terminal monomer linkage are present in the 
astrocytoma and metastatic cancers: (1) a core fucose-substituted hybrid glycan 
possessing Galal ,3Gal(31,4GlcNAc- extension; and (2), a core fucose- 
substituted hybrid glycan possessing Gal1,4Gal|31,4GlcNAc- extension (Figure
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33, structural isomers 3 and 4, respectively). Interesting, the astrocyte control 
expresses almost exclusively the unanticipated core fucose-substituted hybrid 
glycan possessing a Gall ,4Gal(31,4GlcNAc- extension, not the expected core 
fucose-substituted hybrid glycan possessing Gala1,3Gal(31,4GlcNAc- extension.
The A-ion fragmentation pattern present in the MS4 spectra demonstrates 
that the cancer cell lines possess a unique structural isomer that is absent from 
the astrocyte control. As mentioned previously, m/z 690 is the base ion in the 
VM-M2 sample’s MS2 spectra (m/z 1121.1), while m/z 690 is only 19% and 24%, 
of the base ion in the non-metastatic and astrocyte control, respectively. The 
differential expression of m/z690 insinuates that a core fucose-substituted hybrid 
isomer possessing Galal ,3Gal(31,4GlcNAc- extension is elevated in metastatic 
cancers relative to the non-metastatic astrocytoma. The presence of the 3-linked 
Hex-Hex B2-ion in VM-NM1, VM-M2, and VM-M3, while completely absent in the 
astrocyte control suggests an up regulation of a1,3-galactosyltransferase activity 
in the cancer samples, particularly in the metastatic VM-M2 cell line. Only using 
an ion trap instrument performing sequential rounds of product ion isolation and 
fragmentation down to disaccharide units, in this case MS4, can the differences in 
these isomeric structures be elucidated.
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Figure 28. Comparison of ESI-MSn disassembly of B3-ion fragment m/z 690 in the astrocyte 
control and astrocytoma, VM-NM1.
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Lewis epitopes, particularly Lewisx structures, are up-regulated in various 
types of cancer (Itzkowitz, S.H., Yuan, M., et al. 1986, Kim, Y.S., Itzkowitz, S.H., 
et al. 1988). The cancer specific glycosylation patterns discovered during 
comparative glycomic profiling are consistent with these earlier findings 
suggesting outer-arm fucosylated structures are elevated in the cancer samples, 
particularly VM-NM1. The increased abundance of m/z 660 in VM-NM1 parallels 
these findings. The ion at m/z 660 was selected for CID analysis to verify outer- 
arm fucosylation (Figure 30). MS3 spectra from both the astrocyte and 
astrocytoma sample provide fragment ions consistent with two topologies, Hex- 
(Fuc-)HexNAc- and Fuc-HexNAc-Hex. VM-M2 and VM-M3 demonstrate similar 
fragmentation patterns (data not shown). Fragment ions at m/z 241 (B-ion), m/z 
259 (C-ion), m/z 442 (Y-ion), m/z424 (Z-ion), and m/z329 (3,5A-ion) are unique 
ions consistent with a Lewisx epitope (Figure 30). Interestingly, a second 
fucosylated isomer is also present. Fragment ions at m/z 456 (B2-ion), m/z 474 
(C-ion), m/z 227 (Y-ion), and m/z 544 (3,5A-ion) indicate an isomer with a Fuc- 
HexNAc-Hex topology. Both isomers have identical fragment ions at m/z 211 (B- 
ion), m/z472 (Y- ion), and m/z229 (C-ion). As with m/z 690, the detection and 
confirmation of the isomeric structures of m/z 660 required at least three 
sequential rounds of disassembly (MS3). These findings demonstrate two 
structural isomers are present at m/z 660: (1) the putative Lewisx hybrid glycan 
(Figure 33, structural isomer 2); and (2), an unanticipated isomer containing a 
terminal fucose attached to a penultimate HexNAc. The Lex epitope is highly 
regulated during the development of the central nervous system (Roberts, C.,
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Platt, N., Streit, A., Schachner, M., Stern, C.D. 1991, Streit, A., Nolte, C.,
Rasony, T., Schachner, M. 1993, Streit, A., Yuen, C.-T., Loveless, R.W., Lawson, 
A.M., Finne, J., Schmitz, B., Feizi, T., Stern, C.D. 1996). Increased Lex epitopes 
are associated with increased cell-adhesion activities in cancer tissues (Itzkowitz, 
S.H., Yuan, M., et al. 1986, Kim, Y.S., Itzkowitz, S.H., et al. 1988, Mannori, G., 
Crottet, P., et al. 1995). Interestingly, primary carcinomas exhibit enhanced 
levels of the Lexepitope, while in metastatic lesions Lex content diminishes 
(Nakagoe, T., Fukushima, K., et al. 1994). The increased abundance of Lex 
containing isomers in VM-NM1 may contribute to its aggressive malignant non­
metastatic behavior, compared to the metastatic VM-M2 and VM-M3 cell lines. 
Conversely, the lack of Lex isomers may contribute to the metastatic behavior of 
VM-M2 and VM-M3.
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Figure 30. ESI-MS spectral comparison of permethylated B3-ion fragment, m/z 660.
VM-NM1 expresses an anomalous fragmentation ion at m/z 864.5 as well 
as its compliment at m/z 1377.6 (Figure 26). This unique ion was selected for 
MSn disassembly to determine its structural identity. MS3 spectral fragment ions 
at m/z241 (B-ion), m/z 259 (C-ion), m/z445 (B2-ion), m/z463 (C2-ion), m/z442 
(B/Y/Y-ion) and m/z533 (3,5A- ion) are consistent with a B4-ion representing a 
novel galactose extended Lewisx epitope (Figure 31). The fragment ion m/z 445
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(B2-ion) was selected for MS4 CID analysis. The MS4 spectra of m/z445 presents 
fragment ions m/z 241 (B-ion) and m/z 259 (C-ion) consistent with a terminal 
hexose. Fragments at m/z 315 (2,4A-ion), m/z 343 (3,5A-ion), and m/z 371 (0,4A- 
ion) are typical of a a1,3-linked Hex-Hex B2-ion (Ashline, D., Singh, S., et al. 
2005). These spectra, along with the complement MS2 core Y-ion {m/z 1377.6) 
establish the presence of a novel astrocytoma-specific hybrid isomer that bears a 
non-fucosylated reducing end GlcNAc and a novel a1,3-galactose extended Lex 
epitope (Figure 33, structural isomer 5).
A second structural isomer is also present the MS3 spectra of the fragment 
ion m/z 864.3 (Figure 32). The fragment ions at m/z 415 (B2-ion), m/z433 (C2- 
ion), m/z431 (internal B/Y-ion), m/z472 (internal B/Y-ion), m/z 619 (B3-ion), m/z 
637 (C3-ion), m/z 503 (3,5A-ion) m/z707 (3,5A-ion), and m/z268 (Y-ion) indicate 
the presence of a very low abundant B4 isomer having a non-substituted HexNAc 
and a fucose linked to the most distal hexose residue. Fragment ions at m/z 341 
(0,4A-ion) and m/z 313 (3,5A-ion) are typically found in 2-linked Fuc-Hex B2 ions 
(Ashline, D., Singh, S., et al. 2005). Unfortunately, selection of m/z415 (B2-ion) 
for further MSn disassembly was not possible due to sensitivity limitations. 
Therefore only the linear Fuc-Hex-Hex-HexNAc topology maybe confirmed. 
Nonetheless, the collection of MS3 fragmentation ions mentioned along with the 
complement MS2 core Y-ion {m/z 1377.7) depicts a second unique structural 
isomeric present only in the astrocytoma (Figure 33, structural isomer 6). The 
expression of a1,2-fucosyltransferase catalyzes the transfer of a fucose residue 
on to a (3-lactosamine to form type I and type II antigens (Varki, A., Cummings,
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R., Esko, J., Freeze, H., Hart, G. and Marth, J. 1999). To date, a blood type 
antigen having an internal Hex-Hex- disaccharide sequence has not been 
reported elsewhere.
Both a1,2-fucosyltransferase and a1,3-galactosyltransferase competes 
with a-sialyltransferases for the same 3-lactosamine and Lex substrates. 
Increased activity of a1,2-fucosyltransferase has been shown to decrease sialyl- 
Lewis expression as well as metastatic properties in human pancreatic cancers 
(Aubert, M., Panicot, L., et al. 2000). The relative high abundance of m/z 864 
implies that elevated expression of both a1,2-fucosyltransferase and a1,3- 
galactosyltransferase out compete sialyltransferases for Lexand 3-lactosamine 
substrates in the malignant non-metastatic astrocytoma. The up-regulation of 
these terminal capping transferases, along with a1,3-fucosyltransferase may 
promote the adhesive non-metastatic characteristics intrinsic to highly malignant 
astrocytomas.
Although the aberrant ion m/z 864 is detectable in the MS2 spectrum of 
VM-NM1 structural identification and linkage assignment can only be elucidated 
after additional rounds of isolation and fragmentation. Confirmation of structural 
topology and linkage determination via MSn is an extremely sensitive and 
accurate method to detect changes in structural products resulting from aberrant 
glycosyltransferase activity in cancer. The structural determination of a novel 
astrocytoma specific hybrid-type structural isomer bearing a non-fucosylated 
reducing end GlcNAc and a novel a1,3-galactose extended Lex epitope confirms 
the unparalleled structural characterization and discovery abilities of MSn.
112
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(A) MS" Disassambly_m/z 864 (B) MS" Fragmentation Assigments
100 Astrocytoma 
VM-NM1 




445 4 ^  533
m/z 864463.4
67,6.4 822.5




3 4 3  V ',424.3
790.5
MeO OMe11 i*i i r i1








300 scans 257.1 \
211.0 259.1 415.3










Terminal Hex-Hex B, ion
200 260 320 m/z 380 440
(C) Structural Determination via MS": B„ ionjn/z 864 
s . ■ ■
Figure 31. ESI-MS" disassembly of B-ion fragment m/z 864 in the astrocytoma cell line, VM- 
NM1.
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Figure 33. Structural isomers present with molecular composition H6N3F1 in the astrocyte 
control, astrocytoma (VM-NM1), and metastatic cancers (VM-M2 and VM-M3).
Comparative analysis of the MS2 spectra from a second hybrid molecular 
composition H7N3F1 (m/z 1223.1 doubly-charged) reveals B-type fragment ions 
consistent with (3-lactosamine, m/z 486.4, and galactose extended (3- 
lactosamine, m/z 690.5, in all the samples (Figure 34). The existence of these
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reducing-end ions demonstrate that two putative topological isomeric structures: 
(1) a core fucose-substituted hybrid glycan possessing a single terminal (3- 
lactosamine; and (2), a core fucose-substituted hybrid glycan possessing 
Galal ,3Gal(31,4GlcNAc- extension are present in all four samples. Excitingly, 
the ion intensities of the individual B-ions are different in each sample. Similar to 
the MS2 spectra from H6N3F1, the B3-ion at m/z 690 is a dominate ion, 92% of 
the base ion, for VM-M2, while low abundant for the astrocyte control, 
astrocytoma, and the other metastatic cell line, 12%, 8%, and 8% respectively. 
Interestingly, the B3-ion at m/z 660 is unique to VM-NM1, while m/z 864.5 is 
found in VM-NM1, VM-M2, and VM-M3. Consistent with the H6N3F1 spectral 
data, fucosylated B-ions, m/z 660 and m/z 864, are the major reducing end 
epitopes, 24% and 54% of the base ion, in the non-metastatic astrocytoma. All 
B-ion fragments were isolated and subjected to CID analysis. Subsequent MSn 
fragmentation patterns from all the MS2 B-ion fragments were consistent with 
those from H6N3F1 B-ion disassembly. These findings confirm the presence of 
structural isomers adorned with 3-1,4-lactosamine, Lex, Galal ,3Gal31,4GlcNAc, 
and a1,3-galactose extended Lex epitopes (MSn spectral information not shown).
The differential expression of B-ion fragments, hence different structures, 
is consequent of different aberrant glycosyltransferase activities occurring in the 
non-metastatic astrocytoma and the metastatic brain cancers. Lewisx and a1,3- 
galactose extend Lex structural isomers are up-regulated in the astrocytoma, 
while Galal ,3Gal31,4GlcNAc- and a1,3-galactose extended Lex structural 
isomers are up-regulated in the metastatic cancers. This differential expression
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is likely the result of over-expression of a1,3-fucosyltransferases and a1,3- 
galactosyltransferase over-expression in the non-metastatic astrocytoma, VM- 
NM1, while drastic over-expression of a1,3-galactosyltransferase and normal 
expression of a1,3-fucosyltransferases promotes the differential B-ion expression 
in the metastatic cancers, VM-M2 and VM-M3.
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Figure 34. Comparative analysis of ESI-MS2 spectra, m/z2423.2 (* m/z 1223.1 doubly-charged).
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Comparative MSn analysis of H6N4F1 (m/z 1243.1) reinforces that the 
presence and abundance of different structural isomers in the astrocytoma and 
metastatic cancers are responsible for the increased relative intensity of the 
H6N4F1 molecular ion (Figure 35). The non-fucosylated B-ion fragments, m/z 
486 and m/z 690, are present in all the samples. Characteristic of VM-M2 B-ion 
fragmentation, m/z 690 is a major ion, 56% of the base ion and elevated relative 
to the astrocyte control, 14% of the base ion. Emblematic of VM-NM1, 
fucosylated B3- and B4-ions, m/z 660 and m/z 864, are major B-ion fragments 
and elevated compared to VM-M2 and VM-M3. These fucosylated B-ion 
fragments are completely absent in the astrocyte. The subsequent MSn 
fragmentation patterns of all MS2 B-ions were in agreement with B-ion fragments 
of FI6N3F1 and H7N3F1 (data not shown). Common to all MS2 spectra (m/z 
1243.1) is an ion at m/z 894.6, which is consistent with a terminal epitope which 
includes three hexoses and an A/-acetylhexosamine. Unfortunately, due to 
limitation in sensitivity, structural analysis could not be performed on this ion.
As demonstrated in Figure 21, the relative abundance of FI6N4F1 is 
elevated in both, the astrocytoma, 0.82% of the neutral glycan pool, and 
metastatic cancers, 0.66% and 0.55% of the neutral glycan pool, relative to the 
astrocyte control, 0.37% of the neutral glycan pool. As Figure 35 illustrates, only 
core fucosylated structural isomers are present in the astrocyte, meanwhile core 
fucosylated structures as well as isomeric structures bearing Lex and galactose- 
extend Lex are present in the astrocytoma. Additionally, the elevation in VM-M2
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
is the result of elevated levels of the Galal ,3Gal(31,4GlcNAc containing isomer 
consequent of up-regulated a1,3-galactosyltransferase activity.
The comparative analysis of the MS2 spectra of H7N4F1 (m/z 1345.7 
doubly-charged) follow by subsequent B-ion isolation and fragmentation is 
another example underpinning different structural isomers present in the 
astrocytoma and metastatic cancers, while absent from the astrocyte control are 
responsible for the increased relative intensity of the H7N4F1 molecular ion 
(Figure 36). The B2-ion, m/z 486, which is consistent with p-lactosamine, is 
noticeably absent from the astrocyte control, while present in very low 
abundance in VM-NM1, VM-M2, and VM-M3. However, the fragment ion 
consistent with the Lex epitope, m/z 660, is present and in low abundance in the 
astrocyte. As expected, VM-NM1 expresses an ion at m/z 660. Interestingly, 
only the cancer samples express the B3-ion, m/z 690. Archetypical of VM-M2 
m/z690 is a major ion, 88% of the base ion. This fragment ion is also prominent 
in both VM-NM1 and VM-M3, 49% and 41%, respectively. An ion at m/z 864 was 
found in VM-NM1, VM-M2, and VM-M3. The ion at m/z 864 was completely 
absent from the normal astrocyte. Structural characterization of the B-ions via 
MSn disassembly confirmed m/z 486 as the disaccharide (3-1,4-lactosamine, m/z 
660 as a Lex epitope, m/z 690 as Galal ,3Gal(31,4GlcNAc, and m/z 864 as the 
cancer specific a1,3-galactose extended Lex epitope (data not shown).
Interestingly, all H7N4F1 MS2 spectra exhibit an ion at m/z 894. The 
fragment ion m/z 894 was isolated and subjected to subsequent rounds of 
fragmentation (Figure 37). MS3 fragment ions m/z 649 (B3-ion), m/z 667(C3-ion),
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and m/z 737(3,5A-ion) suggest an A/-acetylhexosamine is the reducing end termini 
of this product ion. Fragment ion m/z 667 is a B/Y-ion remaining from the neutral 
loss of a terminal hexose. The ion at m/z 667 was selected for MS4 analysis. The 
MS4 product ions m/z 241 (B-ion), m/z 259 (C-ion), and m/z458 (B/Y/Y-ion) 
indicate a second terminal hexose. Cross-ring cleavage ions at m/z 329 (3,5A- 
ion) and m/z 301 (0,4A-ion) indicate the second terminal hexose residue is 6- 
linked. This A-ion fragmentation pattern is analogous to the pattern observed 
from the purchased standard panose (Ashline, D., Singh, S., et al. 2005). The 
ion at m/z 268 (Y-ion) indicates the neutral loss of an /V-acetylhexosamine 
residue. Fragment ions m/z431 (B/Y-ion), m/z449 (C/Y-ion), m/z241 (B-ion), 
and m/z259 (C-ion) indicate a terminal Flex-Flex disaccharide with a single scar 
(open hydroxyl group). Fragment ions m/z 458 (B/Y/Y-ion) is consistent with a 
Hex-HexNAc topology with two open hydroxyl groups (Ashline, D.J., Lapadula, 
A.J., et al. 2007). To confirm the expected B/Y/Y Flex-FlexNAc disaccharide 
topology, m/z458 underwent CID analysis. The MS5product ions at m/z2~\3 
(B/Y/Y-ion), m/z230 (C/Y/Y-ion), and m/z268 (Y-ion) confirm the branched Hex- 
HexNAc topology. This set of MSn disassembly spectra proves the MS2 ion at 
m/z 894 is a B4 terminal branched Flex3FlexNAci structure. The observed 
fragmentation pattern of m/z 894 in the astrocyte, VM-NM1, VM-M2, and VM-M3 
matched m/z 894 fragmentation pattern from previous works (Flanneman, A.J., 
Rosa, J.C., et al. 2006). To my knowledge, this is the first account of an A/-linked 
branched B4 HexsHexNACi epitope found in a mammalian system.
121
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Under the umbrella of a single molecular ion peak, a collection of 
structures with the same atomic composition arranged in different configurations 
exist. Individual structural isomers are the products of different glycosylation 
pathways and each performs a unique biological functions specific to the 
orientation of its functional groups. Comparative analysis of glycomic maps 
uncovered 11 relevant mono-fucosylated molecular compositions effected by 
cancer glycodynamics. MSn spectral analysis of H6N3F1, H7N3F1, H6N4F1, 
and H7NF1, as well as the 7 other mono-fucosylated glycans, four of which are 
shown in Appendix B, clearly demonstrate distinct structural isomers created by 
aberrant glycosyltransferase activity are responsible for the differential 
expression of mono-fucosylated molecular ions in the cancer samples observed 
during glycomic profiling. Only through gas-phase separation and subsequent 
fragmentation (MSn) can isomeric structures be distinguished from one another.
A shift in B-ion fragmentation pattern, hence a shift in structural isomer 
presence, occurs between the astrocyte control, astrocytoma, and two metastatic 
cancers. As shown in Table 9, the fragment ion, m/z486, represents 31.4% of 
the neutral terminal epitopes in the astrocyte, which decreases to 12.2%, 13.6%, 
and 14.3% in VM-NM1, VM-M2, and VM-M3, respectively. The fragment 
corresponding to the Lex epitope, m/z 660, is elevated in the astrocytoma, 23.2% 
of the terminal epitope pool, compared to the astrocyte, 15.9% of the terminal 
epitope pool. Interestingly, both VM-M2 and VM-M3 express suppressed levels 
of m/z 660, 5.8% and 9.1 % of the terminal epitope pool, respectively. However, 
m/z 690 representing an a 1,3-galactose extended (3-lactosamine epitope is
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drastically elevated in VM-M2 and VM-M3 occupying 71.1% and 63.3% of the 
total terminal epitope pool. This epitope is suppressed in VM-NM1, 36.9%, 
compared to the astrocyte control, 52.4%. The expression of the terminal 
epitope ion, m /z 864, is greatly elevated in VM-NM1, 27.7% compared to VM-M2 
and VM-M3, 9.6% and 13.7%, respectively.
Malignant non-metastatic astrocytomas and metastatic brain tumors 
express different A/-linked glycans. Lewisx and a1,3-galactose extend Lex 
structural isomers are up-regulated in the astrocytoma, while Galal,
3Gal[31,4GlcNAc- and a1,3-galactose extend Lex structural isomers are up- 
regulated in the metastatic cancers. This differential expression is likely the 
result of over-expression of a1,3-fucosyltransferases in the non-metastatic 
astrocytoma VM-NM1 and over-expression of a1,3-galactosyltransferase and 
normal expression of a 1,3-fucosyltransferases in the metastatic cancers, VM-M2 
and VM-M3. These collections of MSn spectral data indicate that during the 
different stages of cancer progression the expression and activities of aberrant 
glycosyltransferases change; and consequently, produce a distinct repertoire of 
isomers that bear terminal epitopes pertinent for the specific activities (i.e., 
adhesion, motility and receptor activation) necessary for that particular stage of 
cancer progression.
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Prevalence of 
Terminal Epitopes Sample
MS^ Fragment Ions (m/z) Astrocyte Astrocytoma VM-M2 VM-M3
o* 486 31.4 17.12 12.2 81.6 13.6 18.02 14.3 27.17
°T 660 15.9 17.26 23.2 24.49 5.8 14.75 9.1 8.58
o o »  690 52.4 21.4 36.9 20.28 71.1 22.73 63.0 23.4
°ST864 ND 27.7 15.8 9.6 10.7 13.7 28.7
Table 9. Prevalence of terminal epitopes. The first value represents the percent of terminal 
epitope pool defined as the intensity of the individual epitope normalized to the intensity sum of all 
epitopes. The second value represents the coefficient of variation, defined as the standard 
deviation divided by the mean value multiplied by 100. The values are based on the analysis of 
seven mono-fucosylated molecular compositions from three individual samples of each cell type. 
ND is the abbreviation for Not Detected.
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Figure 35. Comparative analysis of ESI-MS2 spectra, m/z2463.3 (* m/z 1243.1 doubly-charged).
125
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.




















MS2 m/z 1345.7* 
NL:Z60E1 8 , 8 c  














) 11  ..... r: MW-trr'fA-
500 m/z 750
VM-NM1






600 1000 m/z 1400











MS2 m/z 1345 7*












































o o *  MS2 m/z 1345.7* Magnified View 
690.4 NL: 3.72E1 o





600 1000 m/z 1400 1800 m/z 7 5 0 1000
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CHAPTER 8
STRUCTURAL CHARACTERIZATION OF PAUCIMANNOSE 
GLYCANS
The differential expression of high mannose glycans between the 
astrocyte control, astrocytoma, and two metastatic cell lines indicate aberrant 
glycosylation processing in the ER, cis- and mediai-Golgi with regards to cancer 
progression. MSn analysis was performed investigating potential alterations in 
glycan structure consequent of abnormal early glycan processing. As discussed 
in section 6.3.1, the expression of paucimannose glycans is different in the 
astrocyte control, non-metastatic astrocytoma, and metastatic cancer cell lines. 
The metastatic cancers express elevated levels compared to the astrocyte 
control, while non-metastatic cancer demonstrate diminished levels of 
paucimannose glycans. Although not discussed in section 6.3.1, M2N2F1 is 
suppressed in the astrocytoma, 3.67% of the neutral glycan pool, compared to 
the astrocyte control, 9.96% of the neutral glycan pool, while elevated in VM-M2, 
15.33% of the neutral glycan pool. The paucimannose glycan M2N2F1, m/z 
1157.7, was selected for CID analysis to investigate potential isomeric structures 
(Figure 38 and Figure 39). In the astrocyte and astrocytoma two major ions are 
observed m/z 690.4 and m/z 490.4. These ions represent B-type and Y-type 
product ions from a glycosidic rupture between the penultimate and fucose-
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substituted reducing-end GlcNAc. The B3-ion was selected for MS3 analysis. 
MS3 fragment ions at m/z 241 (B-ion), m/z 445 (B2-ion), /77/z268(Y-ion), m/z 472 
(B/Y-ion), m/z259 (C-ion) and m/z 463 (C2-ion) confirm the expected Man-Man- 
GlcNAc truncated core topology. The cis-Golgi enzyme a-Mannosidase II 
cleaves both a1,3- and a1,6-mannose residues from the a1,6-arm of the 
chitobiose core (Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G. and 
Marth, J. 1999). M2N2F1 is likely a product of excessive trimming by a- 
Mannosidase II. It is unknown whether excessive a-Mannosidase II cleaves the 
underlying a1,6-mannose of the tri-mannosyl core or requires 3-hexaminidase 
activity and cleaves the newly exposed a1,3-mannose. The B2-ion, m/z 445, was 
subjected to MS4 analysis. The astrocyte and astrocytoma exhibit identical MS4 
m/z 445 spectra (Figure 38 and Figure 39). Both samples exhibit fragment ions 
at m/z 329 (3,5A-ion) and m/z 301 (0,4A-ion) as well as the ion intensity pattern 
typical of a 6-linked Hex-Hex B2-ion (Ashline, D., Singh, S., et al. 2005). Both 
samples express trace amounts of m/z 343 and m/z 371 indicative of a 3-linked 
Hex-Hex B2-ion. These spectra imply a-mannosidase preferentially cleaves the 
a1,3-mannose after the removal of the GlcNAc residue by (3-hexaminidase. 
Although not shown VM-M2 and VM-M3 spectra are consistent with these 
findings. Fragment ion m/z472 (internal B/Y-ion) is indicative of the core 
Man(31,4GlcNAc. The MS4 spectra of m/z 472 from both samples present B/Y- 
ion (m/z 227, m/z 268), and C/Y-ion (m/z 245) fragments confirming an internal 
Hex-HexNAc topology (Figure 38 and Figure 39). Fragment ions, m/z 301, m/z 
315, and m/z 398 represent 2,4A, 3,5A, and 0,4A-ions, respectively. This A-ion
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fragmentation pattern is consistent with the expected Man(31,4GlcNAc structure. 
Interestingly, the astrocytoma expresses an ion at m/z 370 (3,5A-ion) indicative of 
an pi ,3 linkage. The ion intensity pattern is also consistent with the 
Hex(31,3HexNAc B2-type fragment from the standard lacto-A/-tetraose (Ashline, 
D., Singh, S., et al. 2005). This data suggests the astrocytoma expresses the 
typical Man(31,4GlcNAc core as well as an alternative Man(31,3GlcNAc core.
The chitobiose core is an artifact from the conserved lipid-linked 
oligosaccharide precursor transferred en bloc to a nascent protein during 
translation (Taylor, M.E., Drickamer, K. 2003). The initial linkage of the two 
proximal GlcNAc residues and the first five mannose residues to the dolichol 
anchor occur on the cytosolic side of the ER (Trombetta, E.S. 2003). These 
spectral findings suggest cytosolic mannosyltransferase activity is affected by 
cancer pathology. This anomalous core structure may have a tremendous effect 
on downstream glycosyltransferase activity leading to a unique set of glycans 
which are expressed exclusively in cancer. The presence of M2N2F1 with the 
alternative Man(31,3GlcNAc core proves processing enzymes, a-mannosidases, 
as well as a1,6-core fucosyltransferase utilize this alternative structure as a 
substrate. Further MSn analysis disassembling the cores of complex-type 
glycans is necessary to elucidate the effect a Man(31,3GlcNAc has on glycan 
assembly. This finding insinuates that the initial cytosolic steps in A/-linked 
glycosylation are affected by cancer.
Although structural characterization of the differentially expressed high 
mannose and sialylated structures is necessary to gain a more complete
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understanding of aberrant glycosylation in the VM-NM1, VM-M2, and VM-M3, 
this body of work clearly demonstrates that a systematic approach establishing 
cancer-specific glycomic patterns and structural characterization via MSn 
elucidates actual glycan structures and sub-structural epitopes aberrantly 
expressed in cancer.
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CHAPTER 9
CONCLUSION
Aberrancies in glycan processing lead to a unique array of glycan terminal 
elaborations and glycomic patterns that are essential determinants in malignant 
function. The expression, localization, and activity of glycosyltransferases 
govern the structural variability of glycan moieties (Brockhausen, I. 2006).
Cancer uniquely shifts glycosyltransferase dynamics promoting cancer-specific 
glycan construction, subsequently creating cancer-specific glycomic patterns 
observed in MALDI-MS glycomic profiles. Change in glycan structure leads to a 
myriad of adverse functional events witnessed during each stage of tumor 
progression.
Analytical advancement in ion trap MSn methodology provides an 
unprecedented platform for glycoanalytic investigation (Hanneman, A.J., Rosa, 
J.C., et al. 2006, Reinhold, V.N., Reinhold, B.B., et al. 1996, Reinhold, V.N., 
Reinhold, B.B., et al. 1995, Sheeley, D.M. and Reinhold, V.N. 1998) (Ashline, D., 
Singh, S., et al. 2005, Ashline, D.J., Lapadula, A.J., et al. 2007). With this 
glycoanalytic approach precise details of individual glycan epitopes and isobaric 
compositions of cancerous tissue can be analyzed under great scrutiny. Using 
VM-M2 and VM-M3 cell lines as a metastatic model and the VM-NM1 cell line as 
a non-metastatic model, this body of work systematically uncovered and
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characterized anomalous N-linked glycan structures unique to non-metastatic 
and metastatic cancers. This investigation establishes ion trap MSn disassembly 
as the glycoanalytic approach, par excellence, for structural glycomic 
investigation with regards to cancer. The application of this approach toward 
early detection biomarker discovery and cancer biology could be potentially far 
reaching.
135
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 10
FUTURE WORKS
High mannose glycans have not been extensively studied by MSn 
glycoanalytic approach. Prior to investigating aberrant oligomannosidic 
structures resultant from cancer structural characterization of isomeric 
oligomannosidic glycans from normal biological samples must be analyzed to 
establish a standard. High mannose glycans were released and subject to MSn 
disassembly from three controls; chicken egg ovalbumin, astrocyte cell lysate, 
and macrophage cell lysate. To start, the fully processed tri-mannosyl core 
structure M3N2, m/z 1187, underwent CID analysis (Figure 40). As expected all 
three standards exhibit the expected tri-mannosyl core B-type ion, m/z 894, from 
the labile glycosidic cleavage between the penultimate and reducing-end GlcNAc 
residues. Due to the selected mass range, the reducing end Y-ion complement, 
m/z 316, was not observed. The MS3 spectra of m/z 894 from both ovalbumin 
and the astrocyte present diagnostic ions consistent with the putative branched 
tri-mannosyl core (Hanneman, A.J., Rosa, J.C., et al. 2006). The most abundant 
ion resulting from a neutral loss of a terminal hexose is observed at m/z 676. 
Subsequent MS4 disassembly of m/z 676 demonstrates major ions at m/z 519 
(3,5A-ion), m/z 458 (B/Y/Y-ion), and m/z 431 (B/Y-ion) consistent with the
1 3 6
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expected branched tri-mannosyl structure (Figure 40). Interestingly, an ion 
inconsistent with the putative structure is present at m/z 472 is present. This ion 
is characteristic of a Hex-HexNAc disaccharide having a single open hydroxyl 
group (Ashline, D.J., Lapadula, A.J., et al. 2007). The MS5spectrum confirms m/z 
472 is Hex-HexNAc disaccharide with a singly open hydroxyl group implying a 
second linear tri-mannosyl chitibiose core is present in the astrocytoma (Figure 
40, structural isomer 2). Trace levels of m/z 472 are also observed in ovalbumin, 
however due to limitations in sensitivity subsequent disassembly events could 
not be performed.
The MS2 spectra {m/z 1187) from the astrocyte and macrophage samples 
reveal ions at m/z 690.4 and m/z 520, which are inconsistent with the putative 
branched tri-mannosyl core (Figure 40, structure 1). Subsequent fragmentation 
of m/z 690 exhibits fragment ions consistent with a Hex-Hex-HexNAc topology 
(Figure 41, spectra B1). MS4 spectral analysis of m/z 472 is consistent with the 
expected Manf31,4GlcNAc core (Figure 41, spectra B2). The B2-ion, m/z445, 
reveals an ion at m/z 329 (3,5A-ion) as well as an ion intensity pattern congruent 
with a 6-linked Hex-Hex B2 type structure (Ashline, D., Singh, S., et al. 2005).
This sequential disassembly confirms m/z 690 is a B3-ion representing a 
Manal ,6Man(31,4GlcNAc core structure. The reducing end complement to m/z 
690 is m/z 520. The MS3 spectra of m/z 520 express complementary ions at m/z 
241 (B-ion) and m/z 302 (Y-ion). The fragment ion m/z 259 (C-ion) is consistent 
with the loss of a terminal hexose residue. All fragments in the spectra can be 
accounted for and suggest a hexose-substituted reducing end GlcNAc. These
1 3 7
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spectra demonstrate a third structural isomer containing a hexose-substituted 
reducing end GlcNAc. This is the first account of a hexose-substituted reducing- 
end GlcNAc. Unfortunately, the hexose monomer identity is unknown. A 
mannose-substituted reducing GlcNAc would suggest this novel structure is the 
result of lipid linked oligosaccharide precursor formation in cytosol or ER. An 
a1,6-galactosyltransferase has never been reported. Therefore, a galactose- 
substituted reducing-end GlcNAc would suggest the known a1,6-core 
fucosyltransferase can utilize UDP-Gal nucleotide sugar donors. Interestingly, 
mutant Chinese .Hamster Ovary (CHO) cells that do not convert GDP-Man to 
GDP-Fuc form underfucosylated glycoproteins (Sullivan, F.X., Kumar, R., et al.
1998). It also possible that GDP-Man nucleotide sugars are utilized by a1,6-core 
fucosyltransferase constitutively at low levels in normal cells. This structural 
isomer is a product of this lesser process. Although the anomalous ions 
representing this structural isomer are present in the MS2 spectra, subsequent 
rounds of product ion isolation and fragmentation are essential to confirm this 
novel structural isomer. The MS2 spectra of the paucimannose glycan H4N2 in 
the astrocyte and macrophage controls demonstrates fragment ions consistent 
with a structural isomer having a hexose-substituted reducing-end GlcNAc 
(Figure 42). While the major ion observed represents the B5-ion of the putative 
oligomannosidic structure (MSn data not shown) (Figure 42), two aberrant ions, 
m/z 894.4 and m/z 520, which correspond to a B4-ion, which includes three 
hexoses and an N-acetylglucosamine, and its reciprocal Y-ion are present. MSn 
spectral data confirm the ion at m/z 894.4 represents a terminal branched tri-
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mannosyl core (Figure 42). These sequential spectra are in agreement with the 
m/z 894 fragmentation patterns from the putative H3N2 structure, shown in 
Figure 40, as well as other biological and purchased standards (Hanneman, A.J., 
Rosa, J.C., et al. 2006). The presence and pattern of fragmentation ions in the 
MS3 spectra of m/z 520 are consistent with a hexose-substituted reducing-end 
GlcNAc (Figure 42). MSn disassembly of the molecular ion for H5N2 in the 
astrocyte as well as the macrophage conveys a structure isomer containing a 
hexose-substituted reducing end GlcNAc (Figure 43). Again, two aberrant ions 
are observed in the MS2 spectra, m/z 1098 and m/z 520, consistent with a B5-ion 
and its reciprocal reducing end, respectively. As Figure 43 demonstrates, 
subsequent isolation and MSn disassembly of m/z 1098 and m/z 520 confirm the 
presence of a structural isomer bearing a hexose-substituted-reducing end 
GlcNAc. Interestingly, isomeric structures adorned with a hexose-substituted 
reducing-end GlcNAc were found throughout the entire oligomannosidic series 
up to M8N2. The MS3 spectrum of m/z520 between samples and across 
different oligomannosidic compositions demonstrates complete congruency. 
Unfortunately, purified hexose-substituted reducing end standards do not exist.
An alternative or orthogonal fragmentation pathway utilizing sequential 
neutral loss was implemented to verify the presence of core hexosylated 
oligomannosidic glycans. The MS2 spectra (m/z 1187) of M3N2 reveals an ion at 
m/z 969.5 that is consistent with neutral loss of terminal hexose (-218 amu) 
(Figure 41). This ion, m/z 969, was isolated and subjected to MS3 analysis 
(Figure 45). Two terminal hexoses are present on a structural isomer bearing a
139
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hexose-substituted reducing GlcNAc and truncated di-mannosyl core as shown 
in Figure 44. The neutral loss of the terminal hexose may come from either 
location. The structures C1 and C2 in Figure 44 illustrate the two products 
consequent of a neutral loss of a terminal hexose. All major ions observed in the 
MS3 spectra are consistent with the classic branched chitobiose core; however, 
three ions, m/z 472, m/z 520, and m/z 690, are inconsistent with the classic 
structure. The uncharacteristic ions at m/z 520 and m/z 690 can only arise from 
an alternative structural isomer with a truncated di-mannosyl core and a hexose- 
substituted reducing end GlcNAc shown in Figure 41. The aberrant ion at m/z 
472 may originate from two atypical structural isomers either a linear tri-mannosyl 
core (Figure 40, structure 2) or the truncated hexose-substituted reducing end 
GlcNAc isomer (Figure 42). Due to limitations in sensitivity subsequent 
disassembly of the aberrant ions could not be undertaken. Although further 
structural analysis was not performed, the occurrence of the diagnostic ions, m/z 
472, m/z 520 and m/z 690, in two orthogonal pathways implies these isomeric 
structures are present.
Similarly, an orthogonal fragmentation pathway following sequential 
neutral losses of hexose monomers supports the presence of a novel structural 
isomer with the molecular composition H4N2 (Figure 45). The ion at m/z 1173 in 
the MS2 spectrum (m/z 1392) of H4N2 corresponds to the neutral loss of a 
terminal hexose (-218 amu). The major ion fragments observed in the MS3 
spectrum of m/z 1173 are indicative of the putative H4N2 structure bearing four 
non-reducing end hexose residues (Figure 45). Interestingly, the astrocyte and
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macrophage samples reveal two ions of low abundance, m/z 894 and m/z 520, 
that are inconsistent with the putative H4N2 structure, while these ions are 
completely absent in the ovalbumin samples. These low abundant ions are 
characteristic of an alternative structure bearing three non-reducing mannose 
residues and a hexose-substituted reducing-end GlcNAc. The low abundant 
fragment ion m/z 955 in the MS3 spectrum of m/z 1157 is consistent with the 
neutral loss of a second terminal hexose. Although of poor quality, the MS4 
spectrum of m/z 955 reveals a diagnostic ion at m/z 520. The occurrence of 
diagnostic ions, m/z 894 and m/z 520 in a second orthogonal MSn fragmentation 
pathway implies a structural isomer bearing only three non-reducing end 
mannose residues and a hexose-substituted reducing end core is present.
MSn disassembly of H3N2, H4N2, and H5N2 illustrates multiple isomeric 
structures composed of the same molecular building blocks exist. 
Oligomannosidic glycans have been extensively analyzed, however these 
isomeric structure have never been reported. Neither the biosynthetic pathways 
constructing these novels glycans nor the functions of these novel 
oligomannosidic structures are known. This, however, doesn’t mean they do not 
exist. Only through gas-phase separation and subsequent fragmentation can 
such isomeric structure be resolved. In the future, with a healthier understanding 
of oligomannosidic isomeric structures, a comparative analysis of 
oligomannosidic structural isomers with regard to cancer maybe properly 
investigated.
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Two distinct cohorts of sialylated structures are differentially expressed 
the non-metastatic and metastatic cancers. Further analysis investigating the 
identity of the structures responsible for these discrepancies must also be 
pursued.
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APPENDIX A 







A s t r o c y t e
C 8 -D 3 0
A s t r o c y t o m a
V M -N M 1
M e t a s t a t ic
V M - M 2
M e t a s t a t ic
V M - M 3
Molecular
Composition [rrv+Naf [m+ZNaf" % of TGP
% Relative 
to M5N2 % of TGP
% Relative 
to M5N2 % of TGP
% Relative 
to M5N2 % of TGP
% Relative 
to M5N2
H3N3F1A1 1968 995.5 0.49 24.6 4.75 23.9 0.59 27.6 7.67 55.9 0.72 52.7 11.22 60.8 0.84 10.4 6.90 41.2
H4N3F1A1 1097.6 2172.1 0.49 10.0 4.74 9.3 0.54 23.9 6.89 52.6 0.77 32.6 11.97 41.5 0.59 15.7 4.63 16.2
H4N3A1gA1 1104 2185 0.36 13.7 3.49 13.0 0.42 10.1 5.28 40.1 0.42 25.7 6.46 34.9 0.45 67.0 4.04 89.1
H5N3A1 1112.6 2202.1 0.41 41.7 3.91 41.1 0.57 9.0 7.21 39.0 0.43 14.4 6.54 4.8 0.59 87.6 5.42 104.7
H4N3A2 1191.1 2359.2 0.33 3.4 3.21 2.8 0.47 0.9 5.81 31.5 0.44 26.8 6.77 36.0 0.36 33.5 3.06 61.7
H5N3F1A1 1199.6 2376.2 0.34 32.6 3.28 33.2 0.44 10.5 5.42 20.3 0.28 21.8 4.23 12.3 0.33 76.7 2.99 96.5
H6N3A1 1214.6 2406.2 0.36 31.8 3.51 31.2 0.42 13.6 5.29 43.3 0.35 18.7 5.32 28.1 0.42 60.2 3.73 83.8
H4N3F3A1 1271.7 2520.3 0.25 22.8 2.45 23.4 0.38 16.0 4.66 14.8 0.31 3.5 4.66 13.1 0.31 71.9 2.81 92.9
H5N3A2 1293.2 2563.3 0.15 140.2 1.40 140.2 0.41 18.2 4.97 12.7 0.28 2.1 4.30 7.5 0.26 58.7 2.28 82.6
H6N3F1A1 1301.7 2580.3 0.33 14.3 3.15 15.0 0.37 2.8 4.52 27.8 0.28 12.7 4.30 22.2 0.24 54.3 2.15 79.1
H4N3F1gA2 1308.2 2593.3 0.26 12.2 2.50 12.9 0.37 2.0 4.56 28.7 0.27 1.5 4.13 8.1 0.28 64.5 2.48 87.2
H6N3F3A1 1475.7 2928.4 0.21 34.6 2.05 35.2 0.37 1.9 4.67 28.7 0.24 7.5 3.74 17.1 0.31 68.3 2.76 90.2
H5N3A3gA1 1669.3 3315.6 0.23 46.3 2.19 46.9 0.34 6.1 4.16 24.7 0.25 17.0 3.86 26.4 0.27 77.9 2.45 97.5
% Total 
Glycan Pool 4.22 n/a 5.69 n/a 5.05 n/a 5.23 n/a
Table A1. Relative abundance of sialylated hybrid (N3) glycans.
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C8-D30 VM-NM1 VM-M2 VM-M3
Molecular
Composition [m+Naf [rm.2Naf % of TGP
% Relative 
to M5N2 % of TGP
% Relative to 
M5N2 % of TGP
% Relative to 
M5N2 % of TGP
% Relative to 
M5N2
H3N4A1 2039 1031 0.51 5.2 4.87 5.8 0.49 3.1 6.00 27.6 3.05 43.7 47.41 52.2 1.62 50.6 12.11 20.7
H3N4gA1 2069.1 1046.1 0.38 22.6 3.70 21.9 0.41 24.3 5.31 53.0 0.96 24.6 14.80 33.8 0.52 7.4 4.26 38.5
H4N4A1 2243.1 1133.1 0.49 2.2 4.72 2.8 0.68 2.1 8.47 28.5 2.94 51.0 45.85 59.2 1.59 42.0 12.06 11.5
H4N4gA1 2273.2 1148.1 0.37 1.1 3.54 0.4 0.52 6.5 6.52 36.7 1.09 21.4 16.77 30.7 0.54 9.8 4.41 40.8
H3N4A1gA1 2430.2 1226.6 0.25 13.6 2.44 14.2 0.33 15.1 4.05 15.8 0.88 14.2 13.51 23.6 0.53 45.7 4.62 72.8
H3N4gA2 2460.2 1241.6 0.27 10.9 2.60 11.5 0.33 3.8 4.06 26.9 0.58 9.7 8.91 19.2 0.42 42.2 3.64 69.2
H5N4gA1 2477.3 1250.2 0.30 1.5 2.94 2.2 0.51 1.4 6.38 29.2 1.11 31.3 17.10 40.3 0.60 5.9 4.80 25.9
H4N4A2 2604.3 1313.7 0.21 6.9 2.04 7.6 0.33 0.2 4.13 30.4 0.24 2.3 3.71 11.8 0.27 69.1 2.44 90.7
H5N4F1A1 2621.3 1322.2 0.42 33.5 4.07 34.1 0.72 3.8 8.88 26.9 0.36 14.1 5.56 23.5 0.28 74.7 2.55 95.1
H6N4A1 2651.3 1337.2 0.31 27.4 3.03 28.0 0.56 17.5 7.10 46.8 0.69 26.4 10.64 35.5 0.57 53.6 4.98 78.6
H4N4gA2 2664.3 1343.7 0.27 22.0 2.57 22.6 0.33 10.2 3.98 20.7 0.24 3.8 3.68 13.4 0.29 77.7 2.60 97.4
H5N4F2A1 2795.4 1409.2 0.27 37.6 2.64 38.2 0.59 1.0 7.31 31.5 0.28 15.6 4.23 25.1 0.31 74.0 2.79 94.5
H5N4A2 2808.4 1415.7 0.32 51.7 3.12 52.3 0.74 1.6 9.14 29.1 0.34 17.5 5.26 26.8 0.52 104.5 4.88 116.9
H6N4F1A1 2825.4 1424.2 0.34 42.1 3.32 42.7 0.81 25.1 10.40 53.7 0.62 17.4 9.59 26.7 0.33 70.7 2.97 92.1
H5N4A1gA1 2838.4 1430.7 0.23 45.8 2.18 46.4 0.38 28.3 4.56 2.3 0.29 20.2 4.42 10.7 0.26 86.4 2.38 103.9
H7N4A1 2855.4 1439.2 0.24 33.4 1.54 124.4 0.48 13.9 2.35 109.9 0.43 15.7 3.58 126.3 0.28 72.3 2.13 132.5
H5N4gA2 2868.4 1445.7 0.26 38.2 2.55 38.8 0.40 3.5 4.92 27.1 0.28 21.7 4.16 12.2 0.23 60.4 2.03 84.0
H5N4F1A2 2982.5 1502.8 0.35 77.2 3.42 77.6 0.51 1.9 6.31 32.4 0.35 3.1 5.34 12.6 0.28 70.0 2.51 91.5
H6N4F2A1 2999.6 1511.3 0.26 50.7 2.48 51.2 0.68 28.8 8.79 56.9 0.27 9.4 4.14 18.9 0.27 70.6 2.43 92.0
H6N4A2 3012.5 1517.8 0.22 56.7 2.14 57.2 0.33 10.2 3.98 20.7 0.29 13.4 4.37 3.84 0.91 122.9 8.77 129.4
H5N4F1gA2 3042.5 1532.8 0.19 25.6 1.17 122.5 0.36 10.8 1.82 111.1 0.28 25.5 4.16 128.2 0.26 79.7 2.06 133.7
H6N4A1gA1 3042.5 1532.75 0.19 25.6 1.85 26.2 0.36 10.8 4.56 40.7 0.28 25.5 4.16 16.0 0.26 79.7 2.36 98.9
H5N4F2A2 3156.6 1589.8 0.22 23.8 2.10 24.4 0.32 8.7 3.89 22.1 0.26 22.7 4.06 31.9 0.24 69.3 2.20 91.0
H5N4A3 3169.6 1596.3 0.17 53.6 1.69 54.2 0.29 16.9 3.56 14.1 0.22 5.2 3.34 14.8 0.27 89.1 2.51 105.8
H6N4F1A2 3186.6 1604.8 0.19 24.3 1.83 24.9 0.33 6.8 4.08 37.1 0.25 21.2 3.82 30.5 0.25 50.3 2.19 75.9
H9N4A1 3263.6 1643.3 0.12 23.2 1.16 23.8 0.26 7.1 3.30 37.3 0.21 15.7 3.23 25.1 0.28 78.6 2.52 98.1
H6N4A3 3373.6 1698.3 0.06 114.0 0.53 113.8 0.32 10.6 3.88 20.3 0.25 4.2 3.77 13.8 0.23 70.1 2.12 91.5
% Total 
Glycan Pool 7.44 n/a 12.35 n/a 17.04 n/a 12.38 n/a
Table A2. Relative abundance of sialylated bi-antennary (N4) glycans.
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% Relative to 
M5N2 % of TGP
% Relative 
to M5N2 % of TGP
% Relative to 
M5N2
H5N5A1 2692.3 1357.7 0.26 8.2 2.55 8.9 0.40 13.9 4.87 17.1 0.26 11.8 3.98 2.2 0.28 77.0 2.53 96.8
H5N5gA1 2722.4 1372.7 0.21 0.7 2.02 1.3 0.36 2.7 4.54 33.2 0.26 3.4 3.99 13.0 0.29 63.3 2.57 86.3
H4N5F2A1 2836.4 1429.7 0.17 5.4 1.64 4.7 0.24 8.4 2.98 22.4 0.20 6.0 3.11 3.6 0.21 60.2 1.87 83.8
H6N5A1 2896.5 1459.8 0.27 32.9 2.58 33.5 0.48 8.3 6.10 38.5 0.29 6.2 4.38 15.8 0.32 74.0 2.94 94.5
H5N5A2 3053.5 1538.3 0.23 37.0 2.21 37.6 0.40 2.2 4.93 32.7 0.25 3.4 3.79 13.0 0.26 83.8 2.40 101.9
H6N5F1A1 3070.6 1546.8 0.27 40.8 2.56 41.4 0.47 8.5 5.89 38.5 0.32 18.1 4.87 27.4 0.27 74.7 2.47 95.0
H7N5A1 3100.5 1561.8 0.19 27.9 1.79 28.5 0.36 5.9 4.57 36.2 0.31 5.2 4.76 14.8 0.39 66.4 3.49 88.6
H7N5gA1 3130.6 1576.8 0.18 27.1 1.73 27.7 0.31 3.2 3.90 33.5 0.24 7.2 3.58 2.4 0.28 73.9 2.56 94.4
H5N5F1A2 3227.6 1625.3 0.23 63.1 2.17 63.6 0.37 14.8 4.45 16.1 0.26 30.1 4.03 39.1 0.24 69.3 2.20 91.0
H6N5A2 3257.6 1640.3 0.35 92.3 3.35 92.6 0.91 22.2 11.74 51.1 0.39 36.2 5.98 45.1 0.39 66.3 3.56 104.7
H7N5F1A1 3274.6 1648.8 0.21 52.8 2.04 53.3 0.52 11.0 6.52 40.9 0.36 30.9 5.63 39.9 0.29 71.6 2.57 92.7
H6N5F1gA2 3287.6 1655.3 0.19 45.8 1.84 46.4 0.41 23.7 5.28 52.5 0.27 20.3 4.21 29.6 0.31 73.3 2.79 94.0
H8N5gA1 3334.6 1678.8 0.15 32.1 1.46 32.8 0.37 14.7 4.67 44.3 0.26 3.9 3.98 5.7 0.29 71.6 2.57 92.7
H6N5F1A2 3431.7 1727.4 0.29 66.0 2.77 66.5 0.35 14.1 4.25 16.8 0.30 26.4 4.65 35.5 0.30 72.5 2.72 93.9
H7N5A2 3461.7 1742.4 0.20 59.1 1.94 59.7 0.30 12.4 3.69 18.5 0.29 15.0 4.39 24.5 0.35 77.2 3.14 96.9
H8N5F1A1 3478.7 1750.9 0.18 41.5 1.70 42.1 0.38 12.2 4.78 41.9 0.37 21.6 5.74 30.8 0.29 64.8 2.55 87.4
% Total Glycan 
Pool 3.56 n/a 6.63 n/a 4.64 n/a 4.75 n/a
Table A3. Relative abundance of sialylated tri-antennary (N5) glycans.
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APPENDIX B
Additional Neutral Mono-fucosylated MS2 Spectra
(A) MS2 Spectra: m/z 2872.5_HeXaHexNAc„Fuc, (B) MS2 Spectra: Magnified View_m/z 1000*1250
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Figure B1. Comparative analysis of ESI-MS2 spectra, m/z 2872.5 (* m/z 1448.0 doubly 
charged).
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Figure B2. Comparative analysis of ESI-MS2 spectra, m/z 2913.5 (* m/z 1468.2 doubly 
charged).
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MS2 Spectra: m/z 3117.6_Hex8HexNAC;,Fuc, (B) MS2 Spectra: Magnified View_m/z 1100-1400
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Figure B3. Comparative analysis of ESI-MS2 spectra, m/z 3117.6 (* m/z 1570.3 doubly 
charged).
155
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(A) MS2Spectra: m/z 3321.7_Hex„HexNAc5Fuc. (B) MS2 Spectra: Magnified view_m/z 1200-1500
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Figure B4. Comparative analysis of ESI-MS2 spectra, m/z 3321.7 (* m/z 1672.3 doubly 
charged).
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